HPVomics

A therapeutic and epitome resource for Human Papillomaviruses

Experimentally proven T-cell epitopes (IEDB)

---

HPV type	Gene region	Epitope sequence	Start	Stop	Length	Epitope IRI	Protein IRI	Allele	MHC type	Cell type	Assay Method	Assay group	Assay reference	PMID
HPV16	E7	DRAHYNIVTFCCKCD	48	62	15	9947	P03129	HLA-DR15	II	T cell CD4+	ELISPOT	IFNg release	1743	15161683
HPV16	E7	DRAHYNIVTFCCKCD	48	62	15	9947	P03129	HLA-DR15	II	T cell CD4+	ELISPOT	IL-5 release	2471	15161683
HPV16	E7	MHGDTPTLHEYM	1	12	12	41659	P03129	HLA class II	II	T cell CD4+	ELISPOT	IL-5 release	2472	15161683
HPV16	E7	MHGDTPTLHEYM	1	12	12	41659	P03129	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	2473	15161683
HPV16	E7	DSTLRLCVQSTHVD	62	75	14	10251	P03129	HLA class II	II	T cell CD4+	ELISPOT	IL-5 release	2474	15161683
HPV16	E7	DSTLRLCVQSTHVD	62	75	14	10251	P03129	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	2475	15161683
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	5975	15609329
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell	ELISPOT	IFNg release	5984	15609329
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	5991	15609329
HPV52	E7	YILDLQPETT	11	20	10	74288	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	8834	15609329
HPV31	E7	YVLDLQPEAT	11	20	10	76334	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	8838	15609329
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell	ELISPOT	IFNg release	8854	15609329
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	51 chromium	cytotoxicity	21273	11581382
HPV16	E7	GIVCPICSQK	88	97	10	20471	P03129	HLA-A*11:01	I	T cell	51 chromium	cytotoxicity	1005933	9366399
HPV16	E6	LLIRCINCQK	106	115	10	37421	P03126	HLA-A*11:01	I	T cell	51 chromium	cytotoxicity	1005937	9366399
HPV16	E6	LLIRCINCQK	106	115	10	37421	P03126	HLA-A*11:01	I	T cell CD8+	51 chromium	cytotoxicity	1005957	9366399
HPV16	E7	GIVCPICSQK	88	97	10	20471	P03129	HLA-A*11:01	I	T cell CD8+	51 chromium	cytotoxicity	1005962	9366399
HPV44	L1	HNNGICWGN	315	323	9	24390	P04012	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	1022861	11689620
HPV29	L1	YLKGNNGRET	276	285	10	74736	P50791	HLA class II	II	T cell	3H-thymidine	proliferation	1068983	16150497
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	PBMC	51 chromium	cytotoxicity	1069581	8564975
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	PBMC	51 chromium	cytotoxicity	1069582	8564975
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A2	I	T cell CD8+	ELISA	TNF release	1244095	12519392
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A2	I	T cell CD8+	ELISA	GM-CSF release	1244096	12519392
HPV16	E7	HVDIRTLED	73	81	9	25028	P03129	HLA-A2	I	T cell CD8+	ELISA	IL-2 release	1244099	12519392
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A2	I	T cell CD8+	ELISA	IL-2 release	1244103	12519392
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A2	I	T cell CD8+	ELISA	GM-CSF release	1244104	12519392
HPV16	E7	GTLGIVCPI	85	93	9	22738	P03129	HLA-A2	I	T cell CD8+	ELISA	GM-CSF release	1244109	12519392
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1244375	11714814
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell	51 chromium	cytotoxicity	1244392	12384540
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1244399	12384540
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1244400	12384540
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	T cell	ELISPOT	IFNg release	1244401	12384540
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	T cell	ELISPOT	IFNg release	1244402	12384540
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell	ELISPOT	IFNg release	1244403	12384540
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1244404	12384540
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell	ELISPOT	IFNg release	1244405	12384540
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1244406	12384540
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1244407	12384540
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell	ELISPOT	IFNg release	1244408	12384540
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1244409	12384540
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell	ELISPOT	IFNg release	1244410	12384540
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell	51 chromium	cytotoxicity	1244651	11714814
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell	ELISA	IFNg release	1277921	10096544
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell	ELISA	IFNg release	1277922	10096544
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell	ELISA	IFNg release	1277930	10096544
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell	ELISA	IFNg release	1277931	10096544
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1354827	8617954
HPV16	E7	MLDLQPETT	12	20	9	41919	P03129	HLA class I	I	T cell	51 chromium	cytotoxicity	1409066	10999722
HPV16	E7	MLDLQPETT	12	20	9	41919	P03129	-	-	T cell	ELISA	IFNg release	1409067	10999722
HPV16	E7	MLDLQPETT	12	20	9	41919	P03129	-	-	-	in vivo assay	decreased disease	1409070	10999722
HPV16	E6	EVYDFAFRDL	48	57	10	14909	P03126	H2-b class II	II	Splenocyte	3H-thymidine	proliferation	1418710	15709713
HPV16	E6	GRWTGRCM	137	144	8	22254	P03126	H2-b class I	I	Splenocyte	51 chromium	cytotoxicity	1418739	15709713
HPV16	E6	GRWTGRCM	137	144	8	22254	P03126	H2-b class II	II	Splenocyte	3H-thymidine	proliferation	1418740	15709713
HPV16	E7	DLYCYEQLND	21	30	10	9336	P03129	H2-b class I	I	Splenocyte	51 chromium	cytotoxicity	1418741	15709713
HPV16	E7	DRAHYNI	48	54	7	9946	P03129	H2-b class II	II	Splenocyte	3H-thymidine	proliferation	1418743	15709713
HPV16	E6	GRWTGRCM	137	144	8	22254	P03126	-	-	-	in vivo assay	tumor burden after challenge	1418745	15709713
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class II	II	Splenocyte	3H-thymidine	proliferation	1418746	15709713
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	Splenocyte	51 chromium	cytotoxicity	1418747	15709713
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	-	-	-	in vivo assay	tumor burden after challenge	1418748	15709713
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-b class I	I	Splenocyte	51 chromium	cytotoxicity	1418749	15709713
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	-	-	-	in vivo assay	tumor burden after challenge	1418750	15709713
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-b class II	II	Splenocyte	3H-thymidine	proliferation	1418751	15709713
HPV1a	E4	PNSQDRGRPRRSD	39	51	13	48705	P06923	HLA-DQ7	II	T cell CD4+	3H-thymidine	proliferation	1420984	7682626
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	ELISA	IFNg release	1436175	17067378
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1436176	17067378
HPV16	E7	MLDLQPETTDLYCYEQLN	12	29	18	41920	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1474397	1712110
HPV16	E7	ETTDLYCYEQLNDSSEEEDE	18	37	20	14557	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1474398	1712110
HPV16	E7	EIDGPAGQAEPDRAHYNIVT	37	56	20	12415	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1474400	1712110
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1474401	1712110
HPV16	E7	DRAHYNI	48	54	7	9946	P03129	H2-a class II	II	Lymph node cells	3H-thymidine	proliferation	1474415	1712110
HPV16	E7	DRAHYNI	48	54	7	9946	P03129	H2-s class II	II	Lymph node cells	3H-thymidine	proliferation	1474416	1712110
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2 class II	II	Lymph node cells	3H-thymidine	proliferation	1474417	1712110
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-a class II	II	Lymph node cells	3H-thymidine	proliferation	1474418	1712110
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1474419	1712110
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-a class II	II	Lymph node cells	3H-thymidine	proliferation	1474420	1712110
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-s class II	II	Lymph node cells	3H-thymidine	proliferation	1474421	1712110
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1474422	1712110
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1474423	1712110
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2 class II	II	Lymph node cells	3H-thymidine	proliferation	1474424	1712110
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-d class II	II	Lymph node cells	3H-thymidine	proliferation	1474425	1712110
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1474426	1712110
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474775	7538538
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474785	7538538
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474820	7538538
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474821	7538538
HPV16	E6	LQTTIHDII	26	34	9	39002	P03126	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474827	7538538
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474828	7538538
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474829	7538538
HPV16	E6	FAFRDLCIV	52	60	9	15173	P03126	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474831	7538538
HPV16	E7	TLHEYMLDL	7	15	9	64830	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474833	7538538
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474834	7538538
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474835	7538538
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474930	7538538
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474931	7538538
HPV16	E7	MLDLQPETT	12	20	9	41919	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474933	7538538
HPV16	E7	GTLGIVCPI	85	93	9	22738	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474936	7538538
HPV16	E7	GTLGIVCPI	85	93	9	22738	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474937	7538538
HPV16	E7	TLGIVCPIC	86	94	9	64819	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474939	7538538
HPV16	E7	TLGIVCPIC	86	94	9	64819	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474941	7538538
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474962	7538538
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474963	7538538
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474964	7538538
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1474965	7538538
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-a class II	II	Lymph node cells	3H-thymidine	proliferation	1475437	1712110
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-a class II	II	Lymph node cells	3H-thymidine	proliferation	1475438	1712110
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2 class II	II	Unknown/Unspecified	biological activity	antibody help	1475446	1712110
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Kb	I	Splenocyte	ELISPOT	IFNg release	1505982	17689584
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Kb	I	Splenocyte	51 chromium	cytotoxicity	1505988	17689584
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Kb	I	-	in vivo assay	survival from challenge	1505990	17689584
HPV16	E7	TLIDVCPI	0	0	8	79659	P03129	HLA-A*02:01	I	Splenocyte	51 chromium	cytotoxicity	1508675	7527444
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	Splenocyte	51 chromium	cytotoxicity	1508676	7527444
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	Splenocyte	51 chromium	cytotoxicity	1508680	7527444
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	Splenocyte	51 chromium	cytotoxicity	1508681	7527444
HPV16	E7	EYMLDLQPETTDL	10	22	13	108358	P03129	HLA class II	II	Splenocyte	ELISPOT	IFNg release	1650413	19520206
HPV16	E7	EYMLDLQPETTDL	10	22	13	108358	P03129	HLA class II	II	-	biological activity	T cell help	1650465	19520206
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	HLA class II	II	-	in vivo assay	cytotoxicity	1650469	19520206
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell CD8+	multimer/tetramer	qualitative binding	1651230	17321896
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell CD8+	ICS	IFNg release	1651232	17321896
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell CD8+	in vitro assay	cytotoxicity	1651240	17321896
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell CD8+	in vitro assay	cytotoxicity	1651245	17321896
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell CD8+	ELISPOT	IFNg release	1651262	17321896
HPV16	E7	HYNIVTFCCKCDSTLRLCVQ	51	70	20	109306	P03129	HLA class II	II	T cell CD4+	ICS	IFNg release	1651445	18778290
HPV16	E7	LRLCVQSTHVDIRTLEDLLM	65	84	20	109519	P03129	HLA class II	II	T cell CD4+	ICS	IFNg release	1651446	18778290
HPV16	E7	LEDLLMGTLGIVCPICSQKP	79	98	20	109477	P03129	HLA class II	II	T cell CD4+	ICS	IFNg release	1651447	18778290
HPV16	E7	LRLCVQSTHVDIRTLEDLLM	65	84	20	109519	P03129	HLA class II	II	T cell CD4+	ICS	IL-4 release	1651449	18778290
HPV16	E7	LEDLLMGTLGIVCPICSQKP	79	98	20	109477	P03129	HLA class II	II	T cell CD4+	ICS	IL-4 release	1651450	18778290
HPV16	E7	LRLCVQSTHVDIRTLEDLLM	65	84	20	109519	P03129	HLA class II	II	T cell CD4+	ICS	IFNg release	1651454	18778290
HPV16	E7	LEDLLMGTLGIVCPICSQKP	79	98	20	109477	P03129	HLA class II	II	T cell CD4+	ICS	IFNg release	1651455	18778290
HPV16	E6	KLPQLCTEL	18	26	9	32085	P03126	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	1651581	17589293
HPV16	E6	KLPQLCTEL	18	26	9	32085	P03126	HLA-A*02:01	I	T cell CD8+	ELISA	IFNg release	1651587	17589293
HPV16	E6	KLPQLCTEL	18	26	9	32085	P03126	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	1651645	17589293
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1652713	12566712
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1652714	12566712
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	51 chromium	cytotoxicity	1652715	12566712
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	ICS	IFNg release	1652719	16107858
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	1652721	16107858
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	1652722	16107858
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1652742	16107858
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	-	in vivo assay	tumor burden after challenge	1652820	17555571
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	T cell CD8+	ICS	IFNg release	1652867	17555571
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	ICS	IFNg release	1652903	17555571
HPV16	L1	AGVDNRECI	165	173	9	110186	P03101	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	1653180	12663770
HPV16	E6	ISEYRHYCY	80	88	9	28484	P03126	HLA-B18	I	T cell CD8+	51 chromium	cytotoxicity	1653520	10940919
HPV16	E6	ISEYRHYCY	80	88	9	28484	P03126	HLA-B18	I	T cell CD8+	51 chromium	cytotoxicity	1653525	10940919
HPV16	E7	QAEPDRAHY	44	52	9	50240	P03129	HLA-B18	I	T cell CD8+	51 chromium	cytotoxicity	1653548	10940919
HPV16	E6	ISEYRHYCY	80	88	9	28484	P03126	HLA-B18	I	T cell CD8+	51 chromium	cytotoxicity	1653549	10940919
HPV16	E6	GRWTGRCM	137	144	8	22254	P03126	H2-Kb	I	T cell CD8+	51 chromium	cytotoxicity	1653555	7499833
HPV16	E6	GRWTGRCM	137	144	8	22254	P03126	H2-Kb	I	T cell CD8+	51 chromium	cytotoxicity	1653556	7499833
HPV16	E6	EVYDFAFRDL	48	57	10	14909	P03126	H2-Kb	I	T cell CD8+	51 chromium	cytotoxicity	1653588	7499833
HPV16	E6	GRWTGRCM	137	144	8	22254	P03126	H2-Kb	I	T cell CD8+	51 chromium	cytotoxicity	1653591	7499833
HPV16	E6	GRWTGRCM	137	144	8	22254	P03126	H2-Kb	I	T cell CD8+	51 chromium	cytotoxicity	1653592	7499833
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD8+	ELISPOT	IFNg release	1653644	17274003
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	51 chromium	cytotoxicity	1653693	19126233
HPV16	E2	ALQAIELQL	69	77	9	108770	P03120	HLA-A2	I	Splenocyte	ELISPOT	IFNg release	1653698	16425257
HPV16	E2	YICEEASVTV	138	147	10	110125	P03120	HLA-A2	I	Splenocyte	ELISPOT	IFNg release	1653701	16425257
HPV16	E2	ALQAIELQL	69	77	9	108770	P03120	HLA-A2	I	Splenocyte	ELISPOT	IFNg release	1653704	16425257
HPV16	E2	YICEEASVTV	138	147	10	110125	P03120	HLA-A2	I	Splenocyte	ELISPOT	IFNg release	1653706	16425257
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	HLA-A2	I	Splenocyte	ELISA	IFNg release	1653710	16425257
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	HLA-A2	I	Splenocyte	ELISA	IL-10 release	1653711	16425257
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD4+	ELISA	IFNg release	1653712	19180468
HPV16	L1	PPVPVSKVVSTDEYVARTNIYYHA	40	63	24	109716	P03101	H2-IEk	II	Lymph node cells	3H-thymidine	proliferation	1653736	1701481
HPV16	L1	VSGLQYRVFRIHLPDP	91	106	16	110064	P03101	H2-IEk	II	Lymph node cells	3H-thymidine	proliferation	1653737	1701481
HPV16	L1	EQMFVRHLFNRAGTVG	279	294	16	108925	P03101	H2-IEk	II	Lymph node cells	3H-thymidine	proliferation	1653740	1701481
HPV16	L1	PPVPVSKVVSTDEYVARTNIYYHA	40	63	24	109716	P03101	H2-IAk	II	Lymph node cells	3H-thymidine	proliferation	1653752	1701481
HPV16	L1	PPVPVSKVVSTDEYVARTNIYYHA	40	63	24	109716	P03101	H2-IEd	II	Lymph node cells	3H-thymidine	proliferation	1653753	1701481
HPV16	L1	PPVPVSKVVSTDEYVARTNIYYHA	40	63	24	109716	P03101	H2-IAd	II	Lymph node cells	3H-thymidine	proliferation	1653754	1701481
HPV16	L1	VSGLQYRVFRIHLPDP	91	106	16	110064	P03101	H2-IAk	II	Lymph node cells	3H-thymidine	proliferation	1653755	1701481
HPV16	L1	VSGLQYRVFRIHLPDP	91	106	16	110064	P03101	H2-IEd	II	Lymph node cells	3H-thymidine	proliferation	1653756	1701481
HPV16	L1	EQMFVRHLFNRAGTVG	279	294	16	108925	P03101	H2-IAk	II	Lymph node cells	3H-thymidine	proliferation	1653757	1701481
HPV16	L1	EQMFVRHLFNRAGTVG	279	294	16	108925	P03101	H2-IEd	II	Lymph node cells	3H-thymidine	proliferation	1653758	1701481
HPV16	L1	PPVPVSKVVSTDEYVARTNIYYHA	40	63	24	109716	P03101	H2-IEk	II	Lymph node cells	3H-thymidine	proliferation	1653759	1701481
HPV16	L1	PPVPVSKVVSTDEYVARTNIYYHA	40	63	24	109716	P03101	H2-IAk	II	Lymph node cells	3H-thymidine	proliferation	1653760	1701481
HPV16	L1	PPVPVSKVVSTDEYVARTNIYYHA	40	63	24	109716	P03101	H2-IEd	II	Lymph node cells	3H-thymidine	proliferation	1653761	1701481
HPV16	L1	PPVPVSKVVSTDEYVARTNIYYHA	40	63	24	109716	P03101	H2-IAd	II	Lymph node cells	3H-thymidine	proliferation	1653762	1701481
HPV16	L1	VSGLQYRVFRIHLPDP	91	106	16	110064	P03101	H2-IEk	II	Lymph node cells	3H-thymidine	proliferation	1653763	1701481
HPV16	L1	VSGLQYRVFRIHLPDP	91	106	16	110064	P03101	H2-IAk	II	Lymph node cells	3H-thymidine	proliferation	1653764	1701481
HPV16	L1	VSGLQYRVFRIHLPDP	91	106	16	110064	P03101	H2-IEd	II	Lymph node cells	3H-thymidine	proliferation	1653765	1701481
HPV16	L1	EQMFVRHLFNRAGTVG	279	294	16	108925	P03101	H2-IEk	II	Lymph node cells	3H-thymidine	proliferation	1653766	1701481
HPV16	L1	EQMFVRHLFNRAGTVG	279	294	16	108925	P03101	H2-IAk	II	Lymph node cells	3H-thymidine	proliferation	1653767	1701481
HPV16	L1	EQMFVRHLFNRAGTVG	279	294	16	108925	P03101	H2-IEd	II	Lymph node cells	3H-thymidine	proliferation	1653768	1701481
HPV16	E7	EDEIDGPAGQAEPDRAHYNI	35	54	20	110824	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1653807	7513919
HPV16	E7	EDEIDGPAGQAEPDRAHYNI	35	54	20	110824	P03129	H2-b class II	II	Lymph node cells	bioassay	IL-2 release	1653816	7513919
HPV16	E7	EDEIDGPAGQAEPDRAHYNI	35	54	20	110824	P03129	-	-	Lymph node cells	bioassay	IL-3 release	1653829	7513919
HPV16	E7	EDEIDGPAGQAEPDRAHYNI	35	54	20	110824	P03129	H2-b class II	II	Lymph node cells	bioassay	IL-4 release	1653830	7513919
HPV16	E7	GQAEPDRAHYNIVTFCCKCD	43	62	20	110869	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1653838	7513919
HPV16	E7	GQAEPDRAHYNIVTFCCKCD	43	62	20	110869	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1653839	7513919
HPV16	E7	TLHEYMLDL	7	15	9	64830	P03129	HLA-B8	I	T cell CD8+	ELISA	IFNg release	1654076	15609316
HPV16	E7	TLHEYMLDL	7	15	9	64830	P03129	HLA-B8	I	T cell CD8+	ELISA	IFNg release	1654150	15609316
HPV16	E7	CCKCDSTL	58	65	8	110195	P03129	HLA-B8	I	T cell CD8+	ELISA	IFNg release	1654152	15609316
HPV16	E7	TLHEYMLDL	7	15	9	64830	P03129	HLA-B8	I	T cell CD8+	ELISA	IFNg release	1654157	15609316
HPV16	E7	TLHEYMLDL	7	15	9	64830	P03129	HLA-B8	I	T cell CD8+	multimer/tetramer	qualitative binding	1654160	15609316
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A2	I	Lymph node cells	51 chromium	cytotoxicity	1654257	10709786
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1654267	12804851
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1654268	12804851
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1654269	12804851
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1654270	12804851
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1654271	12804851
HPV18	E7	QLFLNTLSFV	88	97	10	110381	P06788	HLA-A2	I	T cell CD8+	51 chromium	cytotoxicity	1654273	11418310
HPV18	E7	SEEENDEIDGVNHQHLPARR	34	53	20	110420	P06788	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1654296	12569558
HPV18	E7	PQRHTMLCMCCKCEARIKLV	56	75	20	110371	P06788	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1654298	12569558
HPV18	E7	FQQLFLNTL	86	94	9	110225	P06788	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1654300	12569558
HPV18	E7	LFLNTLSFVCPWCASQQ	89	105	17	110318	P06788	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1654301	12569558
HPV18	E7	FQQLFLNTL	86	94	9	110225	P06788	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1654302	12569558
HPV18	E7	FQQLFLNTL	86	94	9	110225	P06788	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1654313	12569558
HPV18	E7	FQQLFLNTL	86	94	9	110225	P06788	HLA-A*02:01	I	T cell CD8+	3H-thymidine	proliferation	1654320	12569558
HPV18	E7	FQQLFLNTL	86	94	9	110225	P06788	HLA-A*02:01	I	T cell CD8+	3H-thymidine	proliferation	1654321	12569558
HPV18	E7	FQQLFLNTL	86	94	9	110225	P06788	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1654322	12569558
HPV18	E7	FQQLFLNTL	86	94	9	110225	P06788	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1654325	12569558
HPV18	E7	FQQLFLNTL	86	94	9	110225	P06788	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1654329	12569558
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1654334	11390461
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1654335	11390461
HPV16	L1	PPVPVSKVVSTDEYVARTNIYYHA	40	63	24	109716	P03101	HLA-DRB1*04:01	II	PBMC	3H-thymidine	proliferation	1654339	1689768
HPV16	L1	VSGLQYRVFRIHLPDP	91	106	16	110064	P03101	HLA class II	II	PBMC	3H-thymidine	proliferation	1654340	1689768
HPV16	L1	TVIQDGDMVHTGFGAMDFTTLQANKS	219	244	26	110012	P03101	HLA-DRB1*04:01	II	PBMC	3H-thymidine	proliferation	1654342	1689768
HPV16	L1	EQMFVRHLFNRAGTVG	1	16	16	108925	P03101	HLA-DR7	II	PBMC	3H-thymidine	proliferation	1654343	1689768
HPV16	L1	PPVPVSKVVSTDEYVARTNIYYHA	40	63	24	109716	P03101	HLA-DRB1*04:01	II	PBMC	3H-thymidine	proliferation	1654350	1689768
HPV16	L1	PPVPVSKVVSTDEYVARTNIYYHA	40	63	24	109716	P03101	HLA-DRB1*04:01	II	PBMC	3H-thymidine	proliferation	1654351	1689768
HPV16	L1	PPVPVSKVVSTDEYVARTNIYYHA	40	63	24	109716	P03101	HLA-DRB1*04:01	II	PBMC	3H-thymidine	proliferation	1654352	1689768
HPV16	L1	VSGLQYRVFRIHLPDP	91	106	16	110064	P03101	HLA class II	II	PBMC	3H-thymidine	proliferation	1654356	1689768
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell	ELISPOT	IFNg release	1654357	11342606
HPV16	L1	VSGLQYRVFRIHLPDP	91	106	16	110064	P03101	HLA class II	II	PBMC	3H-thymidine	proliferation	1654359	1689768
HPV16	L1	IHSMNSTIL	417	425	9	109332	P03101	HLA-B*39:01	I	PBMC	3H-thymidine	proliferation	1654362	12376754
HPV18	L1	IHSMNSSIL	453	461	9	109331	P06794	HLA-B*39:01	I	PBMC	3H-thymidine	proliferation	1654369	12376754
HPV16	L1	IHSMNSTIL	417	425	9	109332	P03101	HLA-B*39:01	I	PBMC	51 chromium	cytotoxicity	1654372	12376754
HPV18	L1	IHSMNSSIL	453	461	9	109331	P06794	HLA-B*39:01	I	PBMC	51 chromium	cytotoxicity	1654375	12376754
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	Splenocyte	51 chromium	cytotoxicity	1654389	12153516
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	Splenocyte	51 chromium	cytotoxicity	1654395	12153516
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	HLA-A*02:01	I	Splenocyte	51 chromium	cytotoxicity	1654396	12153516
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	HLA-A*02:01	I	Splenocyte	51 chromium	cytotoxicity	1654407	12153516
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	HLA-A*02:01	I	Splenocyte	51 chromium	cytotoxicity	1654413	12153516
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	HLA-A*02:01	I	Splenocyte	51 chromium	cytotoxicity	1654416	12153516
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	1654455	12960314
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1654465	12960314
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1654467	12960314
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1654468	12960314
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1654469	12960314
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	HLA-A*02:01	I	-	in vivo assay	tumor burden after challenge	1654470	12153516
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	Splenocyte	51 chromium	cytotoxicity	1654471	12153516
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	HLA-A*02:01	I	Splenocyte	51 chromium	cytotoxicity	1654472	12153516
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	1654473	18366058
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1654480	18366058
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	HLA-A*02:01	I	Splenocyte	51 chromium	cytotoxicity	1654483	12153516
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	in vitro assay	cytotoxicity	1654488	18366058
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	1654489	12153516
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	cytometric bead array	IFNg release	1654490	18366058
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	cytometric bead array	TNF release	1654492	18366058
HPV11	E7	TLKDIVLDL	7	15	9	110438	P04020	HLA-A*02:01	I	T cell	ELISA	IFNg release	1654611	18299861
HPV11	E7	TLKDIVLDL	7	15	9	110438	P04020	HLA-A*02:01	I	T cell	multimer/tetramer	qualitative binding	1654614	18299861
HPV11	E7	TLKDIVLDL	7	15	9	110438	P04020	HLA-A*02:01	I	T cell	in vitro assay	cytotoxicity	1654615	18299861
HPV11	E7	LQPPDPVGL	15	23	9	110327	P04020	HLA-A*02:01	I	T cell	multimer/tetramer	qualitative binding	1654616	18299861
HPV11	E7	LQPPDPVGL	15	23	9	110327	P04020	HLA-A*02:01	I	T cell	in vitro assay	cytotoxicity	1654617	18299861
HPV11	E7	LQPPDPVGL	15	23	9	110327	P04020	HLA-A*02:01	I	T cell	ELISA	IFNg release	1654618	18299861
HPV11	E7	PLTQHYQIL	47	55	9	110366	P04020	HLA-A*02:01	I	T cell	multimer/tetramer	qualitative binding	1654619	18299861
HPV11	E7	PLTQHYQIL	47	55	9	110366	P04020	HLA-A*02:01	I	T cell	in vitro assay	cytotoxicity	1654620	18299861
HPV11	E7	PLTQHYQIL	47	55	9	110366	P04020	HLA-A*02:01	I	T cell	ELISA	IFNg release	1654621	18299861
HPV11	E7	DLLLGTLNI	81	89	9	110206	P04020	HLA-A*02:01	I	T cell	multimer/tetramer	qualitative binding	1654622	18299861
HPV11	E7	DLLLGTLNI	81	89	9	110206	P04020	HLA-A*02:01	I	T cell	in vitro assay	cytotoxicity	1654623	18299861
HPV11	E7	DLLLGTLNI	81	89	9	110206	P04020	HLA-A*02:01	I	T cell	ELISA	IFNg release	1654624	18299861
HPV11	E7	LLLGTLNIV	82	90	9	110323	P04020	HLA-A*02:01	I	T cell	multimer/tetramer	qualitative binding	1654625	18299861
HPV11	E7	LLLGTLNIV	82	90	9	110323	P04020	HLA-A*02:01	I	T cell	in vitro assay	cytotoxicity	1654626	18299861
HPV11	E7	LLLGTLNIV	82	90	9	110323	P04020	HLA-A*02:01	I	T cell	ELISA	IFNg release	1654627	18299861
HPV16	L1	IHSMNSTIL	417	425	9	109332	P03101	HLA-B*39:01	I	PBMC	3H-thymidine	proliferation	1654649	12376754
HPV18	L1	IHSMNSSIL	453	461	9	109331	P06794	HLA-B*39:01	I	PBMC	3H-thymidine	proliferation	1654650	12376754
HPV16	E6	MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDI	1	33	33	110338	P03126	HLA class I	I	T cell CD4-	ELISPOT	IFNg release	1654687	14712488
HPV16	E6	KLPQLCTELQTTIHDIILECVYCKQQLLRREV	18	49	32	110306	P03126	HLA class I	I	T cell CD4-	ELISPOT	IFNg release	1654717	14712488
HPV16	E6	FRDLCIVYRDGNPYAVCDKCLKFYSKISEYRHY	54	86	33	110227	P03126	HLA class I	I	T cell CD4-	ELISPOT	IFNg release	1654723	14712488
HPV16	E6	RCINCQKPLCPEEKQRHLDKKQRFHNIRGRWT	109	140	32	110394	P03126	HLA class I	I	T cell CD4-	ELISPOT	IFNg release	1654731	14712488
HPV16	E6	DKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL	127	158	32	110205	P03126	HLA class I	I	T cell CD4-	ELISPOT	IFNg release	1654734	14712488
HPV16	E6	DKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL	127	158	32	110205	P03126	HLA class I	I	T cell CD4-	ELISPOT	IFNg release	1654735	14712488
HPV16	E7	MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSS	1	32	32	110335	P03129	HLA class I	I	T cell CD4-	ELISPOT	IFNg release	1654737	14712488
HPV16	E7	MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSS	1	32	32	110335	P03129	HLA class I	I	T cell CD4-	ELISPOT	IFNg release	1654738	14712488
HPV16	E7	TDLYCYEQLNDSSEEEDEIDGPAGQAEPDRAHYNIV	20	55	36	110431	P03129	HLA class I	I	T cell CD4-	ELISPOT	IFNg release	1654740	14712488
HPV16	E7	TDLYCYEQLNDSSEEEDEIDGPAGQAEPDRAHYNIV	20	55	36	110431	P03129	HLA class I	I	T cell CD4-	ELISPOT	IFNg release	1654741	14712488
HPV16	E7	AGQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDI	42	76	35	110184	P03129	HLA class I	I	T cell CD4-	ELISPOT	IFNg release	1654743	14712488
HPV16	E7	AGQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDI	42	76	35	110184	P03129	HLA class I	I	T cell CD4-	ELISPOT	IFNg release	1654744	14712488
HPV18	E6	SLQDIEITCV	24	33	10	111789	P06463	HLA-A*02:01	I	PBMC	in vitro assay	cytotoxicity	1654800	9660068
HPV18	E6	LQDIEITCV	25	33	9	111512	P06463	HLA-A*02:01	I	PBMC	in vitro assay	cytotoxicity	1654802	9660068
HPV18	E6	ELTEVFEFA	40	48	9	111252	P06463	HLA-A*02:01	I	PBMC	in vitro assay	cytotoxicity	1654808	9660068
HPV18	E6	FAFKDLFVV	47	55	9	111266	P06463	HLA-A*02:01	I	PBMC	in vitro assay	cytotoxicity	1654812	9660068
HPV18	E6	KLTNTGLYNL	92	101	10	111462	P06463	HLA-A*02:01	I	PBMC	in vitro assay	cytotoxicity	1654818	9660068
HPV18	E6	KLPDLCTEL	13	21	9	32073	P06463	HLA-A*02:01	I	PBMC	in vitro assay	cytotoxicity	1654828	9660068
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-b class I	I	Splenocyte	51 chromium	cytotoxicity	1654835	17291642
HPV16	E6	QLLRREVYDFAFRDL	43	57	15	111677	P03126	H2-b class I	I	Splenocyte	51 chromium	cytotoxicity	1654836	17291642
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	Splenocyte	51 chromium	cytotoxicity	1654837	17291642
HPV16	E6	VYDFAFRDLC	49	58	10	111937	P03126	H2-b class I	I	Splenocyte	51 chromium	cytotoxicity	1654838	17291642
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	-	-	T cell	ICS	IFNg release	1654839	17291642
HPV16	E6	QLLRREVYDFAFRDL	43	57	15	111677	P03126	-	-	T cell	ICS	IFNg release	1654841	17291642
HPV16	E7	YEQLNDSSEEEDEI	25	38	14	111061	P03129	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1654866	1375481
HPV16	E7	YEQLNDSSEEEDEI	25	38	14	111061	P03129	HLA class II	II	T cell CD4+	51 chromium	cytotoxicity	1654867	1375481
HPV16	E7	HVDIRTLEDLLMGT	73	86	14	110895	P03129	HLA class II	II	T cell CD4+	51 chromium	cytotoxicity	1654868	1375481
HPV16	E7	HVDIRTLEDLLMGT	73	86	14	110895	P03129	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1654869	1375481
HPV16	E7	PETTDLYCYEQLND	17	30	14	110959	P03129	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1654871	1375481
HPV16	E7	DLYCYEQLNDSSEE	21	34	14	110808	P03129	HLA class II	II	T cell CD4+	51 chromium	cytotoxicity	1654872	1375481
HPV16	E7	DLYCYEQLNDSSEE	21	34	14	110808	P03129	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1654873	1375481
HPV16	E7	VQSTHVDIRTLEDL	69	82	14	111053	P03129	HLA class II	II	T cell CD4+	51 chromium	cytotoxicity	1654874	1375481
HPV16	E7	VQSTHVDIRTLEDL	69	82	14	111053	P03129	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1654875	1375481
HPV16	E7	TPTLHEYMLDLQPE	5	18	14	111046	P03129	HLA class II	II	T cell	3H-thymidine	proliferation	1654877	1375481
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Lymph node cells	51 chromium	cytotoxicity	1654878	9754566
HPV16	E7	CCKCDSTLRLC	58	68	11	110196	P03129	HLA-DR17	II	T cell CD4+	ELISPOT	IFNg release	1654969	18446336
HPV16	E6	KFYSKISEY	75	83	9	30892	P03126	HLA-B62	I	T cell CD8+	ELISPOT	IFNg release	1654972	18448624
HPV16	E6	KFYSKISEY	75	83	9	30892	P03126	HLA-B62	I	PBMC	ELISPOT	IFNg release	1654974	18448624
HPV16	E6	HNIRGRWTGR	133	142	10	110285	P03126	HLA-A*68:01	I	T cell CD8+	ELISPOT	IFNg release	1654976	18448624
HPV16	E6	HNIRGRWTGR	133	142	10	110285	P03126	HLA-A*68:01	I	PBMC	multimer/tetramer	qualitative binding	1654977	18448624
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1654982	10667589
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1654983	10667589
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	1654984	10667589
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	1654986	10667589
HPV16	L1	NLASSNYFPTPSGSM	311	325	15	110343	P03101	HLA class II	II	PBMC	bioassay	IL-2 release	1654989	10073700
HPV16	L1	PSGSMVTSDAQIFNK	321	335	15	110375	P03101	HLA class II	II	PBMC	bioassay	IL-2 release	1654990	10073700
HPV16	L1	PSGSMVTSDAQIFNK	321	335	15	110375	P03101	HLA class II	II	PBMC	bioassay	IL-2 release	1654992	10073700
HPV16	L1	NLASSNYFPTPSGSM	311	325	15	110343	P03101	HLA class II	II	PBMC	bioassay	IL-2 release	1654993	10073700
HPV16	L1	PSGSMVTSDAQIFNK	321	335	15	110375	P03101	HLA class II	II	PBMC	bioassay	IL-2 release	1654994	10073700
HPV16	L1	NLASSNYFPTPSGSM	311	325	15	110343	P03101	HLA class II	II	PBMC	bioassay	IL-2 release	1654995	10073700
HPV16	L1	PSGSMVTSDAQIFNK	321	335	15	110375	P03101	HLA class II	II	PBMC	bioassay	IL-2 release	1654996	10073700
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	1655054	10362134
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	1655055	10362134
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	1655056	9485027
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	51 chromium	cytotoxicity	1655057	9485027
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	51 chromium	cytotoxicity	1655058	9485027
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	51 chromium	cytotoxicity	1655059	9485027
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell CD8+	ELISA	IFNg release	1655061	9748126
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	51 chromium	cytotoxicity	1655072	9621057
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	51 chromium	cytotoxicity	1655073	9621057
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	1655074	9601506
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	1655075	9601506
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	Splenocyte	51 chromium	cytotoxicity	1655077	9601506
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	Splenocyte	51 chromium	cytotoxicity	1655079	9601506
HPV16	E6	VYDFAFRDL	49	57	9	71988	P03126	HLA-A*24:02	I	T cell CD8+	ICS	IFNg release	1655092	17096336
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	-	-	Splenocyte	ELISA	IFNg release	1655093	15330171
HPV16	E6	VYDFAFRDL	49	57	9	71988	P03126	HLA-A*24:02	I	T cell CD8+	51 chromium	cytotoxicity	1655094	17096336
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	-	-	Splenocyte	ELISA	IFNg release	1655095	15330171
HPV16	E7	PAGQAEPDRAHYNIVTFCCKCD	41	62	22	110348	P03129	-	-	Splenocyte	ELISA	IFNg release	1655096	15330171
HPV16	E7	PAGQAEPDRAHYNIVTFCCKCD	41	62	22	110348	P03129	-	-	Splenocyte	ELISA	IFNg release	1655097	15330171
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	-	in vivo assay	cytotoxicity	1655098	15330171
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	-	in vivo assay	cytotoxicity	1655099	15330171
HPV16	E6	VYDFAFRDL	49	57	9	71988	P03126	HLA-A*24:02	I	T cell CD8+	51 chromium	cytotoxicity	1655102	17096336
HPV16	E6	VYDFAFRDL	49	57	9	71988	P03126	HLA-A*24:02	I	T cell CD8+	ELISA	IFNg release	1655129	17096336
HPV16	E6	VYDFAFRDL	49	57	9	71988	P03126	HLA-A*24:02	I	T cell CD8+	51 chromium	cytotoxicity	1655133	17096336
HPV16	E6	VYDFAFRDL	49	57	9	71988	P03126	HLA-A*24:02	I	T cell CD8+	multimer/tetramer	qualitative binding	1655136	17096336
HPV16	E6	VYDFAFRDL	49	57	9	71988	P03126	HLA-A*24:02	I	T cell CD8+	multimer/tetramer	qualitative binding	1655137	17096336
HPV16	E7	EIDGPAGQAEPDRAHYNI	37	54	18	110828	P03129	HLA class II	II	PBMC	3H-thymidine	proliferation	1655138	12010863
HPV16	E7	EIDGPAGQAEPDRAHYNI	37	54	18	110828	P03129	HLA class II	II	PBMC	3H-thymidine	proliferation	1655139	12010863
HPV16	E6	PRKLPQLCTELQTTI	9	23	15	110967	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1655140	12010863
HPV16	E6	PRKLPQLCTELQTTI	9	23	15	110967	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1655141	12010863
HPV16	E6	PRKLPQLCTELQTTIHDIILECVYC	16	40	25	110373	P03126	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1655512	16085919
HPV16	E6	HDIILECVYCKQQLLRREVYDFAFR	31	55	25	110282	P03126	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1655513	16085919
HPV16	E6	RREVYDFAFRDLCIVYRDGNPYAVC	46	70	25	110401	P03126	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1655514	16085919
HPV16	E6	YRDGNPYAVCDKCLKFYSKISEYRH	61	85	25	110467	P03126	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1655515	16085919
HPV16	E6	EKQRHLDKKQRFHNIRGRWTGRCMS	121	145	25	110215	P03126	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1655519	16085919
HPV16	E6	RGRWTGRCMSCCRSSRTRRETQL	136	158	23	110399	P03126	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1655520	16085919
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	1655633	10915608
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	1655634	10915608
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD4-	ELISPOT	IFNg release	1655646	11406153
HPV16	L1	YYHAGTSRL	60	68	9	110750	P03101	H2-d class I	I	T cell CD4-	ELISPOT	IFNg release	1655647	11406153
HPV16	E1	LYGVSFSEL	214	222	9	110667	P03114	H2-d class I	I	T cell CD4-	ELISPOT	IFNg release	1655648	11406153
HPV16	E1	WYKTGISNI	321	329	9	110740	P03114	-	-	T cell CD8-/CD4-	ELISPOT	IFNg release	1655649	11406153
HPV16	E1	SFLTALKRFL	455	464	10	110704	P03114	-	-	T cell	ELISPOT	IFNg release	1655650	11406153
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR	43	77	35	110276	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1655651	12077264
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR	43	77	35	110276	P03129	H2-Db	I	T cell CD4+	ICS	IFNg release	1655652	12077264
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR	43	77	35	110276	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	1655653	12077264
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR	43	77	35	110276	P03129	H2-Db	I	T cell CD8+	ELISA	IFNg release	1655654	12077264
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR	43	77	35	110276	P03129	H2-Db	I	-	in vivo assay	survival from challenge	1655655	12077264
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1655728	17108051
HPV16	E6	FAFRDLCIVY	52	61	10	110575	P03126	HLA-B35	I	T cell CD8+	ELISPOT	IFNg release	1655979	17108051
HPV16	E7	YEQLNDSSEEEDEIDG	25	40	16	110460	P03129	H2-d class II	II	T cell CD4+	3H-thymidine	proliferation	1655985	7483818
HPV16	E7	AHYNIVTFCCK	50	60	11	110187	P03129	H2-d class II	II	T cell CD4+	3H-thymidine	proliferation	1655991	7483818
HPV16	E6	TIHDIILEC	29	37	9	110720	P03126	HLA-B*48:01	I	T cell CD8+	ELISPOT	IFNg release	1655999	17108051
HPV16	E6	HDIILECV	31	38	8	110624	P03126	HLA-B*40:02	I	T cell CD8+	ELISPOT	IFNg release	1656004	17108051
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656005	17108051
HPV16	E6	FAFRDLCIVY	52	61	10	110575	P03126	HLA-B35	I	T cell CD8+	51 chromium	cytotoxicity	1656006	17108051
HPV16	E6	TIHDIILEC	29	37	9	110720	P03126	HLA-B*48:01	I	T cell CD8+	51 chromium	cytotoxicity	1656007	17108051
HPV16	E6	HDIILECV	31	38	8	110624	P03126	HLA-B*40:02	I	T cell CD8+	51 chromium	cytotoxicity	1656008	17108051
HPV16	E6	VYDFAFQDL	42	50	9	111055	P03126	HLA-A24	I	T cell CD8+	ELISA	IFNg release	1656009	16211234
HPV16	E6	EYRHYCYSL	75	83	9	110846	P03126	HLA-A24	I	T cell CD8+	ELISA	IFNg release	1656010	16211234
HPV16	E6	QYNKPLCDLL	91	100	10	110982	P03126	HLA-A24	I	T cell CD8+	ELISA	IFNg release	1656011	16211234
HPV16	E6	EYRHYCYSL	75	83	9	110846	P03126	HLA-A24	I	T cell CD8+	51 chromium	cytotoxicity	1656012	16211234
HPV16	E6	QYNKPLCDLL	91	100	10	110982	P03126	HLA-A24	I	T cell CD8+	51 chromium	cytotoxicity	1656014	16211234
HPV16	E7	QAEPDRAHYNIVTF	44	57	14	111662	P03129	H2-b class I	I	Splenocyte	51 chromium	cytotoxicity	1656016	11395193
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1656019	17962940
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Lymphocyte	ELISPOT	IFNg release	1656025	17962940
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	PBMC	ELISA	IFNg release	1656030	11325845
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell	in vitro assay	cytotoxicity	1656033	11325845
HPV16	L1	AGVDNRECI	165	173	9	110186	P03101	H2-Db	I	Splenocyte	ELISPOT	IFNg release	1656044	12663770
HPV1a	L1	TDEYVTRTNLFYHA	30	43	14	110430	P03099	HLA-DRB1*04:01	II	PBMC	3H-thymidine	proliferation	1656045	1689768
HPV6b	L1	TDAYVTRTNIFYHA	23	36	14	110428	P04012	HLA-DRB1*04:01	II	PBMC	3H-thymidine	proliferation	1656046	1689768
HPV33	L1	TDEYVSRTSIYYYA	24	37	14	110429	P03101	HLA-DRB1*04:01	II	PBMC	3H-thymidine	proliferation	1656047	1689768
HPV18	L1	VSAYQYRVFRVQLPDP	126	141	16	110454	P06794	HLA-DRB1*04:01	II	PBMC	3H-thymidine	proliferation	1656048	1689768
HPV33	L1	VSGLQYRVFRVRLPDP	66	81	16	110455	P03101	HLA-DRB1*04:01	II	PBMC	3H-thymidine	proliferation	1656049	1689768
HPV16	E1	TLLQQYCLYL	253	262	10	110439	P03114	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	1656057	17325352
HPV16	E2	ALQAIELQL	69	77	9	108770	P03120	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	1656058	17325352
HPV16	E2	TLQDVSLEV	93	101	9	109984	P03120	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	1656060	17325352
HPV16	E2	YICEEASVTV	138	147	10	110125	P03120	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	1656062	17325352
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell CD8+	51 chromium	cytotoxicity	1656116	10479508
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell CD8+	51 chromium	cytotoxicity	1656117	10479508
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell CD8+	3H-thymidine	proliferation	1656118	10479508
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A2	I	T cell CD8+	51 chromium	cytotoxicity	1656119	10479508
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A2	I	T cell CD8+	51 chromium	cytotoxicity	1656122	10479508
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	Splenocyte	in vitro assay	cytotoxicity	1656141	15846491
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell CD8+	ELISA	IFNg release	1656142	17439726
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	-	-	-	in vivo assay	survival from challenge	1656145	9754652
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656151	17439726
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell CD8+	ELISPOT	IFNg release	1656152	15819706
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell CD8+	in vitro assay	cytotoxicity	1656153	15819706
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell CD8+	ELISPOT	IFNg release	1656154	15819706
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell CD8+	ELISPOT	IFNg release	1656155	15819706
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell CD8+	ELISPOT	IFNg release	1656156	15819706
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A2	I	T cell CD8+	ELISPOT	IFNg release	1656157	15819706
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A2	I	T cell CD8+	in vitro assay	cytotoxicity	1656158	15819706
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A2	I	T cell CD8+	ELISPOT	IFNg release	1656159	15819706
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A2	I	T cell CD8+	ELISPOT	IFNg release	1656160	15819706
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A2	I	T cell CD8+	ELISPOT	IFNg release	1656161	15819706
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell CD8+	ELISA	IFNg release	1656162	17439726
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656164	17439726
HPV18	E6	DIEITCVYCKTVLEL	27	41	15	111198	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IFNg release	1656208	17982110
HPV18	E6	DIEITCVYCKTVLEL	27	41	15	111198	P06463	HLA-DR	II	T cell CD4+	bioassay	IL-5 release	1656215	17982110
HPV18	E6	DIEITCVYCKTVLEL	27	41	15	111198	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-4 release	1656216	17982110
HPV18	E6	DIEITCVYCKTVLEL	27	41	15	111198	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IFNg release	1656225	17982110
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	Dendritic cell	ELISA	IL-12 release	1656230	17439726
HPV18	E6	DIEITCVYCKTVLEL	27	41	15	111198	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-10 release	1656232	17982110
HPV18	E6	DIEITCVYCKTVLEL	27	41	15	111198	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-5 release	1656233	17982110
HPV18	E6	DIEITCVYCKTVLEL	27	41	15	111198	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-4 release	1656234	17982110
HPV18	E6	DIEITCVYCKTVLEL	27	41	15	111198	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IFNg release	1656238	17982110
HPV18	E6	DIEITCVYCKTVLEL	27	41	15	111198	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-10 release	1656239	17982110
HPV18	E6	DIEITCVYCKTVLEL	27	41	15	111198	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-5 release	1656240	17982110
HPV18	E6	DIEITCVYCKTVLEL	27	41	15	111198	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-4 release	1656241	17982110
HPV16	L2	LVEETSFIDAGAP	108	120	13	97484	P03107	H2-d class II	II	-	biological activity	antibody help	1656298	11163673
HPV18	E6	DIEITCVYCKTVLEL	27	41	15	111198	P06463	HLA-DR	II	T cell CD4+	3H-thymidine	proliferation	1656311	17982110
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	in vitro assay	cytotoxicity	1656312	9807734
HPV18	E6	LFVVYRDSIPHAACH	52	66	15	110656	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IFNg release	1656323	17982110
HPV18	E6	LFVVYRDSIPHAACH	52	66	15	110656	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IFNg release	1656324	17982110
HPV18	E6	LFVVYRDSIPHAACH	52	66	15	110656	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-10 release	1656325	17982110
HPV18	E6	LFVVYRDSIPHAACH	52	66	15	110656	P06463	HLA-DR	II	T cell CD4+	bioassay	IL-5 release	1656326	17982110
HPV18	E6	LFVVYRDSIPHAACH	52	66	15	110656	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-4 release	1656327	17982110
HPV18	E6	LFVVYRDSIPHAACH	52	66	15	110656	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IFNg release	1656328	17982110
HPV18	E6	LFVVYRDSIPHAACH	52	66	15	110656	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-10 release	1656329	17982110
HPV18	E6	LFVVYRDSIPHAACH	52	66	15	110656	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-5 release	1656330	17982110
HPV18	E6	LFVVYRDSIPHAACH	52	66	15	110656	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-4 release	1656331	17982110
HPV18	E6	LFVVYRDSIPHAACH	52	66	15	110656	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-5 release	1656333	17982110
HPV18	E6	LFVVYRDSIPHAACH	52	66	15	110656	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-4 release	1656334	17982110
HPV18	E6	LFVVYRDSIPHAACH	52	66	15	110656	P06463	HLA-DR	II	T cell CD4+	3H-thymidine	proliferation	1656335	17982110
HPV18	E6	GLYNLLIRCLRCQKP	97	111	15	110605	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IFNg release	1656337	17982110
HPV18	E6	GLYNLLIRCLRCQKP	97	111	15	110605	P06463	HLA-DR	II	T cell CD4+	bioassay	IL-5 release	1656340	17982110
HPV18	E6	GLYNLLIRCLRCQKP	97	111	15	110605	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IFNg release	1656342	17982110
HPV18	E6	GLYNLLIRCLRCQKP	97	111	15	110605	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-10 release	1656343	17982110
HPV18	E6	GLYNLLIRCLRCQKP	97	111	15	110605	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-5 release	1656344	17982110
HPV18	E6	GLYNLLIRCLRCQKP	97	111	15	110605	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-4 release	1656345	17982110
HPV18	E6	GLYNLLIRCLRCQKP	97	111	15	110605	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-10 release	1656346	17982110
HPV18	E6	GLYNLLIRCLRCQKP	97	111	15	110605	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-5 release	1656347	17982110
HPV18	E6	GLYNLLIRCLRCQKP	97	111	15	110605	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-4 release	1656348	17982110
HPV18	E6	GLYNLLIRCLRCQKP	97	111	15	110605	P06463	HLA-DR	II	T cell CD4+	3H-thymidine	proliferation	1656349	17982110
HPV18	E6	GLYNLLIRCLRCQKP	97	111	15	110605	P06463	HLA-DR	II	T cell CD4+	3H-thymidine	proliferation	1656350	17982110
HPV18	E6	CLRCQKPLNPAEKLR	105	119	15	110556	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IFNg release	1656351	17982110
HPV18	E6	CLRCQKPLNPAEKLR	105	119	15	110556	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IFNg release	1656352	17982110
HPV18	E6	CLRCQKPLNPAEKLR	105	119	15	110556	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-4 release	1656355	17982110
HPV18	E6	CLRCQKPLNPAEKLR	105	119	15	110556	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IFNg release	1656356	17982110
HPV18	E6	CLRCQKPLNPAEKLR	105	119	15	110556	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-10 release	1656357	17982110
HPV18	E6	CLRCQKPLNPAEKLR	105	119	15	110556	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-5 release	1656358	17982110
HPV18	E6	CLRCQKPLNPAEKLR	105	119	15	110556	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-10 release	1656360	17982110
HPV18	E6	CLRCQKPLNPAEKLR	105	119	15	110556	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-5 release	1656361	17982110
HPV18	E6	CLRCQKPLNPAEKLR	105	119	15	110556	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-4 release	1656362	17982110
HPV18	E6	CLRCQKPLNPAEKLR	105	119	15	110556	P06463	HLA-DR	II	T cell CD4+	3H-thymidine	proliferation	1656363	17982110
HPV18	E6	CVYCKTVLELTEVPAV	32	47	16	111181	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IFNg release	1656365	17982110
HPV18	E6	CVYCKTVLELTEVPAV	32	47	16	111181	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IFNg release	1656366	17982110
HPV18	E6	CVYCKTVLELTEVPAV	32	47	16	111181	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-10 release	1656367	17982110
HPV18	E6	CVYCKTVLELTEVPAV	32	47	16	111181	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IFNg release	1656370	17982110
HPV18	E6	CVYCKTVLELTEVPAV	32	47	16	111181	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-10 release	1656371	17982110
HPV18	E6	CVYCKTVLELTEVPAV	32	47	16	111181	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-5 release	1656372	17982110
HPV18	E6	CVYCKTVLELTEVPAV	32	47	16	111181	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-4 release	1656373	17982110
HPV18	E6	CVYCKTVLELTEVPAV	32	47	16	111181	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-10 release	1656374	17982110
HPV18	E6	CVYCKTVLELTEVPAV	32	47	16	111181	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-5 release	1656375	17982110
HPV18	E6	CVYCKTVLELTEVPAV	32	47	16	111181	P06463	HLA-DR	II	T cell CD4+	cytometric bead array	IL-4 release	1656376	17982110
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell CD8+	multimer/tetramer	qualitative binding	1656408	16284959
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell	ELISPOT	IFNg release	1656412	16284959
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell	ELISPOT	IFNg release	1656413	16284959
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A2	I	T cell CD8+	multimer/tetramer	qualitative binding	1656417	16284959
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A2	I	T cell	ELISPOT	IFNg release	1656418	16284959
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A2	I	T cell	ELISPOT	IFNg release	1656419	16284959
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	1656434	9807734
HPV18	E6	LFVVYRDSIPHAACH	52	66	15	110656	P06463	HLA-DR	II	T cell CD4+	3H-thymidine	proliferation	1656439	15719368
HPV18	E6	GLYNLLIRCLRCQKP	97	111	15	110605	P06463	HLA-DR	II	T cell CD4+	3H-thymidine	proliferation	1656440	15719368
HPV18	E6	GLYNLLIRCLRCQKP	97	111	15	110605	P06463	HLA-DR	II	T cell CD4+	ELISA	IFNg release	1656442	15719368
HPV18	E6	LFVVYRDSIPHAACH	52	66	15	110656	P06463	HLA-DR	II	T cell CD4+	ELISA	IFNg release	1656443	15719368
HPV18	E6	LFVVYRDSIPHAACH	52	66	15	110656	P06463	HLA-DR	II	T cell CD4+	ELISA	IFNg release	1656444	15719368
HPV18	E6	GLYNLLIRCLRCQKP	97	111	15	110605	P06463	HLA-DR	II	T cell CD4+	ELISA	IFNg release	1656445	15719368
HPV18	E6	GLYNLLIRCLRCQKP	97	111	15	110605	P06463	HLA-DR	II	T cell CD4+	51 chromium	cytotoxicity	1656446	15719368
HPV18	E6	GLYNLLIRCLRCQKP	97	111	15	110605	P06463	HLA-DR	II	T cell CD4+	51 chromium	cytotoxicity	1656447	15719368
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	51 chromium	cytotoxicity	1656450	9862352
HPV33	E7	ASDLRTIQQLLMGTV	73	87	15	110792	P03129	HLA-DRB1*04:02	II	T cell CD4+	ELISA	IFNg release	1656470	10864677
HPV33	E7	ASDLRTIQQLLMGTV	73	87	15	110792	P03129	HLA-DRB1*04:01	II	T cell CD4+	ELISA	IFNg release	1656555	10864677
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656556	9225046
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656557	9225046
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656563	9225046
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656564	9225046
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	1656573	12744885
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1656574	12744885
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	51 chromium	cytotoxicity	1656576	12744885
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD8+	51 chromium	cytotoxicity	1656578	17602804
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	Splenocyte	ELISA	IFNg release	1656579	17602804
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	1656678	11559797
HPV16	E5	YIIFVYIPL	63	71	9	110744	P06927	HLA-A*02:01	I	T cell CD8+	ICS	IFNg release	1656681	17202211
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	1656683	11559797
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	TNFa release	1656684	11559797
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1656685	11559797
HPV16	E5	YIIFVYIPL	63	71	9	110744	P06927	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656686	17202211
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1656697	11559797
HPV16	E5	FLLCFCVLL	15	23	9	110579	P06927	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656708	17202211
HPV16	E5	VLLCVCLLI	21	29	9	110736	P06927	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656709	17202211
HPV16	E5	VLLLWITAA	46	54	9	110737	P06927	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656711	17202211
HPV16	E5	FLLCFCVLL	15	23	9	110579	P06927	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1656712	17202211
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	1656713	11559797
HPV16	E5	VLLCVCLLI	21	29	9	110736	P06927	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1656714	17202211
HPV16	E5	VLLLWITAA	46	54	9	110737	P06927	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1656715	17202211
HPV16	E5	YIIFVYIPL	63	71	9	110744	P06927	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1656716	17202211
HPV16	E5	YIIFVYIPL	63	71	9	110744	P06927	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656717	17202211
HPV16	E5	YIIFVYIPL	63	71	9	110744	P06927	HLA-A*02:01	I	T cell CD8+	ELISA	IFNg release	1656719	17202211
HPV16	E6	TIHDIILEC	29	37	9	110720	P03126	HLA-B*48:01	I	T cell CD8+	ELISPOT	IFNg release	1656753	17108051
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1656759	17108051
HPV16	E6	HDIILECV	31	38	8	110624	P03126	HLA-B*40:02	I	T cell CD8+	ELISPOT	IFNg release	1656761	17108051
HPV16	E6	FAFRDLCIVY	52	61	10	110575	P03126	HLA-B35	I	T cell CD8+	ELISPOT	IFNg release	1656764	17108051
HPV18	E6	LQDIEITCV	25	33	9	111512	P06463	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656797	11300474
HPV18	E6	ELTEVFEFA	40	48	9	111252	P06463	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656799	11300474
HPV18	E6	KTVLELTEV	36	44	9	111465	P06463	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656800	11300474
HPV18	E6	KLPDLCTEL	13	21	9	32073	P06463	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656801	11300474
HPV18	E6	FAFKDLFVV	47	55	9	111266	P06463	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656802	11300474
HPV18	E7	TLQDIVLHL	7	15	9	110440	P06788	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1656803	11300474
HPV16	E6	TELQTTIHDIILECVYCK	24	41	18	110718	P03126	H2-q class II	II	Lymph node cells	3H-thymidine	proliferation	1656808	11172923
HPV16	E7	DLYCYEQL	21	28	8	110208	P03129	H2-Kb	I	T cell	51 chromium	cytotoxicity	1656809	7660065
HPV16	E6	VCDKCLKFYSKISEYRHY	69	86	18	110730	P03126	H2-q class II	II	Lymph node cells	3H-thymidine	proliferation	1656810	11172923
HPV16	E7	DRAHYNIV	48	55	8	110813	P03129	H2-Kb	I	T cell	51 chromium	cytotoxicity	1656827	7660065
HPV16	E7	DLYCYEQL	21	28	8	110208	P03129	H2-Kb	I	T cell	51 chromium	cytotoxicity	1656828	7660065
HPV16	E7	DRAHYNIV	48	55	8	110813	P03129	H2-Kb	I	T cell	51 chromium	cytotoxicity	1656829	7660065
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	Splenocyte	51 chromium	cytotoxicity	1656830	12718907
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	-	in vivo assay	tumor burden after challenge	1656831	12718907
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	-	in vivo assay	decreased disease	1656832	12718907
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	Splenocyte	51 chromium	cytotoxicity	1656834	12718907
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	1656835	15480657
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	Splenocyte	51 chromium	cytotoxicity	1656837	15480657
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	Splenocyte	ELISPOT	IFNg release	1656839	15480657
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	1656840	15480657
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	-	in vivo assay	pathogen burden after challenge	1656865	17602804
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1656910	17548594
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1656919	17548594
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1656920	17548594
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1656921	17548594
HPV16	E5	VCLLIRPLL	25	33	9	110731	P06927	H2-b class I	I	T cell CD8+	ICS	IFNg release	1656929	14722288
HPV16	L1	AGVDNRECI	165	173	9	110186	P03101	H2-Db	I	T cell	51 chromium	cytotoxicity	1656942	17548594
HPV16	L1	AGVDNRECI	165	173	9	110186	P03101	H2-Db	I	T cell	51 chromium	cytotoxicity	1656943	17548594
HPV16	E5	STYTSLIIL	37	45	9	110712	P06927	H2-b class I	I	T cell CD8+	ICS	IFNg release	1656948	14722288
HPV16	E7	DSSEEEDEIDGPAGQAEPDRAHYNIVTFCCKCDSTLRL	30	67	38	110567	P03129	H2-b class II	II	T cell CD4+	ELISPOT	IFNg release	1656954	17548594
HPV16	E5	VCLLIRPLL	25	33	9	110731	P06927	H2-b class I	I	T cell CD8+	ICS	IFNg release	1656966	14722288
HPV16	E5	VCLLIRPLL	25	33	9	110731	P06927	H2-b class I	I	-	in vivo assay	tumor burden after challenge	1656975	14722288
HPV16	E5	VCLLIRPLL	25	33	9	110731	P06927	H2-b class I	I	-	in vivo assay	decreased disease	1656976	14722288
HPV16	E7	PETTDLYCYEQLNDSSEEEDE	17	37	21	110960	P03129	H2-q class II	II	Mononuclear cell	3H-thymidine	proliferation	1656981	9143315
HPV16	E7	GQAEPDRAHYNIVTFCCKCD	43	62	20	110869	P03129	H2-Db	I	Mononuclear cell	3H-thymidine	proliferation	1656983	9143315
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell	ELISPOT	IFNg release	1656985	11291058
HPV16	L1	ICWGNQLFV	349	357	9	110629	P03101	HLA-A*02:01	I	T cell	ICS	IFNg release	1656986	11291058
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1656989	11291058
HPV16	L1	ICWGNQLFV	349	357	9	110629	P03101	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1656990	11291058
HPV16	E6	EVYDFAFRDL	48	57	10	14909	P03126	H2-Kb	I	T cell CD8+	ICS	IFNg release	1656994	15280455
HPV16	E6	EVYDFAFRDL	48	57	10	14909	P03126	H2-Kb	I	T cell CD8+	51 chromium	cytotoxicity	1657032	15280455
HPV16	E7	CDSTLRLCVQSTHVDIRTLE	61	80	20	111146	P03129	HLA-DRB1*09:01	II	T cell CD4+	ICS	IL-4 release	1657036	15009616
HPV16	E7	DLLMGTLGIVCPICSQKP	81	98	18	108870	P03129	HLA-DRB1*09:01	II	T cell CD4+	ICS	IL-4 release	1657037	15009616
HPV16	E7	CDSTLRLCVQSTHVDIRTLE	61	80	20	111146	P03129	HLA-DRB1*09:01	II	T cell CD4+	ICS	TNF release	1657039	15009616
HPV16	E7	CDSTLRLCVQSTHVDIRTLE	61	80	20	111146	P03129	HLA-DRB1*09:01	II	T cell CD4+	ICS	IFNg release	1657040	15009616
HPV16	E7	DLLMGTLGIVCPICSQKP	81	98	18	108870	P03129	HLA-DRB1*09:01	II	T cell CD4+	ICS	TNF release	1657041	15009616
HPV59	E7	LFMDTLSFVCPLC	91	103	13	110655	P06788	HLA-DR4	II	T cell CD4+	ELISA	TNF release	1657042	10553103
HPV68	E7	LFMDSLNFVCPWC	93	105	13	110654	P06788	HLA-DR4	II	T cell CD4+	ELISA	TNF release	1657044	10553103
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	ELISPOT	IFNg release	1657046	12534940
HPV16	E7	QAEPD	44	48	5	110376	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1657057	7544248
HPV16	E7	QAEPD	44	48	5	110376	P03129	H2-b class II	II	Lymph node cells	bioassay	IL-2 release	1657058	7544248
HPV16	E7	QAEPD	44	48	5	110376	P03129	H2-b class II	II	Lymph node cells	bioassay	IL-4 release	1657059	7544248
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Lymph node cells	51 chromium	cytotoxicity	1657060	7544248
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Lymph node cells	51 chromium	cytotoxicity	1657061	7544248
HPV16	E7	QAEPD	44	48	5	110376	P03129	-	-	-	in vivo assay	survival from challenge	1657067	7544248
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	in vitro assay	cytotoxicity	1657069	7589138
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	in vitro assay	cytotoxicity	1657070	7589138
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	1657072	7589138
HPV16	E6	HYCYSVYGTTLEQQY	85	99	15	111406	P03126	HLA-DR	II	T cell CD4+	ICS	IFNg release	1657074	17412975
HPV16	E6	LPQLCTELQTTIHDI	19	33	15	111508	P03126	HLA class II	II	PBMC	ELISPOT	IFNg release	1657076	17412975
HPV18	E6	FKDLFVVYRDSIPHA	49	63	15	111278	P06463	HLA-DR	II	T cell CD4+	ELISPOT	IFNg release	1657077	17412975
HPV18	E6	EVFEFAFKDLFVVYR	43	57	15	111263	P06463	HLA-DR15	II	T cell CD4+	ELISPOT	IFNg release	1657078	17412975
HPV16	E6	DKKQRFHNIRGRWTG	127	141	15	111200	P03126	HLA-DR1	II	T cell CD4+	ICS	IFNg release	1657079	17412975
HPV16	E4	PAATKPLLKLLGSTWPTTPPRPIPK	0	0	25	111608	P06922	HLA class II	II	PBMC	3H-thymidine	proliferation	1657080	8991637
HPV16	E4	PAATKPLLKLLGSTWPTTPPRPIPK	0	0	25	111608	P06922	HLA class II	II	PBMC	3H-thymidine	proliferation	1657081	8991637
HPV16	E6	TELQTTIHDILLECVYCKQQLL	24	45	22	111824	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1657083	8991637
HPV16	E6	RCINCQKPLCPEEK	109	122	14	111709	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1657084	8991637
HPV16	E6	RCINCQKPLCPEEK	109	122	14	111709	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1657085	8991637
HPV16	E7	QAEPDRAHYNIVTF	44	57	14	111662	P03129	HLA class II	II	PBMC	3H-thymidine	proliferation	1657088	8991637
HPV16	E7	QAEPDRAHYNIVTF	44	57	14	111662	P03129	HLA class II	II	PBMC	3H-thymidine	proliferation	1657089	8991637
HPV16	L1	LNTNFKEYLRHGEEY	0	0	15	111502	P03101	HLA class II	II	PBMC	3H-thymidine	proliferation	1657090	8991637
HPV16	L1	LNTNFKEYLRHGEEY	0	0	15	111502	P03101	HLA class II	II	PBMC	3H-thymidine	proliferation	1657091	8991637
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell CD8+	51 chromium	cytotoxicity	1657092	8987945
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A2	I	T cell CD8+	51 chromium	cytotoxicity	1657093	8987945
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1657094	11673561
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1657095	11673561
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	51 chromium	cytotoxicity	1657096	8574470
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1657097	11673561
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	51 chromium	cytotoxicity	1657098	8574470
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	bioassay	TNFa release	1657100	8574470
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	bioassay	TNFa release	1657101	8574470
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	1657102	8574470
HPV16	E6	VYDFAFRDL	49	57	9	71988	P03126	H2-Kb	I	T cell CD8+	ICS	IFNg release	1657115	17931752
HPV16	E6	VYDFAFRDL	49	57	9	71988	P03126	H2-Kb	I	T cell CD8+	in vitro assay	cytotoxicity	1657116	17931752
HPV16	E6	VYDFAFRDL	49	57	9	71988	P03126	H2-Kb	I	-	in vivo assay	tumor burden after challenge	1657117	17931752
HPV6b	E7	GLHCYEQLV	22	30	9	110601	P04020	HLA-A2	I	T cell CD8+	51 chromium	cytotoxicity	1657119	8157270
HPV6b	E7	GLHCYEQLV	22	30	9	110601	P04020	HLA-A2	I	T cell CD8+	51 chromium	cytotoxicity	1657120	8157270
HPV6b	E7	PLKQHFQIV	47	55	9	110684	P04020	HLA-A2	I	T cell CD8+	51 chromium	cytotoxicity	1657121	8157270
HPV6b	E7	PLKQHFQIV	47	55	9	110684	P04020	HLA-A2	I	T cell CD8+	51 chromium	cytotoxicity	1657122	8157270
HPV11	E7	RLVTLKDIV	4	12	9	54814	P04020	HLA-A2	I	T cell CD8+	51 chromium	cytotoxicity	1657125	8157270
HPV11	E7	RLVTLKDIV	4	12	9	54814	P04020	HLA-A2	I	T cell CD8+	51 chromium	cytotoxicity	1657128	8157270
HPV11	E7	RLVTLKDIV	4	12	9	54814	P04020	HLA-A2	I	T cell CD8+	51 chromium	cytotoxicity	1657129	8157270
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1657194	17439726
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	Splenocyte	ELISPOT	IFNg release	1657219	16472545
HPV16	L1	TNIYYHAGTSRLLAVGHPYF	57	76	20	110724	P03101	-	-	Splenocyte	ELISPOT	IFNg release	1657267	11406153
HPV16	E7	GQAEPDRAHYNIVTFCCKCD	43	62	20	110869	P03129	H2-Db	I	Lymph node cells	51 chromium	cytotoxicity	1657272	9143315
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	PBMC	51 chromium	cytotoxicity	1657285	9230206
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	PBMC	51 chromium	cytotoxicity	1657286	9230206
HPV16	E7	STHVDIRTLEDLLMG	71	85	15	111032	P03129	HLA-DQB1*02:01	II	T cell CD4+	ELISPOT	IFNg release	1657331	17438108
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	PBMC	51 chromium	cytotoxicity	1657336	9230206
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	PBMC	51 chromium	cytotoxicity	1657337	9230206
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	PBMC	51 chromium	cytotoxicity	1657338	9230206
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	PBMC	51 chromium	cytotoxicity	1657339	9230206
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	PBMC	51 chromium	cytotoxicity	1657340	9230206
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	PBMC	51 chromium	cytotoxicity	1657341	9230206
HPV16	E7	STHVDIRTLEDLLMG	71	85	15	111032	P03129	HLA-DQB1*02:01	II	T cell CD4+	ICS	TNF release	1657343	17438108
HPV16	E7	STHVDIRTLEDLLMG	71	85	15	111032	P03129	HLA-DQB1*02:01	II	T cell CD4+	ICS	IL-2 release	1657344	17438108
HPV16	E7	STHVDIRTLEDLLMG	71	85	15	111032	P03129	HLA-DQB1*02:01	II	T cell CD4+	ICS	IFNg release	1657347	17438108
HPV16	E7	STHVDIRTLEDLLMG	71	85	15	111032	P03129	HLA-DQB1*02:01	II	PBMC	ELISPOT	IFNg release	1657348	17438108
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	51 chromium	cytotoxicity	1657363	9094677
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	51 chromium	cytotoxicity	1657367	9094677
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	survival from challenge	1657369	9094677
HPV16	L1	NLASSNYFPTPSGSM	311	325	15	110343	P03101	HLA class II	II	PBMC	3H-thymidine	proliferation	1657381	8627247
HPV16	L1	PSGSMVTSDAQIFNK	321	335	15	110375	P03101	HLA class II	II	PBMC	3H-thymidine	proliferation	1657394	8627247
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	-	-	-	in vivo assay	tumor burden after challenge	1657398	16112257
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD8+	ELISA	IFNg release	1657409	16112257
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	-	-	Splenocyte	ELISA	IL-10 release	1657411	16112257
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD8+	ELISPOT	IFNg release	1657413	16112257
HPV18	E7	DGVNHQHLPARRAE	42	55	14	111195	P06788	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1657422	7542826
HPV18	E7	DDLRAFQQLFLNTLSFVCPW	81	100	20	111188	P06788	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1657426	7542826
HPV18	E6	KCIDFYSRI	67	75	9	111442	P06463	HLA-A*02:01	I	Splenocyte	ELISPOT	IFNg release	1657431	16353149
HPV18	E6	KCIDFYSRI	67	75	9	111442	P06463	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1657437	16353149
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	1657445	12534940
HPV16	E1	LYGVSFSEL	214	222	9	110667	P03114	H2-Kd	I	Splenocyte	ELISPOT	IFNg release	1657472	14959826
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	ELISPOT	IFNg release	1657473	16052529
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	ELISPOT	IFNg release	1657474	16052529
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	1657480	16675074
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-b class I	I	Splenocyte	51 chromium	cytotoxicity	1657481	16052529
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	-	-	-	in vivo assay	tumor burden after challenge	1657482	16052529
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	-	-	PBMC	ELISPOT	IFNg release	1657483	16052529
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	1657484	16675074
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	in vitro assay	cytotoxicity	1657486	16675074
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1657492	16675074
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	ELISPOT	IFNg release	1657493	16675074
HPV16	E6	QLLRREVYDFAFRDL	43	57	15	111677	P03126	H2-b class I	I	Lymph node cells	51 chromium	cytotoxicity	1657502	8833270
HPV16	E6	QLLRREVYDFAFRDL	43	57	15	111677	P03126	H2-b class I	I	Lymph node cells	51 chromium	cytotoxicity	1657505	8833270
HPV16	L1	AGVDNRECI	165	173	9	110186	P03101	H2-b class I	I	Splenocyte	ELISPOT	IFNg release	1657506	17822733
HPV16	E6	MHQKRTAMFQDPQERPRKLPQLCTELQTTI	1	30	30	110943	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1657509	9293919
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	1657510	17114477
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-b class I	I	Lymph node cells	51 chromium	cytotoxicity	1657515	8833270
HPV16	E6	PRKLPQLCTELQTTI	16	30	15	110967	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1657527	9293919
HPV16	E6	QLCTELQTTIHDIILECVYCKQQLLRREVY	14	43	30	110978	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1657528	9293919
HPV16	E6	KQQLLRREVYDFAFRDLCIVYRDGNPYAVC	41	70	30	110924	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1657529	9293919
HPV16	E6	SEYRHYCYSLYGTTLEQQYNKPLCDLLIRC	81	110	30	111018	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1657531	9293919
HPV16	E6	KPLCDLLIRCINCQKPLCPEEKQRHLDKKQ	101	130	30	110919	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1657532	9293919
HPV16	E6	PLCPEEKQRHLDKKQ	116	130	15	110963	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1657533	9293919
HPV16	E6	EKQRHLDKKQRFHNIRGRWTGRCMSCCRSS	121	150	30	110830	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1657534	9293919
HPV16	E6	RGRWTGRCMSCCRSS	136	150	15	111007	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1657535	9293919
HPV16	E6	GRCMSCCRSSRTRRETQL	141	158	18	110871	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1657536	9293919
HPV16	E7	DSTLRLCVQSTHVDIRTLE	62	80	19	110817	P03129	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1657539	9293919
HPV16	E7	THVDIRTLEDLLMGTLGIVCPICSQKP	72	98	27	111040	P03129	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1657540	9293919
HPV16	E6	VYDFAFRDLC	49	58	10	111937	P03126	H2-b class I	I	T cell CD8+	51 chromium	cytotoxicity	1657562	8833270
HPV16	E6	VYDFAFRDLC	49	58	10	111937	P03126	H2-b class I	I	Lymph node cells	51 chromium	cytotoxicity	1657568	8833270
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1657571	17114477
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	Lymph node cells	51 chromium	cytotoxicity	1657582	8833270
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD8+	51 chromium	cytotoxicity	1657583	8833270
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	-	in vivo assay	pathogen burden after challenge	1657602	17114477
HPV16	E6	FAFRDLCIVY	52	61	10	110575	P03126	HLA-B57	I	T cell CD8+	51 chromium	cytotoxicity	1657618	16808432
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	1657621	7512375
HPV16	E6	FAFRDLCIVY	52	61	10	110575	P03126	HLA-B57	I	T cell CD8+	ELISPOT	IFNg release	1657641	16808432
HPV16	E6	FAFRDLCIVY	52	61	10	110575	P03126	HLA-B57	I	T cell CD8+	ELISPOT	IFNg release	1657660	16808432
HPV39	E6	FAFSDLYVVY	47	56	10	112506	P06463	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1657668	16808432
HPV73	E6	FAFSDLCIVY	46	55	10	112505	P36811	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1657669	16808432
HPV45	E6	FAFKDLCIVY	47	56	10	112504	P06463	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1657670	16808432
HPV51	E6	VAFTEIKIVY	45	54	10	112697	P26554	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1657671	16808432
HPV45	E6	KCIDFYSRI	67	75	9	111442	P06463	HLA-A*02:01	I	Splenocyte	ELISPOT	IFNg release	1657673	16353149
HPV18	E6	VYRDSIPHAACHKCI	55	69	15	111942	P06463	HLA-A*02:01	I	Splenocyte	ELISPOT	IFNg release	1657676	16353149
HPV16	E6	EKQRHLDKKQRFHNI	121	135	15	110829	P03126	HLA-DR	II	T cell CD4+	ICS	IFNg release	1657677	17412975
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	1657699	15639645
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1657701	15639645
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	ELISA	IFNg release	1657702	15639645
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	1657705	7512375
HPV16	E7	DLYCYEQL	21	28	8	110208	P03129	H2-Kb	I	Splenocyte	51 chromium	cytotoxicity	1657706	7512375
HPV16	E6	VYRDGNPYA	60	68	9	111941	P03126	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1657731	10630789
HPV16	E6	QYNKPLCDLL	98	107	10	110982	P03126	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1657735	10630789
HPV18	L1	NVFPIFLQM	54	62	9	111604	P06794	HLA-Cw4	I	Lymphocyte	3H-thymidine	proliferation	1657760	10369123
HPV16	E7	MHGDTPTLHEYM	1	12	12	41659	P03129	HLA-DR	II	T cell CD4+	ELISPOT	IFNg release	1657888	16112023
HPV16	E7	MHGDTPTLHEYM	1	12	12	41659	P03129	HLA-DR	II	T cell CD4+	ELISPOT	IFNg release	1657891	16112023
HPV33	E7	LRTIQQLLMGTVNIV	76	90	15	110936	P03129	HLA-DRB1*04:02	II	T cell CD4+	ELISA	IFNg release	1657895	10864677
HPV16	E7	MHGDTPTLHEYM	1	12	12	41659	P03129	HLA-DR	II	T cell CD4+	ELISPOT	IL-5 release	1657899	16112023
HPV16	E6	DFAFRDLCIVYRDGNPYA	44	61	18	110560	P03126	H2-a class II	II	Lymph node cells	3H-thymidine	proliferation	1657905	10630789
HPV16	E7	DRAHYNIVTFCCKCD	48	62	15	9947	P03129	HLA-DR	II	T cell CD4+	ELISPOT	IFNg release	1657908	16112023
HPV16	E7	DRAHYNIVTFCCKCD	48	62	15	9947	P03129	HLA-DR	II	T cell CD4+	ELISPOT	IFNg release	1657910	16112023
HPV16	E7	DRAHYNIVTFCCKCD	48	62	15	9947	P03129	HLA-DR	II	T cell CD4+	ELISPOT	IL-5 release	1657911	16112023
HPV16	E7	DRAHYNIVTFCCKCD	48	62	15	9947	P03129	HLA-DR15	II	T cell CD4+	ELISPOT	IFNg release	1657912	16112023
HPV16	E7	DRAHYNIVTFCCKCD	48	62	15	9947	P03129	HLA-DR15	II	T cell CD4+	ELISPOT	IL-5 release	1657913	16112023
HPV16	E7	DSTLRLCVQSTHVD	62	75	14	10251	P03129	HLA-DR	II	T cell CD4+	ELISPOT	IFNg release	1657916	16112023
HPV16	E7	DSTLRLCVQSTHVD	62	75	14	10251	P03129	HLA-DR	II	T cell CD4+	ELISPOT	IFNg release	1657918	16112023
HPV16	E7	DSTLRLCVQSTHVD	62	75	14	10251	P03129	HLA-DR	II	T cell CD4+	ELISPOT	IL-5 release	1657921	16112023
HPV16	E6	VYRDGNPYA	60	68	9	111941	P03126	H2-b class II	II	-	biological activity	antibody help	1657938	10630789
HPV16	E6	CLKFYSKISEYRHYCYSLYGTTLEQQYNKPLC	73	104	32	111153	P03126	HLA class II	II	T cell CD4+	ICS	IL-5 release	1657939	18404684
HPV16	E6	CVYCKQQLLRREVYDFAFRDLCIVYRDGNPYA	37	68	32	111180	P03126	HLA class I	I	T cell CD8+	ICS	IFNg release	1657940	18404684
HPV16	E6	QYNKPLCDLL	98	107	10	110982	P03126	H2-d class II	II	-	biological activity	antibody help	1657941	10630789
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	Splenocyte	biological activity	proliferation	1657944	15661238
HPV16	E6	VYRDGNPYA	60	68	9	111941	P03126	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1657956	10630789
HPV16	E6	VYRDGNPYA	60	68	9	111941	P03126	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1657966	10630789
HPV16	E6	VYRDGNPYA	60	68	9	111941	P03126	H2-d class II	II	Lymph node cells	3H-thymidine	proliferation	1657972	10630789
HPV16	E7	MLDLQPETT	12	20	9	41919	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1657973	7506573
HPV16	E7	IDGPAGQAEPDRAHYNIVTFCCKC	38	61	24	111413	P03129	H2-b class I	I	-	in vivo assay	pathogen burden after challenge	1657974	15661238
HPV16	E6	VYRDGNPYA	60	68	9	111941	P03126	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1657975	10630789
HPV16	E6	DKKQRFHNIRGRWTG	127	141	15	111200	P03126	HLA-DR1	II	T cell CD4+	ICS	IFNg release	1658047	17412975
HPV16	E6	DKKQRFHNIRGRWTG	127	141	15	111200	P03126	HLA-DR1	II	T cell CD4+	cytometric bead array	IL-4 release	1658048	17412975
HPV16	E6	DKKQRFHNIRGRWTG	127	141	15	111200	P03126	HLA-DR1	II	T cell CD4+	cytometric bead array	IL-10 release	1658049	17412975
HPV16	E6	DKKQRFHNIRGRWTG	127	141	15	111200	P03126	HLA-DR1	II	T cell CD4+	cytometric bead array	IL-2 release	1658050	17412975
HPV6b	L1	GHPYFSIKRANKTVV	45	59	15	112525	P04012	-	-	Lymphocyte	ELISPOT	IFNg release	1658134	17425420
HPV6b	E4	YPFLNLLHTPPHRPP	29	43	15	112734	P04016	-	-	Lymphocyte	ELISPOT	IFNg release	1658137	17425420
HPV6b	E1	AVESEISPRLDAIKL	101	115	15	112460	P04014	HLA class II	II	Lymphocyte	ELISA	IL-13 release	1658138	17425420
HPV6b	L1	GHPYFSIKRANKTVV	45	59	15	112525	P04012	HLA class II	II	Lymphocyte	ELISA	IL-2 release	1658139	17425420
HPV6b	E4	YPFLNLLHTPPHRPP	29	43	15	112734	P04016	HLA class II	II	Lymphocyte	ELISA	IL-2 release	1658140	17425420
HPV6b	E4	YPFLNLLHTPPHRPP	29	43	15	112734	P04016	-	-	Lymphocyte	ELISA	TNFa release	1658142	17425420
HPV6b	L1	GHPYFSIKRANKTVV	45	59	15	112525	P04012	HLA class II	II	Lymphocyte	ELISA	IL-5 release	1658143	17425420
HPV6b	L1	GHPYFSIKRANKTVV	45	59	15	112525	P04012	-	-	Lymphocyte	ELISA	GM-CSF release	1658145	17425420
HPV6b	E4	YPFLNLLHTPPHRPP	29	43	15	112734	P04016	HLA class II	II	Lymphocyte	ELISA	IL-5 release	1658146	17425420
HPV6b	E4	YPFLNLLHTPPHRPP	29	43	15	112734	P04016	HLA class II	II	Lymphocyte	ELISA	IL-13 release	1658147	17425420
HPV6b	E4	YPFLNLLHTPPHRPP	29	43	15	112734	P04016	-	-	Lymphocyte	ELISA	GM-CSF release	1658148	17425420
HPV16	E7	MHGDTPTLHEYMLDLQPETT	1	20	20	41660	P03129	H2-s class II	II	Lymph node cells	3H-thymidine	proliferation	1658150	1316944
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1658204	19234187
HPV16	E7	LQPETTDLYCYEQLNDSSEE	15	34	20	111515	P03129	H2-s class II	II	Lymph node cells	3H-thymidine	proliferation	1658260	1316944
HPV16	E7	GPAGQAEPDRAHYNIVTFCC	40	59	20	111359	P03129	H2-s class II	II	Lymph node cells	3H-thymidine	proliferation	1658265	1316944
HPV16	E7	VTFCCKCDSTLRLCVQSTHV	55	74	20	111929	P03129	H2-s class II	II	Lymph node cells	3H-thymidine	proliferation	1658269	1316944
HPV16	E7	KCDSTLRLCVQSTHVDIRTL	60	79	20	111440	P03129	H2-s class II	II	Lymph node cells	3H-thymidine	proliferation	1658270	1316944
HPV16	E7	DIRTLEDLLMGTLGIVCPIC	75	94	20	8773	P03129	H2-s class II	II	Lymph node cells	3H-thymidine	proliferation	1658273	1316944
HPV16	E7	GTLGIVCPICSQKP	85	98	14	111382	P03129	H2-s class II	II	Lymph node cells	3H-thymidine	proliferation	1658275	1316944
HPV16	E7	VCPICSQKP	90	98	9	111889	P03129	H2-s class II	II	Lymph node cells	3H-thymidine	proliferation	1658276	1316944
HPV16	E2	FNSSHKGRINCNSNTTPIVHLKGDANTLKC	271	300	30	111285	P03120	HLA-DR	II	PBMC	3H-thymidine	proliferation	1658290	11809698
HPV16	E2	TPIVHLKGDANTLKCLRYRFKKHCTLYTAV	286	315	30	111842	P03120	HLA-DR	II	PBMC	3H-thymidine	proliferation	1658298	11809698
HPV16	E2	SSTWHWTGHNVKHKSAIVTLTYDSEWQRDQ	316	345	30	111806	P03120	HLA-DR	II	PBMC	3H-thymidine	proliferation	1658308	11809698
HPV16	E2	AIVTLTYDSEWQRDQFLSQVKIPKTITVSTGFMSI	331	365	35	111103	P03120	HLA-DR	II	PBMC	3H-thymidine	proliferation	1658313	11809698
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	Splenocyte	in vitro assay	cytotoxicity	1658367	15661238
HPV16	E2	SSTWHWTGHNVKHKS	316	330	15	111805	P03120	HLA-DR15	II	PBMC	3H-thymidine	proliferation	1658383	11809698
HPV16	E2	LRYRFKKHCTLYTAVSSTWHWTGHNVKHKS	301	330	30	111518	P03120	HLA-DR	II	PBMC	3H-thymidine	proliferation	1658384	11809698
HPV16	E2	SSTWHWTGHNVKHKSAIVTLTYDSEWQRDQ	316	345	30	111806	P03120	HLA-DR	II	PBMC	3H-thymidine	proliferation	1658385	11809698
HPV16	E2	LYTAVSSTWHWTGHN	311	325	15	111536	P03120	HLA-DQ6	II	PBMC	3H-thymidine	proliferation	1658386	11809698
HPV16	E2	FLSQVKIPKT	346	355	10	111283	P03120	HLA-DR15	II	PBMC	3H-thymidine	proliferation	1658387	11809698
HPV16	E2	KIPKTITVSTGFMSI	351	365	15	111454	P03120	HLA-DR1	II	PBMC	3H-thymidine	proliferation	1658388	11809698
HPV26	E2	LYCNVSSTWHWTSND	322	336	15	111531	P26547	HLA class II	II	PBMC	3H-thymidine	proliferation	1658391	11809698
HPV31	E2	LYEQVSSTWHWTCTD	318	332	15	111532	P03120	HLA class II	II	PBMC	3H-thymidine	proliferation	1658393	11809698
HPV33	E2	LYSSMSSTWHWTSDN	299	313	15	111535	P03120	HLA class II	II	PBMC	3H-thymidine	proliferation	1658394	11809698
HPV45	E2	HYSEISSTWHWTGCN	316	330	15	111409	P06790	HLA class II	II	PBMC	3H-thymidine	proliferation	1658395	11809698
HPV16	E2	LYTAVSSTWHWTGHN	311	325	15	111536	P03120	HLA class II	II	PBMC	3H-thymidine	proliferation	1658396	11809698
HPV16	E2	LYTAVSSTWHWTGHN	311	325	15	111536	P03120	HLA class II	II	PBMC	3H-thymidine	proliferation	1658397	11809698
HPV16	E2	LYTAVSSTWHWTGHN	311	325	15	111536	P03120	HLA class II	II	PBMC	3H-thymidine	proliferation	1658398	11809698
HPV16	E2	LYTAVSSTWHWTGHN	311	325	15	111536	P03120	HLA class II	II	PBMC	3H-thymidine	proliferation	1658399	11809698
HPV16	E2	AIVTLTYDSEWQRDQFLSQVKIPKTITVSTGFMSI	331	365	35	111103	P03120	HLA-DR	II	PBMC	3H-thymidine	proliferation	1658401	11809698
HPV16	E7	EYMLDLQPETTDLYCYEQLN	10	29	20	111264	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658409	1714516
HPV16	E7	LQPETTDLYCYEQLNDSSEE	15	34	20	111515	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658410	1714516
HPV16	E7	EDEIDGPAGQAEPDRAHYNI	35	54	20	110824	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658414	1714516
HPV16	E7	GPAGQAEPDRAHYNIVTFCC	40	59	20	111359	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658415	1714516
HPV16	E7	AEPDRAHYNIVTFCCKCDST	45	64	20	111091	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658416	1714516
HPV16	E7	KCDSTLRLCVQSTHVDIRTL	60	79	20	111440	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658419	1714516
HPV16	E7	EDLLMGTLGIVCPICSQKP	80	98	19	111231	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658423	1714516
HPV16	E7	GTLGIVCPICSQKP	85	98	14	111382	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658424	1714516
HPV16	E6	CVYCKQQLL	37	45	9	111178	P03126	H2-b class I	I	Splenocyte	ELISPOT	IFNg release	1658578	16949679
HPV16	E6	KCLKFYSKI	72	80	9	112558	P03126	H2-b class I	I	Splenocyte	ELISPOT	IFNg release	1658579	16949679
HPV16	E6	EVYDFAFRDL	48	57	10	14909	P03126	H2-Kb	I	Splenocyte	ELISPOT	IFNg release	1658586	16949679
HPV16	L1	YHAGTSRLLAVGHPY	61	75	15	111960	P03101	H2-Kb	I	Splenocyte	51 chromium	cytotoxicity	1658653	1381502
HPV16	L1	VGHPYFPIKKPNNNK	71	85	15	111909	P03101	H2-Kb	I	Splenocyte	51 chromium	cytotoxicity	1658661	1381502
HPV16	L1	VSGLQYRVFRIHLPD	91	105	15	111924	P03101	H2-Kb	I	Splenocyte	51 chromium	cytotoxicity	1658662	1381502
HPV16	L1	VGISGHPLLNKLDDT	141	155	15	111911	P03101	H2-Kb	I	Splenocyte	51 chromium	cytotoxicity	1658663	1381502
HPV16	L1	YAANAGVDNRECISM	161	175	15	111952	P03101	H2-Kb	I	Splenocyte	51 chromium	cytotoxicity	1658664	1381502
HPV16	L1	CTNVAVNPGDCPPLE	201	215	15	111175	P03101	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	1658665	1381502
HPV16	L1	CTSICKYPDYIKMVS	251	265	15	111176	P03101	H2-Kb	I	Splenocyte	51 chromium	cytotoxicity	1658667	1381502
HPV16	L1	YKNTNFKEYLRHGEE	381	395	15	111965	P03101	H2-Kb	I	Splenocyte	51 chromium	cytotoxicity	1658668	1381502
HPV16	L1	TFWEVNLKEKFSADL	471	485	15	111826	P03101	H2-Kb	I	Splenocyte	51 chromium	cytotoxicity	1658669	1381502
HPV16	L1	KAKPKFTLGKRKATP	501	515	15	110910	P03101	H2-Kb	I	Splenocyte	51 chromium	cytotoxicity	1658671	1381502
HPV16	E6	QLLRREVYDF	36	45	10	111676	P03126	H2-Kb	I	Splenocyte	51 chromium	cytotoxicity	1658672	1381502
HPV16	E6	EVYDFAFRDL	41	50	10	14909	P03126	H2-Kb	I	Splenocyte	51 chromium	cytotoxicity	1658673	1381502
HPV16	E6	YSLYGTTLEQ	88	97	10	111974	P03126	H2-Kb	I	Splenocyte	51 chromium	cytotoxicity	1658674	1381502
HPV16	E7	DLYCYEQLND	21	30	10	9336	P03129	H2-Kb	I	Splenocyte	51 chromium	cytotoxicity	1658676	1381502
HPV16	E7	STHVDIRTLE	71	80	10	111810	P03129	H2-Kb	I	Splenocyte	51 chromium	cytotoxicity	1658678	1381502
HPV16	E6	DKKQRFHNIRGRWTG	127	141	15	111200	P03126	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1658705	15623547
HPV16	E4	PAATKPLLKLLGSTWPTTPPRPIPK	0	0	25	111608	P06922	HLA class II	II	PBMC	3H-thymidine	proliferation	1658709	8991637
HPV16	E6	TELQTTIHDILLECVYCKQQLL	24	45	22	111824	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1658710	8991637
HPV16	E6	RCINCQKPLCPEEK	109	122	14	111709	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1658711	8991637
HPV16	E7	DLYCYEQLND	21	30	10	9336	P03129	HLA class II	II	PBMC	3H-thymidine	proliferation	1658712	8991637
HPV16	E7	QAEPDRAHYNIVTF	44	57	14	111662	P03129	HLA class II	II	PBMC	3H-thymidine	proliferation	1658713	8991637
HPV16	L1	LNTNFKEYLRHGEEY	0	0	15	111502	P03101	HLA class II	II	PBMC	3H-thymidine	proliferation	1658714	8991637
HPV16	E4	PAATKPLLKLLGSTWPTTPPRPIPK	0	0	25	111608	P06922	HLA class II	II	PBMC	3H-thymidine	proliferation	1658715	8991637
HPV16	E6	TELQTTIHDILLECVYCKQQLL	24	45	22	111824	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1658716	8991637
HPV16	E6	RCINCQKPLCPEEK	109	122	14	111709	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1658717	8991637
HPV16	E7	QAEPDRAHYNIVTF	44	57	14	111662	P03129	HLA class II	II	PBMC	3H-thymidine	proliferation	1658719	8991637
HPV16	L1	LNTNFKEYLRHGEEY	0	0	15	111502	P03101	HLA class II	II	PBMC	3H-thymidine	proliferation	1658720	8991637
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	1658736	10667589
HPV16	E1	TLLQQYCLYL	253	262	10	110439	P03114	HLA-A2	I	PBMC	51 chromium	cytotoxicity	1658746	9349483
HPV16	E2	ALQAIELQL	69	77	9	108770	P03120	HLA-A2	I	PBMC	51 chromium	cytotoxicity	1658753	9349483
HPV16	E1	LLQQYCLYL	254	262	9	111495	P03114	HLA-A2	I	PBMC	51 chromium	cytotoxicity	1658757	9349483
HPV16	E2	ALQAIELQL	69	77	9	108770	P03120	HLA-A2	I	PBMC	51 chromium	cytotoxicity	1658843	9349483
HPV16	E7	MHGDTPTLHEYMLDLQPETT	1	20	20	41660	P03129	H2 class II	II	Lymph node cells	3H-thymidine	proliferation	1658926	1316944
HPV16	E7	MHGDTPTLHEYMLDLQPETT	1	20	20	41660	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658927	1316944
HPV16	E7	MHGDTPTLHEYMLDLQPETT	1	20	20	41660	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1658929	1316944
HPV16	E7	TPTLHEYMLDLQPETTDLYC	5	24	20	111845	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658932	1316944
HPV16	E7	EYMLDLQPETTDLYCYEQLN	10	29	20	111264	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658937	1316944
HPV16	E7	LQPETTDLYCYEQLNDSSEE	15	34	20	111515	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658940	1316944
HPV16	E7	TDLYCYEQLNDSSEEEDEID	20	39	20	111819	P03129	H2 class II	II	Lymph node cells	3H-thymidine	proliferation	1658943	1316944
HPV16	E7	TDLYCYEQLNDSSEEEDEID	20	39	20	111819	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658944	1316944
HPV16	E7	TDLYCYEQLNDSSEEEDEID	20	39	20	111819	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1658946	1316944
HPV16	E7	EDEIDGPAGQAEPDRAHYNI	35	54	20	110824	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658956	1316944
HPV16	E7	EDEIDGPAGQAEPDRAHYNI	35	54	20	110824	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658957	1316944
HPV16	E7	EDEIDGPAGQAEPDRAHYNI	35	54	20	110824	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1658958	1316944
HPV16	E7	GPAGQAEPDRAHYNIVTFCC	40	59	20	111359	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658961	1316944
HPV16	E7	GPAGQAEPDRAHYNIVTFCC	40	59	20	111359	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1658962	1316944
HPV16	E7	AEPDRAHYNIVTFCCKCDST	45	64	20	111091	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1658966	1316944
HPV16	E7	KCDSTLRLCVQSTHVDIRTL	60	79	20	111440	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658977	1316944
HPV16	E7	KCDSTLRLCVQSTHVDIRTL	60	79	20	111440	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1658978	1316944
HPV16	E7	LRLCVQSTHVDIRTLEDLLM	65	84	20	109519	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1658982	1316944
HPV16	E7	QSTHVDIRTLEDLLMGTLGI	70	89	20	52441	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658985	1316944
HPV16	E7	EDLLMGTLGIVCPICSQKP	80	98	19	111231	P03129	H2 class II	II	Lymph node cells	3H-thymidine	proliferation	1658991	1316944
HPV16	E7	EDLLMGTLGIVCPICSQKP	80	98	19	111231	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1658993	1316944
HPV16	E7	EDLLMGTLGIVCPICSQKP	80	98	19	111231	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1658994	1316944
HPV16	E7	GTLGIVCPICSQKP	85	98	14	111382	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1658998	1316944
HPV16	E7	VCPICSQKP	90	98	9	111889	P03129	H2-k class II	II	Lymph node cells	3H-thymidine	proliferation	1659001	1316944
HPV16	E7	VCPICSQKP	90	98	9	111889	P03129	H2-b class II	II	Lymph node cells	3H-thymidine	proliferation	1659002	1316944
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell	bioassay	TNFa release	1659006	9405669
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell	51 chromium	cytotoxicity	1659048	9405669
HPV16	E7	TDLYCYEQLNDSSEEEDEID	20	39	20	111819	P03129	H2 class II	II	Lymph node cells	3H-thymidine	proliferation	1659053	1316944
HPV16	E7	KCDSTLRLCVQSTHVDIRTL	60	79	20	111440	P03129	H2 class II	II	Lymph node cells	3H-thymidine	proliferation	1659061	1316944
HPV16	E7	GTLGIVCPICSQKP	85	98	14	111382	P03129	H2 class II	II	Lymph node cells	3H-thymidine	proliferation	1659066	1316944
HPV16	E7	EYMLDLQPETTDLYCYEQLN	10	29	20	111264	P03129	H2-r class II	II	Lymph node cells	3H-thymidine	proliferation	1659070	1316944
HPV16	E7	LQPETTDLYCYEQLNDSSEE	15	34	20	111515	P03129	H2-r class II	II	Lymph node cells	3H-thymidine	proliferation	1659071	1316944
HPV16	E2	CQDKILTHYENDSTD	11	25	15	111167	P03120	HLA class II	II	T cell	biological activity	proliferation	1659128	7733923
HPV16	E2	EEASVTVVEGQVDYY	141	155	15	111233	P03120	HLA class II	II	T cell	biological activity	proliferation	1659129	7733923
HPV16	E2	QVILCPTSVFSSNEV	191	205	15	111693	P03120	HLA class II	II	T cell	biological activity	proliferation	1659130	7733923
HPV16	E2	TEETQTTIQRPRSEP	231	245	15	111821	P03120	HLA class II	II	T cell	biological activity	proliferation	1659131	7733923
HPV16	E6	MHQKRTAMFQDPQERPRKLPQLCTELQTTIHD	1	32	32	111547	P03126	HLA class II	II	T cell CD4+	ICS	IFNg release	1659139	15540211
HPV16	E6	LPQLCTELQTTIHDIILECVYCKQQLLRREVY	12	43	32	111509	P03126	HLA class II	II	T cell CD4+	ICS	IFNg release	1659162	15540211
HPV16	E6	CVYCKQQLLRREVYDFAFRDLCIVYRDGNPYA	30	61	32	111180	P03126	HLA class II	II	T cell CD4+	ICS	IFNg release	1659163	15540211
HPV16	E6	CLKFYSKISEYRHYCYSLYGTTLEQQYNKPLC	73	104	32	111153	P03126	HLA class II	II	T cell CD4+	ICS	IFNg release	1659165	15540211
HPV16	E6	RCINCQKPLCPEEKQRHLDKKQRFHNIRGRWT	109	140	32	110394	P03126	HLA class II	II	T cell CD4+	ICS	IFNg release	1659167	15540211
HPV16	E6	DKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL	127	158	32	110205	P03126	HLA class II	II	T cell CD4+	ICS	IFNg release	1659168	15540211
HPV16	E6	MHQKRTAMFQDPQERPRKLPQLCTELQTTIHD	1	32	32	111547	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1659174	15540211
HPV16	E6	LPQLCTELQTTIHDIILECVYCKQQLLRREVY	12	43	32	111509	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1659177	15540211
HPV16	E6	CVYCKQQLLRREVYDFAFRDLCIVYRDGNPYA	30	61	32	111180	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1659178	15540211
HPV16	E6	RDLCIVYRDGNPYAVCDKCLKFYSKISEYRHY	55	86	32	111714	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1659179	15540211
HPV16	E6	CLKFYSKISEYRHYCYSLYGTTLEQQYNKPLC	73	104	32	111153	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1659180	15540211
HPV16	E6	YGTTLEQQYNKPLCDLLIRCINCQKPLCPEEK	91	122	32	110462	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1659181	15540211
HPV16	E6	RCINCQKPLCPEEKQRHLDKKQRFHNIRGRWT	109	140	32	110394	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1659182	15540211
HPV16	E6	DKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL	127	158	32	110205	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1659183	15540211
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	Splenocyte	51 chromium	cytotoxicity	1659454	10364377
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	Lymph node cells	51 chromium	cytotoxicity	1659542	8833270
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	1659567	10364377
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A2	I	T cell CD8+	ELISA	IFNg release	1659812	12692247
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A2	I	T cell CD8+	ELISA	GM-CSF release	1659913	12692247
HPV16	E6	RCINCQKPLCPEEKQRHLDKKQRFHNIRGRWT	109	140	32	110394	P03126	HLA class I	I	T cell CD8+	ICS	IFNg release	1660004	18404684
HPV16	E6	DKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL	127	158	32	110205	P03126	HLA class I	I	T cell CD8+	ICS	IFNg release	1660006	18404684
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A2	I	T cell CD8+	multimer/tetramer	qualitative binding	1660007	12692247
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A2	I	T cell CD8+	multimer/tetramer	qualitative binding	1660008	12692247
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A2	I	T cell CD8+	multimer/tetramer	qualitative binding	1660013	12692247
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A2	I	T cell CD8+	ELISA	GM-CSF release	1660079	12692247
HPV1a	E4	GLTDGEDPEVPEVED	62	76	15	112133	P06923	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660082	12021335
HPV1a	E4	EDPEVPEVEDEEKEN	67	81	15	112091	P06923	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660083	12021335
HPV1a	L1	IPKVSPNAFRVFRVR	66	80	15	112168	P03099	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660084	12021335
HPV1a	E4	PEVEDEEKENQRPLG	0	0	15	112252	P06923	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660085	12021335
HPV1a	E4	EEKENQRPLGHPDLS	0	0	15	112093	P06923	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660086	12021335
HPV1a	E4	TTPNSQDRGRPRRSD	37	51	15	112367	P06923	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660087	12021335
HPV1a	E4	QDRGRPRRSDKDSRK	42	56	15	112262	P06923	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660088	12021335
HPV1a	E4	MADNKAPQGLLGLLQ	0	0	15	112223	P06923	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660089	12021335
HPV1a	E4	APQGLLGLLQYTPTT	7	21	15	112035	P06923	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660090	12021335
HPV1a	E4	LEVYTQRLKRDILQD	0	0	15	112204	P06923	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660091	12021335
HPV1a	E6	ELRCVTCIKKLSVAE	96	110	15	112098	P06929	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660092	12021335
HPV1a	L1	ATCKYPDYIRMNHEA	231	245	15	112049	P03099	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660093	12021335
HPV1a	L1	PDYIRMNHEAYGNSM	236	250	15	112251	P03099	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660094	12021335
HPV1a	E4	HLYADGLTDGEDPEV	57	71	15	112156	P06923	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660095	12021335
HPV1a	E4	LLRETLEVYTQRLKR	0	0	15	112210	P06923	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660096	12021335
HPV1a	E6	VPEIEEILDRPLLQI	81	95	15	112390	P06929	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660097	12021335
HPV1a	E6	EILDRPLLQIELRCV	86	100	15	112096	P06929	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660098	12021335
HPV1a	E6	PLLQIELRCVTCIK	91	104	14	112257	P06929	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660099	12021335
HPV1a	E6	NRLKAKCSLCRLYAI	126	140	15	112242	P06929	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660100	12021335
HPV16	E6	HNIRGRWTGRCMSCC	126	140	15	111399	P03126	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660103	12021335
HPV1a	L1	TNYVGTPSGSMVSSD	296	310	15	112361	P03099	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660105	12021335
HPV6	L1	SIYVNTPSGSLVSS	285	298	14	112317	P04012	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660107	12021335
HPV1a	E6	KLEVVSNGERVHRVR	111	125	15	112181	P06929	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660110	12021335
HPV1a	E6	SNGERVHRVRNRLKA	116	130	15	112325	P06929	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660111	12021335
HPV2	E6	WEEKEALLVGNKRFHNISGR	117	136	20	112397	P25484	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660112	12021335
HPV1a	E4	QRLKRDILQDLDDFC	0	0	15	112272	P06923	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660116	12021335
HPV1a	E4	DILQDLDDFCRKLGI	0	0	15	112078	P06923	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660117	12021335
HPV1a	E4	LDDFCRKLGIHPWSV	0	0	15	112202	P06923	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660118	12021335
HPV1a	L1	VFRVRFADPNRFAFG	76	90	15	112378	P03099	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660119	12021335
HPV2	L1	VFHVKLPDPNKFGLP	87	101	15	112373	P25486	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660120	12021335
HPV6	L1	VFKVVLPDPNKFALP	69	83	15	112374	P04012	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660121	12021335
HPV18	L1	VFRVQLPDPNKFGLP	133	147	15	112377	P06794	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660123	12021335
HPV1a	L1	EDQYRFLGSSLAAKC	421	435	15	112092	P03099	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660124	12021335
HPV1a	L1	FLGSSLAAKCPEQAP	426	440	15	112111	P03099	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660125	12021335
HPV1a	L1	LAAKCPEQAPPEPQT	431	445	15	112193	P03099	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1660126	12021335
HPV1a	L1	CTPASGEHWTSRRCP	0	0	15	112070	P03099	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1660127	12021335
HPV6	L1	CAPPLGEHWGKGTQCT	0	0	16	112061	P69899	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1660129	12021335
HPV16	L1	CKPPIGEHWGKGSPCT	187	202	16	112064	P03101	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1660130	12021335
HPV18	L1	CAPAIGEHWAKGTACK	222	237	16	112060	P06794	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1660131	12021335
HPV1a	L1	PNAFRVFRVRFADPN	71	85	15	112259	P03099	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1660133	12021335
HPV1a	L1	LRGIEIGRGQPLGIG	106	120	15	112211	P03099	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1660134	12021335
HPV1a	L1	IGRGQPLGIGITGHP	111	125	15	112164	P03099	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1660135	12021335
HPV1a	L1	RILSTDEYVTRTNLF	26	40	15	112292	P03099	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1660136	12021335
HPV1a	L1	FEISSNQTVTIPKVS	56	70	15	112105	P03099	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1660137	12021335
HPV1a	L1	NQTVTIPKVSPNAFR	61	75	15	112240	P03099	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1660138	12021335
HPV1a	L1	ISMKNNASTTYSNAN	351	365	15	112171	P03099	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1660139	12021335
HPV1a	L1	NASTTYSNANFNDFL	356	370	15	112232	P03099	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1660140	12021335
HPV2	L1	LCATEASDTNYKATNFKEYL	355	374	20	112200	P25486	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1660141	12021335
HPV1a	L1	MTQRTATSSTTKRKT	481	495	15	112231	P03099	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1660145	12021335
HPV1a	L1	YHATSERLLLVGHPL	41	55	15	112410	P03099	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1660146	12021335
HPV1a	L1	VGHPLFEISSNQTVT	51	65	15	112380	P03099	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1660147	12021335
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A2	I	T cell CD8+	ELISA	GM-CSF release	1660150	12692247
HPV16	E6	EVYDFAFRDL	48	57	10	14909	P03126	H2-Kb	I	Splenocyte	ELISPOT	IFNg release	1660390	16949679
HPV11	L1	MWRPSDSTVYVPPPNPVSKVVATDAYVKRTNIF	1	33	33	112606	P04012	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660628	12097554
HPV11	L1	PDPNKFALPDSSLFDPTTQRLVWACTGLEVGRGQPL	75	110	36	112618	P04012	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660629	12097554
HPV11	L1	GLEVGRGQPLGVGVSGHPLLNKYDDVENSGGY	101	132	32	112527	P04012	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660630	12097554
HPV11	L1	NKYDDVENSGGYGGNPGQDNRVNVGMDYKQTQL	121	153	33	112613	P04012	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660631	12097554
HPV11	L1	GMDYKQTQLCMVGCAPPLGEHWGKGTQCSNTSVQNGDCP	145	183	39	112528	P04012	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660632	12097554
HPV11	L1	EQMFARHFFNRAGTVGEPVPDDLLVKGGNNRS	250	281	32	112499	P04012	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660633	12097554
HPV11	L1	LFVTVVDTTRSTNMTLCASVSKSATYTNSDYKEYMRHVE	326	364	39	112576	P04012	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660634	12097554
HPV11	L1	TNIFYHASSSRLLAV	30	44	15	112676	P04012	HLA-DRB1*07:01	II	T cell CD4+	3H-thymidine	proliferation	1660635	12097554
HPV1a	L1	TNLFYHATSERLLLV	37	51	15	112679	P03099	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660636	12097554
HPV2	L1	TNVYYHGGSSRLLTV	31	45	15	112681	P25486	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660637	12097554
HPV4	L1	TSLYFHAGTERLLTV	32	46	15	112686	Q07860	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660638	12097554
HPV16	L1	TNIYYHAGTSRLLAV	57	71	15	112677	P03101	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660639	12097554
HPV18	L1	TSIFYHAGSSRLLTV	92	106	15	112685	P06794	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660640	12097554
HPV11	L1	RVFKVVLPDPNKFAL	68	82	15	112654	P04012	HLA-DRB1*04:01	II	T cell CD4+	3H-thymidine	proliferation	1660641	12097554
HPV11	L1	DNRVNVGMDYKQTQL	139	153	15	112479	P04012	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660642	12097554
HPV1a	L1	DSRQNTAFDAKQTQM	147	161	15	112483	P03099	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660643	12097554
HPV2	L1	DGRENISMDYKQTQL	139	153	15	112475	P25486	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660644	12097554
HPV4	L1	DNRQDVSLDPKQTQM	143	157	15	112478	Q07860	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660645	12097554
HPV16	L1	DNRECISMDYKQTQL	168	182	15	112477	P03101	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660646	12097554
HPV18	L1	DVRDNVSVDYKQTQL	203	217	15	112490	P06794	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660647	12097554
HPV11	L1	ELITSVIQDGDMVDT	186	200	15	112497	P04012	HLA-DRB1*07:01	II	T cell CD4+	3H-thymidine	proliferation	1660648	12097554
HPV1a	L1	QMIESVIEDGDMMDI	193	207	15	112638	P03099	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660649	12097554
HPV2	L1	QFTNTTIEDGDMVET	185	199	15	112634	P25486	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660650	12097554
HPV3	L1	ELITAPIQDGDMVDT	188	202	15	112496	P50791	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660651	12097554
HPV16	L1	ELINTVIQDGDMVDT	215	229	15	112495	P03101	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660652	12097554
HPV11	L1	IQDGDMVDTGFGAMN	192	206	15	112550	P04012	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660653	12097554
HPV11	L1	AMNFADLQTNKSDVP	204	218	15	112448	P04012	HLA-DRB1*04:01	II	T cell CD4+	3H-thymidine	proliferation	1660654	12097554
HPV11	L1	DPYGDRLFFYLRKEQ	237	251	15	112481	P04012	HLA-DQB1*03:01	II	T cell CD4+	3H-thymidine	proliferation	1660655	12097554
HPV11	L1	LFFYLRKEQ	243	251	9	112573	P04012	HLA-DRB1*13:02	II	T cell CD4+	3H-thymidine	proliferation	1660656	12097554
HPV6b	L1	LFFFLRKEQMFARHF	242	256	15	112572	P04012	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660657	12097554
HPV1a	L1	MFFFARREQMYTRHF	250	264	15	112598	P03099	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660658	12097554
HPV3	L1	MFFYLRKEQLFARHF	245	259	15	112599	P50791	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660659	12097554
HPV4	L1	LFFFGRREQLYARHF	247	261	15	112571	Q07860	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660660	12097554
HPV16	L1	LFFYLRREQMFVRHL	272	286	15	112574	P03101	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660661	12097554
HPV18	L1	MFFCLRREQLFARHF	307	321	15	112597	P06794	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660662	12097554
HPV11	L1	SIYVHTPSGSLVSSE	286	300	15	112663	P04012	HLA-DR	II	T cell CD4+	3H-thymidine	proliferation	1660663	12097554
HPV11	L1	TPSGSLVSSEAQLFN	291	305	15	112683	P04012	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660664	12097554
HPV11	L1	FNKPYWLQKAQGHNN	304	318	15	112511	P04012	HLA-DQB1*06:02	II	T cell CD4+	3H-thymidine	proliferation	1660665	12097554
HPV1a	L1	FNRSYWLQRCQGQNN	314	328	15	112515	P03099	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660666	12097554
HPV2	L1	FNKPYWLRRAQGHNN	302	316	15	112513	P25486	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660667	12097554
HPV3	L1	FNKPYWLRRAQGHNN	309	323	15	112513	P50791	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660668	12097554
HPV4	L1	FNRPYWLNRAQGTNN	316	330	15	112514	Q07860	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660669	12097554
HPV16	L1	FNKPYWLQRAQGHNN	333	347	15	112512	P03101	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660670	12097554
HPV18	L1	FNKPYWLHKAQGHNN	368	382	15	112510	P06794	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660671	12097554
HPV11	L1	YKEYMRHVEEFDLQF	356	370	15	112730	P04012	HLA-DQ2	II	T cell CD4+	3H-thymidine	proliferation	1660672	12097554
HPV11	L1	LCSITLSAEVMAYIH	374	388	15	112569	P04012	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660673	12097554
HPV11	L1	SAEVMAYIHTMNPSV	380	394	15	112656	P04012	HLA-DRB1*07:01	II	T cell CD4+	3H-thymidine	proliferation	1660674	12097554
HPV11	L1	DTYRYVQSQAITCQK	412	426	15	112487	P04012	HLA-DR	II	T cell CD4+	3H-thymidine	proliferation	1660675	12097554
HPV1a	L1	EDQYRFLGSSLAAKC	421	435	15	112092	P03099	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660676	12097554
HPV2	L1	QDTYRYLQSQAITCQ	409	423	15	112633	P25486	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1660677	12097554
HPV58	E6	FVFADLRIVY	45	54	10	112519	P03126	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1660841	16808432
HPV16	E6	FAFRDLCIVY	52	61	10	110575	P03126	HLA-B57	I	T cell CD8+	ELISPOT	IFNg release	1660870	16808432
HPV16	E6	FAFRDLCIVY	52	61	10	110575	P03126	HLA-B57	I	T cell CD8+	ELISPOT	IFNg release	1660871	16808432
HPV16	E6	FAFRDLCIVY	52	61	10	110575	P03126	HLA-B57	I	T cell CD8+	ELISPOT	IFNg release	1660872	16808432
HPV16	E6	FAFRDLCIVY	52	61	10	110575	P03126	HLA-B57	I	T cell CD8+	ELISPOT	IFNg release	1660873	16808432
HPV16	E6	FAFRDLCIVY	52	61	10	110575	P03126	HLA-B57	I	T cell CD8+	ELISPOT	IFNg release	1660874	16808432
HPV16	E6	FAFRDLCIVY	52	61	10	110575	P03126	HLA-B57	I	T cell CD8+	ELISPOT	IFNg release	1660875	16808432
HPV16	E6	MHQKRTAMFQDPQERPRKLPQL	1	22	22	112808	P03126	HLA class II	II	PBMC	ELISPOT	IFNg release	1661014	12566307
HPV16	E6	DPQERPRKLPQLCTELQTTIHD	11	32	22	112764	P03126	HLA class II	II	PBMC	ELISPOT	IFNg release	1661015	12566307
HPV16	E6	HDIILECVYCKQQLLRREVYDF	31	52	22	112787	P03126	HLA class II	II	PBMC	ELISPOT	IFNg release	1661018	12566307
HPV16	E6	DKCLKFYSKISEYRHYCYSLYG	71	92	22	112763	P03126	HLA class II	II	PBMC	ELISPOT	IFNg release	1661022	12566307
HPV16	E6	SEYRHYCYSLYGTTLEQQYNKP	81	102	22	112836	P03126	HLA class II	II	PBMC	ELISPOT	IFNg release	1661023	12566307
HPV16	E6	YGTTLEQQYNKPLCDLLIRCIN	91	112	22	112865	P03126	HLA class II	II	PBMC	ELISPOT	IFNg release	1661024	12566307
HPV16	E6	KPLCDLLIRCINCQKPLCPEEK	101	122	22	112797	P03126	HLA class II	II	PBMC	ELISPOT	IFNg release	1661025	12566307
HPV16	E6	INCQKPLCPEEKQRHLDKKQRF	111	132	22	112794	P03126	HLA class II	II	PBMC	ELISPOT	IFNg release	1661026	12566307
HPV16	E6	EKQRHLDKKQRFHNIRGRWTGR	121	142	22	112768	P03126	HLA class II	II	PBMC	ELISPOT	IFNg release	1661027	12566307
HPV16	E6	RFHNIRGRWTGRCMSCCRSSRT	131	152	22	112829	P03126	HLA class II	II	PBMC	ELISPOT	IFNg release	1661028	12566307
HPV16	E6	GRWTGRCMSCCRSSRTRRETQL	137	158	22	112781	P03126	HLA class II	II	PBMC	ELISPOT	IFNg release	1661029	12566307
HPV16	E6	MHQKRTAMFQDPQERPRKLPQLCTELQTTIHD	1	32	32	111547	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1661030	12566307
HPV16	E6	LPQLCTELQTTIHDIILECVYCKQQLLRREVY	19	50	32	111509	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1661031	12566307
HPV16	E6	CVYCKQQLLRREVYDFAFRDLCIVYRDGNPYA	37	68	32	111180	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1661032	12566307
HPV16	E6	RDLCIVYRDGNPYAVCDKCLKFYSKISEYRHY	55	86	32	111714	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1661033	12566307
HPV16	E6	CLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIR	73	109	37	112757	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1661034	12566307
HPV16	E6	YGTTLEQQYNKPLCDLLIRCINCQKPLCPEEK	91	122	32	110462	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1661036	12566307
HPV16	E6	RCINCQKPLCPEEKQRHLDKKQRFHNIRGRWT	109	140	32	110394	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1661037	12566307
HPV16	E6	DKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL	127	158	32	110205	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1661038	12566307
HPV16	E2	DYWKHMRLECAIYYKAREMGFKHINHQVVPTLAVSKNKALQAIEL	31	75	45	112766	P03120	HLA class II	II	PBMC	3H-thymidine	proliferation	1661043	12566307
HPV16	E2	TLAVSKNKALQAIELQLTLETIYNSQYSNEKWTLQDVSLEVYLTA	61	105	45	112850	P03120	HLA class II	II	PBMC	3H-thymidine	proliferation	1661044	12566307
HPV16	E2	KWTLQDVSLEVYLTAPTGCIKKHGYTVEVQFDGDICNTMHYTNWT	91	135	45	112799	P03120	HLA class II	II	PBMC	3H-thymidine	proliferation	1661045	12566307
HPV16	E2	FNSSHKGRINCNSNTTPIVHLKGDANTLKCLRYRFKKHCTLYTAV	271	315	45	112776	P03120	HLA class II	II	PBMC	3H-thymidine	proliferation	1661051	12566307
HPV16	E2	LRYRFKKHCTLYTAVSSTWHWTGHNVKHKSAIVTLTYDSEWQRDQ	301	345	45	112802	P03120	HLA class II	II	PBMC	3H-thymidine	proliferation	1661052	12566307
HPV16	E2	AIVTLTYDSEWQRDQFLSQVKIPKTITVSTGFMSI	331	365	35	111103	P03120	HLA class II	II	PBMC	3H-thymidine	proliferation	1661053	12566307
HPV16	E6	MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVY	1	50	50	112809	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1661054	12566307
HPV16	E6	CVYCKQQLLRREVYDFAFRDLCIVYRDGNPYAVCDKCLKFYSKISEYRHY	37	86	50	112760	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1661055	12566307
HPV16	E6	CLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLCPEEK	73	122	50	112758	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1661056	12566307
HPV6b	E7	MHGRHVTLKDIVLDLQPPDP	1	20	20	112601	P04020	HLA class II	II	PBMC	3H-thymidine	proliferation	1661083	9261360
HPV6b	E7	IVLDLQPPDPVGLHCYEQLV	11	30	20	112555	P04020	HLA class II	II	PBMC	3H-thymidine	proliferation	1661092	9261360
HPV6b	E7	CTETDIREVQQLLLGTLNIV	71	90	20	112470	P04020	HLA class II	II	PBMC	3H-thymidine	proliferation	1661093	9261360
HPV6b	L1	IKRANKTVVPKVSGYQYRVF	51	70	20	112547	P04012	HLA class II	II	PBMC	3H-thymidine	proliferation	1661106	9261360
HPV6b	L1	KVSGYQYRVFKVVLPDPNKF	61	80	20	112565	P04012	HLA class II	II	PBMC	3H-thymidine	proliferation	1661108	9261360
HPV6b	L1	GLEVGRGQPLGVGVSGHPFL	101	120	20	112526	P04012	HLA class II	II	PBMC	3H-thymidine	proliferation	1661112	9261360
HPV6b	L1	GVGVSGHPFLNKYDDVENSG	111	130	20	112532	P04012	HLA class II	II	PBMC	3H-thymidine	proliferation	1661113	9261360
HPV16	E6	HDIILECVYCKQQLLRREVYDF	31	52	22	112787	P03126	HLA class II	II	PBMC	ELISPOT	IFNg release	1661116	12566307
HPV16	E6	DFAFRDLCIVYRDGNPYAVCDK	51	72	22	112761	P03126	HLA class II	II	PBMC	ELISPOT	IFNg release	1661118	12566307
HPV16	E6	RFHNIRGRWTGRCMSCCRSSRT	131	152	22	112829	P03126	HLA class II	II	PBMC	ELISPOT	IFNg release	1661126	12566307
HPV1a	L1	IPKVSPNAFRVFRVR	66	80	15	112168	P03099	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1661128	12021335
HPV6b	L1	SGGNPGQDNRVNVGMDYKQT	131	150	20	112659	P04012	HLA class II	II	PBMC	3H-thymidine	proliferation	1661130	9261360
HPV6b	L1	VNVGMDYKQTQLCMVGCAPP	141	160	20	112708	P04012	HLA class II	II	PBMC	3H-thymidine	proliferation	1661131	9261360
HPV6b	L1	RLFFFLRKEQMFARHFFNRA	241	260	20	112648	P04012	HLA class II	II	PBMC	3H-thymidine	proliferation	1661145	9261360
HPV6b	L1	KAQGHNNGICWGNQLFVTVV	311	330	20	112556	P04012	HLA class II	II	PBMC	3H-thymidine	proliferation	1661152	9261360
HPV6b	L1	HVEEYDLQFIFQLCSITLSA	361	380	20	112539	P04012	HLA class II	II	PBMC	3H-thymidine	proliferation	1661160	9261360
HPV6b	L1	DTYRYVQSQAITCQKPTPEK	411	430	20	112488	P04012	HLA class II	II	PBMC	3H-thymidine	proliferation	1661164	9261360
HPV6b	L1	ITCQKPTPEKEKPDPYKNLS	421	440	20	112552	P04012	HLA class II	II	PBMC	3H-thymidine	proliferation	1661170	9261360
HPV6b	L1	EKPDPYKNLSFWEVNLKEKF	431	450	20	112494	P04012	HLA class II	II	PBMC	3H-thymidine	proliferation	1661171	9261360
HPV6b	L1	GRSSIRTGVKRPAVSKASAA	471	490	20	112530	P04012	HLA class II	II	PBMC	3H-thymidine	proliferation	1661175	9261360
HPV35	E6	FACYDLCIVY	45	54	10	112503	P03126	HLA class I	I	T cell CD8+	ELISPOT	IFNg release	1662177	16808432
HPV16	E6	QERPRKLPQL	13	22	10	113122	P03126	HLA-B7	I	T cell CD8+	3H-thymidine	proliferation	1662240	17955486
HPV16	E6	DPQERPRKLPQLCTELQTTIHD	11	32	22	112764	P03126	HLA-DP	II	T cell CD4+	3H-thymidine	proliferation	1662241	17955486
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A2	I	T cell CD8+	3H-thymidine	proliferation	1662242	17955486
HPV16	E6	HDIILECVYCKQQLLRREVYDF	31	52	22	112787	P03126	HLA class II	II	T cell	3H-thymidine	proliferation	1662243	17955486
HPV16	E6	CVYCKQQLLRREVYDFAFRDLCIVYRDGNPYA	37	68	32	111180	P03126	HLA-DP	II	T cell CD4+	3H-thymidine	proliferation	1662244	17955486
HPV16	E6	KQQLLRREVYDFAFRDLCIVYR	41	62	22	112798	P03126	HLA-DP	II	T cell	ICS	IFNg release	1662245	17955486
HPV16	E6	FAFRDLCIVY	52	61	10	110575	P03126	HLA class II	II	T cell	3H-thymidine	proliferation	1662246	17955486
HPV16	E6	RDLCIVYRDGNPYAVCDKCLKFYSKISEYRHY	55	86	32	111714	P03126	HLA-DP	II	T cell CD4+	3H-thymidine	proliferation	1662247	17955486
HPV16	E6	YRDGNPYAVCDKCLKFYSKISE	61	82	22	112866	P03126	HLA-DP	II	T cell CD4+	3H-thymidine	proliferation	1662248	17955486
HPV16	E6	DKCLKFYSKISEYRHYCYSLYG	71	92	22	112763	P03126	HLA-DP	II	T cell CD4+	3H-thymidine	proliferation	1662249	17955486
HPV16	E6	CLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCD	73	105	33	112929	P03126	HLA-DP	II	T cell CD4+	3H-thymidine	proliferation	1662250	17955486
HPV16	E6	GTTLEQQYNKPLCDLLIRCINC	92	113	22	113015	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1662252	17955486
HPV16	E6	PLCDLLIRCINCQKPLCPEEKQ	102	123	22	113111	P03126	HLA-DQ	II	T cell CD4+	3H-thymidine	proliferation	1662253	17955486
HPV16	E6	KQRHLDKKQRFHNIRGRWTGRC	122	143	22	113058	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1662255	17955486
HPV16	E6	QRFHNIRGRW	130	139	10	113134	P03126	HLA class II	II	T cell	3H-thymidine	proliferation	1662256	17955486
HPV16	E6	RWTGRCMSCC	138	147	10	113154	P03126	HLA-B27	I	T cell CD8+	3H-thymidine	proliferation	1662257	17955486
HPV16	E6	SSRTRRETQL	149	158	10	113177	P03126	HLA-B14	I	T cell CD8+	3H-thymidine	proliferation	1662258	17955486
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	T cell CD8+	3H-thymidine	proliferation	1662260	17955486
HPV16	E7	DLYCYEQLNDSSEEEDEIDGPA	21	42	22	112938	P03129	HLA-DR4	II	T cell CD4+	3H-thymidine	proliferation	1662261	17955486
HPV16	E7	HYNIVTFCCKCDSTLRLCVQST	51	72	22	113025	P03129	HLA-DP	II	T cell CD4+	3H-thymidine	proliferation	1662264	17955486
HPV16	E7	IRTLEDLLMGT	76	86	11	113033	P03129	HLA-DR12	II	T cell CD4+	3H-thymidine	proliferation	1662266	17955486
HPV18	E6	DLFVVYRDSIPHAACHKCIDFY	51	72	22	112937	P06463	HLA-DQ	II	T cell CD4+	3H-thymidine	proliferation	1662272	17955486
HPV18	E6	FYSRIRELRHYSDSVYGDTLEK	71	92	22	112987	P06463	HLA-DQ	II	T cell CD4+	3H-thymidine	proliferation	1662274	17955486
HPV18	E7	MHGPKATLQDIVLHLEPQNEIP	1	22	22	113092	P06788	HLA-DQ	II	T cell CD4+	3H-thymidine	proliferation	1662281	17955486
HPV18	E7	IPVDLLCHEQLSDSEEENDEID	21	42	22	113031	P06788	HLA-DQ	II	T cell CD4+	3H-thymidine	proliferation	1662283	17955486
HPV16	E6	RWTGRCMSCC	138	147	10	113154	P03126	HLA-B27	I	T cell CD8+	ICS	IFNg release	1662420	17955486
HPV16	E7	IRTLEDLLMGT	76	86	11	113033	P03129	HLA-DR12	II	T cell CD4+	ICS	IFNg release	1662421	17955486
HPV18	E7	IPVDLLCHEQLSDSEEENDEID	21	42	22	113031	P06788	HLA-DQ	II	T cell CD4+	ICS	IFNg release	1662422	17955486
HPV16	E6	KQQLLRREVYDFAFRDLCIVYR	41	62	22	112798	P03126	HLA-DP	II	T cell CD4+	3H-thymidine	proliferation	1662434	17955486
HPV16	E6	FAFRDLCIVY	52	61	10	110575	P03126	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1662435	17955486
HPV16	E6	SSRTRRETQL	149	158	10	113177	P03126	HLA-B14	I	T cell CD8+	ELISPOT	IFNg release	1662441	17955486
HPV16	E6	DPQERPRKLPQLCTELQTTIHD	11	32	22	112764	P03126	HLA-DP	II	T cell CD4+	ELISA	IFNg release	1662450	17955486
HPV16	E6	PLCDLLIRCINCQKPLCPEEKQ	102	123	22	113111	P03126	HLA-DQ	II	T cell CD4+	3H-thymidine	proliferation	1663070	17955486
HPV16	E6	DPQERPRKLPQLCTELQTTIHD	11	32	22	112764	P03126	HLA-DP	II	T cell CD4+	3H-thymidine	proliferation	1663071	17955486
HPV16	E6	DPQERPRKLPQLCTELQTTIHD	11	32	22	112764	P03126	HLA-DP	II	T cell CD4+	ELISA	IFNg release	1663072	17955486
HPV16	E6	KQRHLDKKQRFHNIRGRWTGRC	122	143	22	113058	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1663075	17955486
HPV16	E6	RWTGRCMSCC	138	147	10	113154	P03126	HLA-B27	I	T cell CD8+	3H-thymidine	proliferation	1663079	17955486
HPV16	E6	RWTGRCMSCC	138	147	10	113154	P03126	HLA-B27	I	T cell CD8+	ICS	IFNg release	1663080	17955486
HPV16	E6	SSRTRRETQL	149	158	10	113177	P03126	HLA-B14	I	T cell CD8+	ELISPOT	IFNg release	1663081	17955486
HPV16	E6	HDIILECVYCKQQLLRREVYDF	31	52	22	112787	P03126	HLA class II	II	T cell	3H-thymidine	proliferation	1663082	17955486
HPV16	E6	CVYCKQQLLRREVYDFAFRDLCIVYRDGNPYA	37	68	32	111180	P03126	HLA-DP	II	T cell CD4+	3H-thymidine	proliferation	1663083	17955486
HPV16	E6	KQQLLRREVYDFAFRDLCIVYR	41	62	22	112798	P03126	HLA-DP	II	T cell	ICS	IFNg release	1663084	17955486
HPV16	E6	KQQLLRREVYDFAFRDLCIVYR	41	62	22	112798	P03126	HLA-DP	II	T cell CD4+	3H-thymidine	proliferation	1663085	17955486
HPV16	E6	YRDGNPYAVCDKCLKFYSKISE	61	82	22	112866	P03126	HLA-DP	II	T cell CD4+	3H-thymidine	proliferation	1663086	17955486
HPV16	E6	DKCLKFYSKISEYRHYCYSLYG	71	92	22	112763	P03126	HLA-DP	II	T cell CD4+	3H-thymidine	proliferation	1663087	17955486
HPV16	E6	GTTLEQQYNKPLCDLLIRCINC	92	113	22	113015	P03126	HLA class II	II	T cell CD4+	3H-thymidine	proliferation	1663088	17955486
HPV16	E7	IRTLEDLLMGT	76	86	11	113033	P03129	HLA-DR12	II	T cell CD4+	3H-thymidine	proliferation	1663089	17955486
HPV16	E7	IRTLEDLLMGT	76	86	11	113033	P03129	HLA-DR12	II	T cell CD4+	ICS	IFNg release	1663090	17955486
HPV18	E7	IPVDLLCHEQLSDSEEENDEID	21	42	22	113031	P06788	HLA-DQ	II	T cell CD4+	3H-thymidine	proliferation	1663091	17955486
HPV18	E7	IPVDLLCHEQLSDSEEENDEID	21	42	22	113031	P06788	HLA-DQ	II	T cell CD4+	ICS	IFNg release	1663092	17955486
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1664779	19180468
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	in vivo assay	cytotoxicity	1664780	19180468
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	1664781	19180468
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD4+	ELISA	IFNg release	1664782	19180468
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1664981	19180468
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	1665003	15963358
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1665018	15963358
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1665050	19180468
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1665092	19180468
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	in vivo assay	cytotoxicity	1665096	19180468
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1665110	19180468
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1665123	19180468
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	in vivo assay	cytotoxicity	1665131	19180468
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	in vivo assay	cytotoxicity	1665132	19180468
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1665140	19180468
HPV7	L2	IGGRVHFFKDISPIA	316	330	15	113535	P36745	HLA-DRB1*15:01	II	T cell	3H-thymidine	proliferation	1666856	9645371
HPV7	L2	IGGRVHFFKDISPIA	316	330	15	113535	P36745	HLA-DRB1*04:03	II	T cell	3H-thymidine	proliferation	1666989	9645371
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1667398	12905010
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1667407	12905010
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1667409	12905010
HPV16	E7	TLGIVCPIC	86	94	9	64819	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1667569	17192185
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1667570	17192185
HPV18	E6	KLPDLCTEL	13	21	9	32073	P06463	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1667571	17192185
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD8+	ICS	IFNg release	1667679	16824651
HPV16	E7	DSSEEEDEIDGPAGQAEPDRAHYNIVTFCCKCDSTLRL	30	67	38	110567	P03129	H2-b class II	II	T cell CD4+	ICS	IFNg release	1667684	16824651
HPV7	L2	IGGRVHFFKDISPIASSE	316	333	18	117532	P36745	H2-s class II	II	T cell	3H-thymidine	proliferation	1689610	9802984
HPV7	L2	IGGRVHFFKDISPIASSE	316	333	18	117532	P36745	H2-s class II	II	T cell	3H-thymidine	proliferation	1689630	9802984
HPV7	L2	IGGRVHFFKDISPIASSE	316	333	18	117532	P36745	H2-s class II	II	T cell	3H-thymidine	proliferation	1689638	9802984
HPV7	L2	IGGRVHFFKDISPIASSE	316	333	18	117532	P36745	-	-	-	in vivo assay	disease exacerbation	1689670	9802984
HPV7	L2	IGGRVHFFKDISPIASSE	316	333	18	117532	P36745	-	-	-	in vivo assay	disease exacerbation	1689674	9802984
HPV7	L2	IGGRVHFFKDISPIASSE	316	333	18	117532	P36745	H2-s class II	II	T cell	3H-thymidine	proliferation	1689689	9802984
HPV7	L2	IGGRVHFFKDISPIASSE	316	333	18	117532	P36745	H2-IAs	II	T cell	ELISA	IFNg release	1689718	9802984
HPV7	L2	IGGRVHFFKDISPIASSE	316	333	18	117532	P36745	H2-IAs	II	T cell	ELISA	TNFa release	1689719	9802984
HPV7	L2	IGGRVHFFKDISPIASSE	316	333	18	117532	P36745	H2-IAs	II	T cell	ELISA	IL-10 release	1689720	9802984
HPV7	L2	IGGRVHFFKDISPIASSE	316	333	18	117532	P36745	H2-s class II	II	T cell	3H-thymidine	proliferation	1689943	9802984
HPV7	L2	IGGRVHFFKDISPIASSE	316	333	18	117532	P36745	H2-s class II	II	T cell	3H-thymidine	proliferation	1689944	9802984
HPV7	L2	IGGRVHFFKDISPIA	316	330	15	113535	P36745	HLA class II	II	PBMC	3H-thymidine	proliferation	1689975	7534214
HPV18	E7	GVNHQHLPARRAEPQ	43	57	15	111389	P06788	HLA class II	II	T cell CD4+	ELISPOT	IFNg release	1690869	15623547
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1694383	19500947
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	ELISA	IL-10 release	1694385	19500947
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	survival from challenge	1694392	19500947
HPV16	E6	ERPRKLPQLCTELQTTIHDII	14	34	21	118789	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1694689	19843089
HPV16	E6	LRREVYDFAFRDLCIVYRDGNPYA	45	68	24	118897	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1694691	19843089
HPV16	E6	YRDGNPYAVCDKCLKFYSKI	61	80	20	119061	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1694692	19843089
HPV16	E6	YGTTLEQQYNKPLCDLLIRC	91	110	20	119057	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1694694	19843089
HPV16	E6	DLLIRCINCQKPLCPEEKQRHL	105	126	22	118769	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1694695	19843089
HPV16	E6	EKQRHLDKKQRFHNIRGRWT	121	140	20	118785	P03126	HLA class II	II	PBMC	3H-thymidine	proliferation	1694696	19843089
HPV16	E7	TLHEYMLDLQPETTDLYCYEQ	7	27	21	119032	P03129	HLA class II	II	PBMC	3H-thymidine	proliferation	1694699	19843089
HPV16	E7	DLYCYEQLNDSSEEEDEIDG	21	40	20	108873	P03129	HLA class II	II	PBMC	3H-thymidine	proliferation	1694700	19843089
HPV16	E7	EDEIDGPAGQAEPDRAHYNIV	35	55	21	118778	P03129	HLA class II	II	PBMC	3H-thymidine	proliferation	1694701	19843089
HPV16	E7	KCDSTLRLCVQSTHV	60	74	15	118858	P03129	HLA class II	II	PBMC	3H-thymidine	proliferation	1694703	19843089
HPV16	E7	LRLCVQSTHVDIRTLEDLLMGTL	65	87	23	118895	P03129	HLA class II	II	PBMC	3H-thymidine	proliferation	1694704	19843089
HPV16	E7	TLEDLLMGTLGIVCPICSQKP	78	98	21	119031	P03129	HLA class II	II	PBMC	3H-thymidine	proliferation	1694705	19843089
HPV16	E6	ERPRKLPQLCTELQTTIHDII	14	34	21	118789	P03126	-	-	PBMC	ELISPOT	IFNg release	1694708	19843089
HPV16	E6	LRREVYDFAFRDLCIVYRDGNPYA	45	68	24	118897	P03126	-	-	PBMC	ELISPOT	IFNg release	1694710	19843089
HPV16	E6	YGTTLEQQYNKPLCDLLIRC	91	110	20	119057	P03126	-	-	PBMC	ELISPOT	IFNg release	1694713	19843089
HPV16	E6	DLLIRCINCQKPLCPEEKQRHL	105	126	22	118769	P03126	-	-	PBMC	ELISPOT	IFNg release	1694714	19843089
HPV16	E7	MGGDTPTLHEYMLDLQPETT	0	0	20	118907	P03129	-	-	PBMC	ELISPOT	IFNg release	1694717	19843089
HPV16	E7	TLHEYMLDLQPETTDLYCYEQ	7	27	21	119032	P03129	-	-	PBMC	ELISPOT	IFNg release	1694718	19843089
HPV16	E7	DLYCYEQLNDSSEEEDEIDG	21	40	20	108873	P03129	-	-	PBMC	ELISPOT	IFNg release	1694719	19843089
HPV16	E7	TLEDLLMGTLGIVCPICSQKP	78	98	21	119031	P03129	-	-	PBMC	ELISPOT	IFNg release	1694724	19843089
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	51 chromium	cytotoxicity	1695290	19500947
HPV11	E7	TLKDIVLDL	7	15	9	110438	P04020	HLA-A*02:01	I	T cell CD4+	ELISPOT	IFNg release	1705023	19578865
HPV11	E7	TLKDIVLDL	7	15	9	110438	P04020	HLA-A*02:01	I	T cell CD4+	ELISA	TNF release	1705025	19578865
HPV11	E7	TLKDIVLDL	7	15	9	110438	P04020	HLA-A*02:01	I	T cell CD4+	ELISPOT	IL-2 release	1705026	19578865
HPV11	E7	TLKDIVLDL	7	15	9	110438	P04020	HLA-A*02:01	I	T cell CD8+	in vitro assay	cytotoxicity	1705027	19578865
HPV1a	L2	NNSTGDFEL	486	494	9	125176	P03105	-	-	-	in vivo assay	disease exacerbation	1712423	7594562
HPV7	E7	SSHNRQREQPT	44	54	11	127832	P36816	H2 class II	II	T cell	3H-thymidine	proliferation	1712862	10490973
HPV11	E6	YAYAYKNL	44	51	8	127414	P04019	H2-Kb	I	T cell CD8+	in vitro assay	cytotoxicity	1716630	20025042
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1763847	20006892
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	51 chromium	cytotoxicity	1763848	20006892
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A2	I	T cell CD8+	51 chromium	cytotoxicity	1763918	20006892
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	pathogen burden after challenge	1763993	20006892
HPV7	L2	IGGRVHFFKDISPIA	316	330	15	113535	P36745	H2-IAs	II	-	in vivo assay	decreased disease	1776831	10209044
HPV13	L2	IGGRVHFFKDISPIS	315	329	15	114406	P04013	-	-	-	in vivo assay	decreased disease	1776832	10209044
HPV40	L2	IGGRVHFFRDISPIG	316	330	15	114407	P36745	H2-IAs	II	-	in vivo assay	decreased disease	1776833	10209044
HPV32	L2	IGSRVHFFHDISPIT	320	334	15	114409	P36757	-	-	-	in vivo assay	decreased disease	1776835	10209044
HPV13	L2	IGGRVHFFKDISPIS	315	329	15	114406	P04013	H2-s class II	II	T cell	3H-thymidine	proliferation	1776840	10209044
HPV13	L2	IGGRVHFFKDISPIS	315	329	15	114406	P04013	H2-s class II	II	T cell	ELISA	IL-4 release	1776841	10209044
HPV13	L2	IGGRVHFFKDISPIS	315	329	15	114406	P04013	-	-	T cell	ELISA	IFNg release	1776842	10209044
HPV13	L2	IGGRVHFFKDISPIS	315	329	15	114406	P04013	-	-	-	in vivo assay	decreased disease	1776847	10209044
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	1777298	20126973
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	1777299	20126973
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1777301	20126973
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1777305	20126973
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	-	-	-	in vivo assay	pathogen burden after challenge	1781181	20332046
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	1782864	20463596
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	in vitro assay	cytotoxicity	1782865	20463596
HPV16	E7	GQAEPDRAHYNIVTFCCKCD	43	62	20	110869	P03129	H2-b class I	I	T cell CD8+	ICS	IFNg release	1792234	20541583
HPV16	E7	GQAEPDRAHYNIVTFCCKCD	43	62	20	110869	P03129	H2-b class I	I	-	in vivo assay	tumor burden after challenge	1792237	20541583
HPV16	E7	GQAEPDRAHYNIVTFCCKCD	43	62	20	110869	P03129	H2-b class I	I	-	in vivo assay	survival from challenge	1792238	20541583
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD8+	ICS	IFNg release	1792249	20739505
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD8+	in vivo assay	cytotoxicity	1792250	20739505
HPV16	E6	VYDFAFRDL	49	57	9	71988	P03126	H2-b class I	I	T cell CD8+	ICS	IFNg release	1792251	20739505
HPV16	E6	VYDFAFRDL	49	57	9	71988	P03126	H2-b class I	I	T cell CD8+	in vivo assay	cytotoxicity	1792252	20739505
HPV16	E5	VCLLIRPLL	25	33	9	110731	P06927	H2-b class I	I	T cell CD8+	ICS	IFNg release	1792253	20739505
HPV16	E5	VCLLIRPLL	25	33	9	110731	P06927	H2-b class I	I	T cell CD8+	in vivo assay	cytotoxicity	1792254	20739505
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD8+	biological activity	degranulation	1792298	20739505
HPV16	E6	VYDFAFRDL	49	57	9	71988	P03126	H2-b class I	I	T cell CD8+	biological activity	degranulation	1792299	20739505
HPV16	E5	VCLLIRPLL	25	33	9	110731	P06927	H2-b class I	I	T cell CD8+	biological activity	degranulation	1792300	20739505
HPV58	L1	RVRLPDPNK	101	109	9	137685	P03101	HLA-A11	I	PBMC	ELISPOT	IFNg release	1796156	20668141
HPV58	L1	AVPDDLYIK	296	304	9	137611	P03101	HLA-A11	I	PBMC	ELISPOT	IFNg release	1796160	20668141
HPV58	L1	AVPDDLYIK	296	304	9	137611	P03101	HLA-A11	I	PBMC	ELISPOT	IFNg release	1796161	20668141
HPV58	L1	TSESQLFNK	327	335	9	137702	P03101	HLA-A11	I	PBMC	ELISPOT	IFNg release	1796164	20668141
HPV58	L1	YTFWEVNLK	469	477	9	137724	P03101	HLA-A11	I	PBMC	ELISPOT	IFNg release	1796180	20668141
HPV58	E6	KVCLRLLSK	48	56	9	137659	P03126	HLA-A11	I	PBMC	ELISPOT	IFNg release	1796192	20668141
HPV58	E6	KVCLRLLSK	48	56	9	137659	P03126	HLA-A11	I	PBMC	ELISPOT	IFNg release	1796193	20668141
HPV58	E6	KVCLRLLSK	48	56	9	137659	P03126	HLA-A11	I	PBMC	ELISPOT	IFNg release	1796195	20668141
HPV58	E6	KCLNEILIR	78	86	9	137657	P03126	HLA-A11	I	PBMC	ELISPOT	IFNg release	1796197	20668141
HPV58	E7	ATEVRTLQQ	66	74	9	137609	P03129	HLA-A11	I	PBMC	ELISPOT	IFNg release	1796204	20668141
HPV58	E7	ATEVRTLQQ	66	74	9	137609	P03129	HLA-A11	I	PBMC	ELISPOT	IFNg release	1796205	20668141
HPV58	E7	ATEVRTLQQ	66	74	9	137609	P03129	HLA-A11	I	PBMC	ELISPOT	IFNg release	1796206	20668141
HPV58	E7	ATEVRTLQQ	66	74	9	137609	P03129	HLA-A11	I	PBMC	ELISPOT	IFNg release	1796207	20668141
HPV58	E7	LCINSTATE	60	68	9	137661	P03129	HLA-A11	I	PBMC	ELISPOT	IFNg release	1796209	20668141
HPV58	E7	CTIVCPSCA	88	96	9	137614	P03129	HLA-A11	I	PBMC	ELISPOT	IFNg release	1796215	20668141
HPV58	E6	VYDFVFADL	26	34	9	71990	P03126	HLA-A24	I	Splenocyte	ELISPOT	IFNg release	1796224	20668141
HPV58	E6	VFADLRIVY	30	38	9	137709	P03126	HLA-A24	I	Splenocyte	ELISPOT	IFNg release	1796229	20668141
HPV58	L1	FFPTPSGSI	317	325	9	137643	P03101	HLA-A24	I	Splenocyte	ELISPOT	IFNg release	1796234	20668141
HPV58	L1	VFQLCKITL	400	408	9	137710	P03101	HLA-A24	I	Splenocyte	ELISPOT	IFNg release	1796239	20668141
HPV58	L1	TYIHTMDSN	414	422	9	137704	P03101	HLA-A24	I	Splenocyte	ELISPOT	IFNg release	1796244	20668141
HPV58	L1	TYRFVTSQA	442	450	9	137705	P03101	HLA-A24	I	Splenocyte	ELISPOT	IFNg release	1796249	20668141
HPV58	L1	KYTFWEVNL	468	476	9	137660	P03101	HLA-A24	I	PBMC	ELISPOT	IFNg release	1796251	20668141
HPV58	L1	KYTFWEVNL	468	476	9	137660	P03101	HLA-A24	I	Splenocyte	ELISPOT	IFNg release	1796254	20668141
HPV58	E6	ALETSVHEI	2	10	9	137607	P03126	HLA-A2	I	Splenocyte	ELISPOT	IFNg release	1796259	20668141
HPV58	E6	VCLRLLSKI	49	57	9	137707	P03126	HLA-A2	I	Splenocyte	ELISPOT	IFNg release	1796264	20668141
HPV58	E6	ILIRCIICQ	83	91	9	137656	P03126	HLA-A2	I	PBMC	ELISPOT	IFNg release	1796266	20668141
HPV58	E6	ILIRCIICQ	83	91	9	137656	P03126	HLA-A2	I	Splenocyte	ELISPOT	IFNg release	1796269	20668141
HPV58	E7	CINSTATEV	61	69	9	137613	P03129	HLA-A2	I	Splenocyte	ELISPOT	IFNg release	1796274	20668141
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1803366	20615877
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1803367	20615877
HPV16	E7	TLHEYMLDL	7	15	9	64830	P03129	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1803368	20615877
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1803369	20615877
HPV16	E6	KLPQLCTEL	18	26	9	32085	P03126	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1803370	20615877
HPV16	E6	FAFRDLCIV	52	60	9	15173	P03126	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1803371	20615877
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1803372	20615877
HPV16	E7	TLGIVCPI	86	93	8	64818	P03129	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1803373	20615877
HPV16	E7	GTLGIVCPI	85	93	9	22738	P03129	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1803374	20615877
HPV16	E7	MLDLQPETT	12	20	9	41919	P03129	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1803375	20615877
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	T cell CD8+	3H-thymidine	proliferation	1803376	20615877
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1803377	20615877
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	1803378	20615877
HPV16	E7	RAHYNIVTE	0	0	9	140736	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	1810159	21092195
HPV16	E7	RAHYNIVTE	0	0	9	140736	P03129	H2-Db	I	-	in vivo assay	survival from challenge	1810168	21092195
HPV16	E7	RAHYNIVTE	0	0	9	140736	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	1810169	21092195
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1818225	21145912
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	in vitro assay	cytotoxicity	1818227	21145912
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	-	-	-	in vivo assay	tumor burden after challenge	1818558	21167863
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	-	in vivo assay	tumor burden after challenge	1818572	21167863
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	-	in vivo assay	tumor burden after challenge	1818573	21167863
HPV11	E2	AKRLDACQDQLLE	5	17	13	145077	P04015	HLA-DRB1*03:01	II	T cell CD4+	multimer/tetramer	qualitative binding	1833012	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*03:01	II	T cell CD4+	multimer/tetramer	qualitative binding	1833047	21531896
HPV11	E6	EKLKHILGKARFIKLN	115	130	16	145164	P04019	HLA-DRB1*01:02	II	T cell CD4+	multimer/tetramer	qualitative binding	1833071	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*03:01	II	T cell CD4+	3H-thymidine	proliferation	1833076	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*01:02	II	T cell CD4+	multimer/tetramer	qualitative binding	1833077	21531896
HPV11	E2	AKRLDACQDQLLE	5	17	13	145077	P04015	HLA-DRB1*03:01	II	T cell CD4+	3H-thymidine	proliferation	1833100	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*01:02	II	T cell CD4+	3H-thymidine	proliferation	1833101	21531896
HPV11	E6	EKLKHILGKARFIKLN	115	130	16	145164	P04019	HLA-DRB1*01:02	II	T cell CD4+	3H-thymidine	proliferation	1833102	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*03:01	II	T cell CD4+	multimer/tetramer	qualitative binding	1833103	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*01:02	II	T cell CD4+	multimer/tetramer	qualitative binding	1833104	21531896
HPV11	E6	EKLKHILGKARFIKLN	115	130	16	145164	P04019	HLA-DRB1*01:02	II	T cell CD4+	multimer/tetramer	qualitative binding	1833105	21531896
HPV11	E2	AKRLDACQDQLLE	5	17	13	145077	P04015	HLA-DRB1*03:01	II	T cell CD4+	multimer/tetramer	qualitative binding	1833106	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*03:01	II	T cell CD4+	cytometric bead array	IFNg release	1833223	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*01:02	II	T cell CD4+	cytometric bead array	IFNg release	1833224	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*03:01	II	T cell CD4+	cytometric bead array	IFNg release	1833225	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*01:02	II	T cell CD4+	cytometric bead array	IFNg release	1833226	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*03:01	II	T cell CD4+	cytometric bead array	TNFa release	1833227	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*01:02	II	T cell CD4+	cytometric bead array	TNFa release	1833228	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*03:01	II	T cell CD4+	cytometric bead array	TNFa release	1833229	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*01:02	II	T cell CD4+	cytometric bead array	TNFa release	1833230	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*03:01	II	T cell CD4+	cytometric bead array	IL-5 release	1833231	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*01:02	II	T cell CD4+	cytometric bead array	IL-5 release	1833232	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*03:01	II	T cell CD4+	cytometric bead array	IL-5 release	1833233	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*01:02	II	T cell CD4+	cytometric bead array	IL-5 release	1833234	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*03:01	II	T cell CD4+	cytometric bead array	IL-10 release	1833235	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*01:02	II	T cell CD4+	cytometric bead array	IL-10 release	1833236	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*03:01	II	T cell CD4+	cytometric bead array	IL-10 release	1833237	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*01:02	II	T cell CD4+	cytometric bead array	IL-10 release	1833238	21531896
HPV11	E2	AKRLDACQDQLLE	5	17	13	145077	P04015	HLA-DRB1*03:01	II	T cell CD4+	cytometric bead array	IFNg release	1833239	21531896
HPV11	E2	AKRLDACQDQLLE	5	17	13	145077	P04015	HLA-DRB1*03:01	II	T cell CD4+	cytometric bead array	IFNg release	1833240	21531896
HPV11	E2	AKRLDACQDQLLE	5	17	13	145077	P04015	HLA-DRB1*03:01	II	T cell CD4+	cytometric bead array	TNFa release	1833241	21531896
HPV11	E2	AKRLDACQDQLLE	5	17	13	145077	P04015	HLA-DRB1*03:01	II	T cell CD4+	cytometric bead array	TNFa release	1833242	21531896
HPV11	E2	AKRLDACQDQLLE	5	17	13	145077	P04015	HLA-DRB1*03:01	II	T cell CD4+	cytometric bead array	IL-5 release	1833243	21531896
HPV11	E2	AKRLDACQDQLLE	5	17	13	145077	P04015	HLA-DRB1*03:01	II	T cell CD4+	cytometric bead array	IL-5 release	1833244	21531896
HPV11	E2	AKRLDACQDQLLE	5	17	13	145077	P04015	HLA-DRB1*03:01	II	T cell CD4+	cytometric bead array	IL-10 release	1833245	21531896
HPV11	E2	AKRLDACQDQLLE	5	17	13	145077	P04015	HLA-DRB1*03:01	II	T cell CD4+	cytometric bead array	IL-10 release	1833246	21531896
HPV11	E6	EKLKHILGKARFIKLN	115	130	16	145164	P04019	HLA-DRB1*01:02	II	T cell CD4+	cytometric bead array	IFNg release	1833247	21531896
HPV11	E6	EKLKHILGKARFIKLN	115	130	16	145164	P04019	HLA-DRB1*01:02	II	T cell CD4+	cytometric bead array	IFNg release	1833248	21531896
HPV11	E6	EKLKHILGKARFIKLN	115	130	16	145164	P04019	HLA-DRB1*01:02	II	T cell CD4+	cytometric bead array	TNFa release	1833249	21531896
HPV11	E6	EKLKHILGKARFIKLN	115	130	16	145164	P04019	HLA-DRB1*01:02	II	T cell CD4+	cytometric bead array	TNFa release	1833250	21531896
HPV11	E6	EKLKHILGKARFIKLN	115	130	16	145164	P04019	HLA-DRB1*01:02	II	T cell CD4+	cytometric bead array	IL-5 release	1833251	21531896
HPV11	E6	EKLKHILGKARFIKLN	115	130	16	145164	P04019	HLA-DRB1*01:02	II	T cell CD4+	cytometric bead array	IL-5 release	1833252	21531896
HPV11	E6	EKLKHILGKARFIKLN	115	130	16	145164	P04019	HLA-DRB1*01:02	II	T cell CD4+	cytometric bead array	IL-10 release	1833253	21531896
HPV11	E6	EKLKHILGKARFIKLN	115	130	16	145164	P04019	HLA-DRB1*01:02	II	T cell CD4+	cytometric bead array	IL-10 release	1833254	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*03:01	II	T cell CD4+	ICS	IL-2 release	1833255	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*01:02	II	T cell CD4+	ICS	IL-2 release	1833256	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*03:01	II	T cell CD4+	ICS	IL-2 release	1833257	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*01:02	II	T cell CD4+	ICS	IL-2 release	1833258	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*03:01	II	T cell CD4+	ICS	IL-13 release	1833259	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*01:02	II	T cell CD4+	ICS	IL-13 release	1833260	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*03:01	II	T cell CD4+	ICS	IL-13 release	1833261	21531896
HPV11	E2	PIVQLQGDSNCLKCFR	285	300	16	145412	P04015	HLA-DRB1*01:02	II	T cell CD4+	ICS	IL-13 release	1833262	21531896
HPV11	E2	AKRLDACQDQLLE	5	17	13	145077	P04015	HLA-DRB1*03:01	II	T cell CD4+	ICS	IL-2 release	1833263	21531896
HPV11	E2	AKRLDACQDQLLE	5	17	13	145077	P04015	HLA-DRB1*03:01	II	T cell CD4+	ICS	IL-2 release	1833264	21531896
HPV11	E2	AKRLDACQDQLLE	5	17	13	145077	P04015	HLA-DRB1*03:01	II	T cell CD4+	ICS	IL-13 release	1833265	21531896
HPV11	E2	AKRLDACQDQLLE	5	17	13	145077	P04015	HLA-DRB1*03:01	II	T cell CD4+	ICS	IL-13 release	1833266	21531896
HPV11	E6	EKLKHILGKARFIKLN	115	130	16	145164	P04019	HLA-DRB1*01:02	II	T cell CD4+	ICS	IL-2 release	1833267	21531896
HPV11	E6	EKLKHILGKARFIKLN	115	130	16	145164	P04019	HLA-DRB1*01:02	II	T cell CD4+	ICS	IL-2 release	1833268	21531896
HPV11	E6	EKLKHILGKARFIKLN	115	130	16	145164	P04019	HLA-DRB1*01:02	II	T cell CD4+	ICS	IL-13 release	1833269	21531896
HPV11	E6	EKLKHILGKARFIKLN	115	130	16	145164	P04019	HLA-DRB1*01:02	II	T cell CD4+	ICS	IL-13 release	1833270	21531896
HPV16	E6	KLPQLCTEL	18	26	9	32085	P03126	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838529	21550027
HPV18	E6	KLPDLCTEL	13	21	9	32073	P06463	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838531	21550027
HPV11	E6	SIDQLCKTF	12	20	9	146005	P04019	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838532	21550027
HPV11	E6	SIDQLCKTF	12	20	9	146005	P04019	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838533	21550027
HPV6b	E6	TIDQLCKTF	12	20	9	146028	P04019	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838534	21550027
HPV6b	E6	TIDQLCKTF	12	20	9	146028	P04019	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838535	21550027
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838537	21550027
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838538	21550027
HPV18	E7	LFLNTLSFV	89	97	9	111479	P06788	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838539	21550027
HPV18	E7	LFLNTLSFV	89	97	9	111479	P06788	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838540	21550027
HPV6	E7	LLLGTLNIV	82	90	9	110323	P04020	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838541	21550027
HPV6	E7	LLLGTLNIV	82	90	9	110323	P04020	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838542	21550027
HPV18	E6	NLLIRCLRC	100	108	9	145918	P06463	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838548	21550027
HPV18	E6	NLLIRCLRC	100	108	9	145918	P06463	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838549	21550027
HPV11	E6	KVLIRCYLC	99	107	9	145860	P04019	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838550	21550027
HPV11	E6	KVLIRCYLC	99	107	9	145860	P04019	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838551	21550027
HPV18	E6	NLLIRCLRC	100	108	9	145918	P06463	HLA-A*02:01	I	T cell	ELISPOT	IFNg release	1838552	21550027
HPV18	E6	NLLIRCLRC	100	108	9	145918	P06463	HLA-A*02:01	I	T cell	ELISPOT	IFNg release	1838558	21550027
HPV11	E6	KVLIRCYLC	99	107	9	145860	P04019	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838559	21550027
HPV11	E7	LLLGTLNIV	82	90	9	110323	P04020	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838571	21550027
HPV11	E7	LLLGTLNIV	82	90	9	110323	P04020	HLA-A*02:01	I	T cell CD8+	ELISPOT	IFNg release	1838572	21550027
HPV52	L1	TSESQLFNK	332	340	9	137702	P03101	HLA-A11	I	PBMC	ELISPOT	IFNg release	1838582	21503915
HPV52	L1	TSESQLFNK	332	340	9	137702	P03101	HLA-A11	I	PBMC	ELISPOT	IFNg release	1844872	21503915
HPV52	L1	MTLCAEVKK	373	381	9	147981	P03101	HLA-A11	I	PBMC	ELISPOT	IFNg release	1844874	21503915
HPV52	L1	LQFIFQLCK	402	410	9	147941	P03101	HLA-A11	I	PBMC	ELISPOT	IFNg release	1844875	21503915
HPV52	L1	RIKLPDPNK	103	111	9	148172	P03101	HLA-A11	I	PBMC	ELISPOT	IFNg release	1844876	21503915
HPV52	L1	MTLCAEVKK	373	381	9	147981	P03101	HLA-A11	I	PBMC	ELISPOT	IFNg release	1844881	21503915
HPV52	L1	LQFIFQLCK	402	410	9	147941	P03101	HLA-A11	I	PBMC	ELISPOT	IFNg release	1844882	21503915
HPV52	E6	KTLEERVKK	86	94	9	147891	P03126	HLA-A11	I	PBMC	ELISPOT	IFNg release	1844884	21503915
HPV52	E6	RLQCVQCKK	27	35	9	148177	P03126	HLA-A11	I	PBMC	ELISPOT	IFNg release	1844885	21503915
HPV52	E7	MRGDKATIK	1	9	9	147973	P03129	HLA-A11	I	PBMC	ELISPOT	IFNg release	1844886	21503915
HPV52	E7	QLGDSSDEE	27	35	9	148138	P03129	HLA-A11	I	PBMC	ELISPOT	IFNg release	1844887	21503915
HPV52	E6	VYKFLFTDL	42	50	9	148425	P03126	HLA-A24	I	PBMC	ELISPOT	IFNg release	1844890	21503915
HPV52	E6	PYGVCIMCL	59	67	9	148117	P03126	HLA-A24	I	PBMC	ELISPOT	IFNg release	1844891	21503915
HPV52	E6	PYGVCIMCL	59	67	9	148117	P03126	HLA-A24	I	PBMC	ELISPOT	IFNg release	1844892	21503915
HPV52	E7	CYEQLGDSS	24	32	9	147561	P03129	HLA-A24	I	PBMC	ELISPOT	IFNg release	1844894	21503915
HPV52	L1	YYYAGSSRL	60	68	9	137726	P03101	HLA-A24	I	PBMC	ELISPOT	IFNg release	1844895	21503915
HPV52	L1	YYYAGSSRL	60	68	9	137726	P03101	HLA-A24	I	PBMC	ELISPOT	IFNg release	1844896	21503915
HPV52	L1	QYRVFRIKL	98	106	9	148160	P03101	HLA-A24	I	PBMC	ELISPOT	IFNg release	1844897	21503915
HPV52	L1	QYRVFRIKL	98	106	9	148160	P03101	HLA-A24	I	PBMC	ELISPOT	IFNg release	1844898	21503915
HPV52	E6	ITIRCIICQ	99	107	9	147835	P03126	HLA-A2	I	PBMC	ELISPOT	IFNg release	1844901	21503915
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1849642	21207427
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1849645	21207427
HPV16	E6	EVYDFAFRDL	48	57	10	14909	P03126	H2-Kb	I	T cell CD8+	multimer/tetramer	qualitative binding	1849648	21207427
HPV16	E6	EVYDFAFRDL	48	57	10	14909	P03126	H2-Kb	I	T cell CD8+	multimer/tetramer	qualitative binding	1849649	21207427
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	1849657	21207427
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	cytotoxicity	1849665	21207427
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	1850174	21672263
HPV18	E6	KCIDFYSRI	67	75	9	111442	P06463	H2-b class I	I	T cell CD8+	ICS	IFNg release	1850178	21672263
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	cytotoxicity	1850179	21672263
HPV18	E6	KCIDFYSRI	67	75	9	111442	P06463	H2-b class I	I	-	in vivo assay	cytotoxicity	1850181	21672263
HPV16	E7	GQAEPDRAHYNIVTFCCKCD	43	62	20	110869	P03129	-	-	-	in vivo assay	tumor burden after challenge	1859485	21128743
HPV16	E7	GQAEPDRAHYNIVTFCCKCD	43	62	20	110869	P03129	-	-	-	in vivo assay	survival from challenge	1859489	21128743
HPV16	E7	GQAEPDRAHYNIVTFCCKCD	43	62	20	110869	P03129	H2-b class I	I	T cell CD8+	ICS	IFNg release	1859490	21128743
HPV16	E7	GQAEPDRAHYNIVTFCCKCD	43	62	20	110869	P03129	H2-b class I	I	T cell CD8+	ICS	IFNg release	1859543	21128743
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-b class I	I	-	in vivo assay	tumor burden after challenge	1859839	7690326
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	1859840	7690326
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	in vitro assay	cytotoxicity	1859841	7690326
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	in vitro assay	cytotoxicity	1859842	7690326
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	in vitro assay	cytotoxicity	1859844	7690326
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-b class I	I	T cell CD8+	in vitro assay	cytotoxicity	1859845	7690326
HPV16	E6	VYDFAFRDL	49	57	9	71988	P03126	HLA-A*24:02	I	PBMC	ELISPOT	IFNg release	1931141	22032938
HPV16	E6	PYAVCDKCL	66	74	9	50064	P03126	HLA-A*24:02	I	PBMC	ELISPOT	IFNg release	1931486	22032938
HPV16	E6	EYRHYCYSL	82	90	9	110846	P03126	HLA-A*24:02	I	PBMC	ELISPOT	IFNg release	1931487	22032938
HPV16	E6	CYSLYGTTL	87	95	9	7439	P03126	HLA-A*24:02	I	PBMC	ELISPOT	IFNg release	1931488	22032938
HPV16	E6	QYNKPLCDL	98	106	9	111698	P03126	HLA-A*24:02	I	PBMC	ELISPOT	IFNg release	1931489	22032938
HPV16	E7	LMGTLGIVCPI	83	93	11	165037	P03129	HLA-A*24:02	I	PBMC	ELISPOT	IFNg release	1931490	22032938
HPV16	E7	CDSTLRLCV	61	69	9	168256	P03129	HLA-A*24:02	I	T cell CD8+	ICS	IFNg release	1943094	21918960
HPV16	E7	LCVQSTHVDI	67	76	10	169070	P03129	HLA-A*24:02	I	T cell CD8+	ICS	IFNg release	1943113	21918960
HPV16	E7	CDSTLRLCV	61	69	9	168256	P03129	HLA-A*24:02	I	T cell CD8+	51 chromium	cytotoxicity	1943119	21918960
HPV16	E7	LCVQSTHVDI	67	76	10	169070	P03129	HLA-A*24:02	I	T cell CD8+	51 chromium	cytotoxicity	1943122	21918960
HPV16	E7	CDSTLRLCV	61	69	9	168256	P03129	HLA-A*24:02	I	T cell CD8+	in vivo assay	tumor burden after challenge	1943124	21918960
HPV16	E7	LCVQSTHVDI	67	76	10	169070	P03129	HLA-A*24:02	I	T cell CD8+	in vivo assay	tumor burden after challenge	1943125	21918960
HPV16	E2	KALQAIELQLTLETI	68	82	15	174156	P03120	HLA class II	II	T cell CD4+	ICS	IFNg release	1953398	22590583
HPV16	E2	KALQAIELQLTLETI	68	82	15	174156	P03120	HLA class II	II	T cell CD4+	ICS	IL-2 release	1953399	22590583
HPV16	E2	LQDVSLEVYLTAPTG	94	108	15	174186	P03120	HLA class II	II	T cell CD4+	ICS	IFNg release	1953400	22590583
HPV16	E2	LQDVSLEVYLTAPTG	94	108	15	174186	P03120	HLA class II	II	T cell CD4+	ICS	IL-2 release	1953401	22590583
HPV16	E2	LTYDSEWQRDQFLSQV	335	350	16	174194	P03120	HLA class II	II	T cell CD4+	ICS	IFNg release	1953402	22590583
HPV16	E2	LRYRFKKHCTLYTAV	301	315	15	174189	P03120	HLA class II	II	T cell CD4+	ICS	IFNg release	1953404	22590583
HPV16	E2	LRYRFKKHCTLYTAV	301	315	15	174189	P03120	HLA class II	II	T cell CD4+	ICS	IL-2 release	1953405	22590583
HPV16	E2	KALQAIELQLTLETI	68	82	15	174156	P03120	HLA class II	II	T cell CD4+	ICS	IFNg release	1953406	22590583
HPV16	E2	KALQAIELQLTLETI	68	82	15	174156	P03120	HLA class II	II	T cell CD4+	ICS	IL-2 release	1953407	22590583
HPV16	E2	IELQLTLETIYNSQYS	73	88	16	174148	P03120	HLA class II	II	T cell CD4+	ICS	IFNg release	1953408	22590583
HPV16	E2	IELQLTLETIYNSQYS	73	88	16	174148	P03120	HLA class II	II	T cell CD4+	ICS	IL-2 release	1953409	22590583
HPV16	E2	REMGFKHINHQVVPT	47	61	15	174257	P03120	HLA class II	II	T cell CD4+	ICS	IFNg release	1953410	22590583
HPV16	E2	REMGFKHINHQVVPT	47	61	15	174257	P03120	HLA class II	II	T cell CD4+	ICS	IL-2 release	1953411	22590583
HPV16	E2	LEVYLTAPTGCIKKHG	99	114	16	174180	P03120	HLA class II	II	T cell CD4+	ICS	IFNg release	1953412	22590583
HPV16	E2	CTLYTAVSSTWHWTG	309	323	15	174070	P03120	-	-	PBMC	ELISPOT	IFNg release	1953414	22590583
HPV16	E2	CTLYTAVSSTWHWTG	309	323	15	174070	P03120	-	-	PBMC	ELISPOT	IFNg release	1953415	22590583
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	1958869	23035852
HPV16	E7	MHGDTPTLHEYMLDL	1	15	15	110940	P03129	HLA-A2	I	T cell	ELISPOT	IFNg release	1966456	23211628
HPV16	E7	TPTLHEYMLDLQPET	5	19	15	178351	P03129	HLA-A2	I	T cell	ELISPOT	IFNg release	1966457	23211628
HPV16	E6	ELQTTIHDIILECVY	25	39	15	111251	P03126	HLA-A2	I	T cell	ELISPOT	IFNg release	1966458	23211628
HPV16	E6	VYDFAFRDLCIVYRD	49	63	15	111938	P03126	-	-	T cell	ELISPOT	IFNg release	1966459	23211628
HPV16	E6	AFRDLCIVYRDGNPY	53	67	15	178185	P03126	-	-	T cell	ELISPOT	IFNg release	1966460	23211628
HPV16	E6	EKQRHLDKKQRFHNI	121	135	15	110829	P03126	-	-	T cell	ELISPOT	IFNg release	1966461	23211628
HPV16	E6	HLDKKQRFHNIRGRW	125	139	15	178247	P03126	-	-	T cell	ELISPOT	IFNg release	1966462	23211628
HPV16	E7	HVDIRTLEDLLMGTL	73	87	15	111404	P03129	-	-	T cell	ELISPOT	IFNg release	1966463	23211628
HPV16	E7	MHGDTPTLHEYMLDL	1	15	15	110940	P03129	HLA-A2	I	T cell	51 chromium	cytotoxicity	1966464	23211628
HPV16	E7	TPTLHEYMLDLQPET	5	19	15	178351	P03129	HLA-A2	I	T cell	51 chromium	cytotoxicity	1966465	23211628
HPV16	E6	ELQTTIHDIILECVY	25	39	15	111251	P03126	HLA-A2	I	T cell	51 chromium	cytotoxicity	1966466	23211628
HPV16	E6	VYDFAFRDLCIVYRD	49	63	15	111938	P03126	HLA class I	I	T cell	51 chromium	cytotoxicity	1966467	23211628
HPV16	E6	AFRDLCIVYRDGNPY	53	67	15	178185	P03126	HLA class I	I	T cell	51 chromium	cytotoxicity	1966468	23211628
HPV16	E6	EKQRHLDKKQRFHNI	121	135	15	110829	P03126	HLA class I	I	T cell	51 chromium	cytotoxicity	1966469	23211628
HPV16	E6	HLDKKQRFHNIRGRW	125	139	15	178247	P03126	HLA class I	I	T cell	51 chromium	cytotoxicity	1966470	23211628
HPV16	E7	HVDIRTLEDLLMGTL	73	87	15	111404	P03129	HLA class I	I	T cell	51 chromium	cytotoxicity	1966471	23211628
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	ICS	IFNg release	1970276	23341863
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	-	in vivo assay	cytotoxicity	1970277	23341863
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	T cell CD8+	ICS	IFNg release	1970278	23341863
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	-	in vivo assay	cytotoxicity	1970279	23341863
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class II	II	Splenocyte	in vitro assay	cytotoxicity	1972600	23127963
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD8+	ELISPOT	IFNg release	1972601	23127963
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	Splenocyte	in vitro assay	cytotoxicity	1972602	23127963
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	-	-	-	in vivo assay	survival from challenge	1972603	23127963
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	-	-	T cell	ELISPOT	IFNg release	1975648	23390296
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	-	in vivo assay	cytotoxicity	1975650	23390296
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD8+	multimer/tetramer	qualitative binding	1975856	23266830
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2 class I	I	-	in vivo assay	tumor burden after challenge	1975858	23266830
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	1979475	15703486
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1979481	15703486
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1980593	17102978
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	1982800	23136118
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	1982801	23136118
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	Splenocyte	in vitro assay	proliferation	1982851	23658393
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	Splenocyte	ELISPOT	IFNg release	1982852	23658393
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	Splenocyte	in vitro assay	cytotoxicity	1982853	23658393
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	-	in vivo assay	tumor burden after challenge	1982867	23658393
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	Splenocyte	in vitro assay	cytotoxicity	1983004	23658393
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ELISPOT	IFNg release	1983006	17102978
HPV16	E6	EVYDFAFRDL	48	57	10	14909	P03126	H2-Kb	I	-	in vivo assay	survival from challenge	1983380	23799135
HPV16	E6	EVYDFAFRDL	48	57	10	14909	P03126	H2-Kb	I	T cell CD8+	multimer/tetramer	qualitative binding	1983381	23799135
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Kb	I	T cell CD8+	ICS	IFNg release	1989217	18193057
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	2004449	15501772
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	2004450	15501772
HPV28	L2	FVPRRRRRKR	452	461	10	189972	P50799	HLA-DR13	II	T cell CD4+	3H-thymidine	proliferation	2004679	16362076
HPV33	L2	FILRRRRKRF	447	456	10	189967	P03107	HLA-DR13	II	T cell CD4+	3H-thymidine	proliferation	2004680	16362076
HPV54	L2	YTYVRKRRKR	449	458	10	190176	Q81023	HLA-DR13	II	T cell CD4+	3H-thymidine	proliferation	2004681	16362076
HPV69	L2	LIHKRRRKRV	447	456	10	189994	P26539	HLA-DRB5*01:01	II	T cell CD4+	3H-thymidine	proliferation	2004682	16362076
HPV16	E5	YCIHNITGV	1	9	9	190594	P06927	H2-Db	I	Splenocyte	ELISPOT	IL-2 release	2008416	24142729
HPV28	L2	FVPRRRRRKR	452	461	10	189972	P50799	HLA-DRB5*01:01	II	T cell CD4+	3H-thymidine	proliferation	2008417	16362076
HPV33	L2	FILRRRRKRF	447	456	10	189967	P03107	HLA-DRB5*01:01	II	T cell CD4+	3H-thymidine	proliferation	2008418	16362076
HPV54	L2	YTYVRKRRKR	449	458	10	190176	Q81023	HLA-DRB5*01:01	II	T cell CD4+	3H-thymidine	proliferation	2008419	16362076
HPV16	E5	YCIHNITGV	1	9	9	190594	P06927	H2-Db	I	Splenocyte	ELISPOT	IFNg release	2008482	24142729
HPV16	E5	TSLIILVLL	40	48	9	110726	P06927	H2-Db	I	Splenocyte	ELISPOT	IL-2 release	2008483	24142729
HPV16	E5	TSLIILVLL	40	48	9	110726	P06927	H2-Db	I	Splenocyte	ELISPOT	IFNg release	2008484	24142729
HPV16	E5	IILVLLLWI	43	51	9	110636	P06927	H2-Db	I	Splenocyte	ELISPOT	IL-2 release	2008485	24142729
HPV16	E5	IILVLLLWI	43	51	9	110636	P06927	H2-Db	I	Splenocyte	ELISPOT	IFNg release	2008486	24142729
HPV16	E5	LSVSTYTSL	34	42	9	110664	P06927	H2-Db	I	Splenocyte	ELISPOT	IL-2 release	2008487	24142729
HPV16	E5	LSVSTYTSL	34	42	9	110664	P06927	H2-Db	I	Splenocyte	ELISPOT	IFNg release	2008488	24142729
HPV16	E5	SLIILVLLL	41	49	9	110711	P06927	H2-Db	I	Splenocyte	ELISPOT	IL-2 release	2008489	24142729
HPV16	E5	SLIILVLLL	41	49	9	110711	P06927	H2-Db	I	Splenocyte	ELISPOT	IFNg release	2008490	24142729
HPV16	E5	STYTSLIIL	37	45	9	110712	P06927	H2-Db	I	Splenocyte	ELISPOT	IL-2 release	2008491	24142729
HPV16	E5	STYTSLIIL	37	45	9	110712	P06927	H2-Db	I	Splenocyte	ELISPOT	IFNg release	2008492	24142729
HPV16	E5	LLSVSTYTS	33	41	9	190469	P06927	H2-Db	I	Splenocyte	ELISPOT	IL-2 release	2008493	24142729
HPV16	E5	LLSVSTYTS	33	41	9	190469	P06927	H2-Db	I	Splenocyte	ELISPOT	IFNg release	2008494	24142729
HPV16	E5	YCIHNITGV	1	9	9	190594	P06927	H2-Db	I	-	in vivo assay	tumor burden after challenge	2008495	24142729
HPV16	E5	LSVSTYTSL	34	42	9	110664	P06927	H2-Db	I	Splenocyte	3H-thymidine	proliferation	2008502	24142729
HPV16	E5	TSLIILVLL	40	48	9	110726	P06927	H2-Db	I	-	in vivo assay	tumor burden after challenge	2012399	24142729
HPV16	E5	IILVLLLWI	43	51	9	110636	P06927	H2-Db	I	-	in vivo assay	tumor burden after challenge	2012400	24142729
HPV16	E5	LSVSTYTSL	34	42	9	110664	P06927	H2-Db	I	-	in vivo assay	tumor burden after challenge	2012401	24142729
HPV16	E5	SLIILVLLL	41	49	9	110711	P06927	H2-Db	I	-	in vivo assay	tumor burden after challenge	2012402	24142729
HPV16	E5	STYTSLIIL	37	45	9	110712	P06927	H2-Db	I	-	in vivo assay	tumor burden after challenge	2012403	24142729
HPV16	E5	LLSVSTYTS	33	41	9	190469	P06927	H2-Db	I	-	in vivo assay	tumor burden after challenge	2012404	24142729
HPV16	E5	LSVSTYTSL	34	42	9	110664	P06927	H2-Db	I	-	in vivo assay	survival from challenge	2012405	24142729
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	2014899	15604239
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	2021339	24177312
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	ELISPOT	IFNg release	2021340	24177312
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vitro assay	cytotoxicity	2021341	24177312
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	2021343	24177312
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	survival from challenge	2021344	24177312
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Mononuclear cell	ELISPOT	IFNg release	2028733	24385146
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	2071860	23990055
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	2094195	23990055
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	ELISPOT	IFNg release	2104929	11691804
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	2104930	11691804
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	in vitro assay	cytotoxicity	2104931	11691804
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	2105025	23011589
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	2105597	11390600
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD8+	multimer/tetramer	qualitative binding	2105599	11390600
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	2105601	11390600
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD8+	51 chromium	cytotoxicity	2105603	11390600
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	-	in vivo assay	tumor burden after challenge	2105605	11390600
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	ELISPOT	IFNg release	2105988	15138603
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	2105989	15138603
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	2110979	23615841
HPV16	E7	DRAHYNI	48	54	7	9946	P03129	H2-b class I	I	T cell CD8+	multimer/tetramer	qualitative binding	2117137	24083082
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	2117534	23011589
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD8+	ICS	IFNg release	2118347	21587210
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD8+	multimer/tetramer	qualitative binding	2118353	21587210
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD8+	ICS	IL-2 release	2118358	21587210
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	T cell CD8+	ICS	TNFa release	2118364	21587210
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	2118377	17279610
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	2118378	17279610
HPV18	E7	DDLRAFQQLFLNTLS	81	95	15	230211	P06788	HLA-A*02:01	I	T cell CD8+	ICS	IFNg release	2119011	25141788
HPV18	E7	DDLRAFQQLFLNTLS	81	95	15	230211	P06788	HLA-A*24:02	I	T cell CD8+	ICS	IFNg release	2119012	25141788
HPV18	E7	DDLRAFQQLFLNTLS	81	95	15	230211	P06788	HLA-A*11:01	I	T cell CD8+	ICS	IFNg release	2119013	25141788
HPV18	E7	DDLRAFQQLFLNTLS	81	95	15	230211	P06788	HLA-A*33:03	I	T cell CD8+	ICS	IFNg release	2119014	25141788
HPV18	E7	LFLNTLSFVCPWCAS	89	103	15	230236	P06788	HLA-A*02:01	I	T cell CD8+	ICS	IFNg release	2119019	25141788
HPV18	E7	LFLNTLSFVCPWCAS	89	103	15	230236	P06788	HLA-A*24:02	I	T cell CD8+	ICS	IFNg release	2119020	25141788
HPV18	E7	LFLNTLSFVCPWCAS	89	103	15	230236	P06788	HLA-A*11:01	I	T cell CD8+	ICS	IFNg release	2119021	25141788
HPV18	E7	LFLNTLSFVCPWCAS	89	103	15	230236	P06788	HLA-A*33:03	I	T cell CD8+	ICS	IFNg release	2119022	25141788
HPV18	E7	DDLRAFQQLFLNTLS	81	95	15	230211	P06788	HLA-A*02:01	I	PBMC	51 chromium	cytotoxicity	2119027	25141788
HPV18	E7	DDLRAFQQLFLNTLS	81	95	15	230211	P06788	HLA-A*24:02	I	PBMC	51 chromium	cytotoxicity	2119028	25141788
HPV18	E7	DDLRAFQQLFLNTLS	81	95	15	230211	P06788	HLA-A*11:01	I	PBMC	51 chromium	cytotoxicity	2119029	25141788
HPV18	E7	DDLRAFQQLFLNTLS	81	95	15	230211	P06788	HLA-A*33:03	I	PBMC	51 chromium	cytotoxicity	2119030	25141788
HPV18	E7	LFLNTLSFVCPWCAS	89	103	15	230236	P06788	HLA-A*02:01	I	PBMC	51 chromium	cytotoxicity	2119031	25141788
HPV18	E7	LFLNTLSFVCPWCAS	89	103	15	230236	P06788	HLA-A*24:02	I	PBMC	51 chromium	cytotoxicity	2119032	25141788
HPV18	E7	LFLNTLSFVCPWCAS	89	103	15	230236	P06788	HLA-A*11:01	I	PBMC	51 chromium	cytotoxicity	2119033	25141788
HPV18	E7	LFLNTLSFVCPWCAS	89	103	15	230236	P06788	HLA-A*33:03	I	PBMC	51 chromium	cytotoxicity	2119034	25141788
HPV18	E7	DDLRAFQQLFLNTLS	81	95	15	230211	P06788	HLA-A*02:01	I	PBMC	51 chromium	cytotoxicity	2119035	25141788
HPV18	E7	LFLNTLSFVCPWCAS	89	103	15	230236	P06788	HLA-A*02:01	I	PBMC	51 chromium	cytotoxicity	2119036	25141788
HPV18	E7	DDLRAFQQLFLNTLS	81	95	15	230211	P06788	HLA-A*24:02	I	PBMC	51 chromium	cytotoxicity	2119037	25141788
HPV18	E7	LFLNTLSFVCPWCAS	89	103	15	230236	P06788	HLA-A*24:02	I	PBMC	51 chromium	cytotoxicity	2119038	25141788
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	2119116	25137039
HPV16	E6	QQLLRREVYDFAFRD	42	56	15	232671	P03126	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366594	24824905
HPV16	E6	FRDLCIVYRDGNPYA	54	68	15	232638	P03126	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366596	24824905
HPV16	E6	LKFYSKISEYRHYCY	74	88	15	232660	P03126	HLA-DRB1	II	T cell CD4+	ELISPOT	IFNg release	2366597	24824905
HPV16	E6	GTTLEQQYNKPLCDL	92	106	15	232645	P03126	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366598	24824905
HPV16	E6	KQRFHNIRGRWTGRC	129	143	15	232656	P03126	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366599	24824905
HPV16	E7	MLDLQPETTDLYCYE	12	26	15	232665	P03129	HLA-DRB1	II	T cell CD4+	ELISPOT	IFNg release	2366600	24824905
HPV16	E7	STLRLCVQSTHVDIR	63	77	15	232676	P03129	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366601	24824905
HPV16	E7	TLRLCVQSTHVDIRT	64	78	15	232679	P03129	HLA-DRB1	II	T cell CD4+	ELISPOT	IFNg release	2366602	24824905
HPV16	E7	STHVDIRTLEDLLMG	71	85	15	111032	P03129	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366603	24824905
HPV16	E7	HVDIRTLEDLLMGTL	73	87	15	111404	P03129	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366604	24824905
HPV16	E7	IRTLEDLLMGTLGIV	76	90	15	110908	P03129	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366605	24824905
HPV16	E2	RDHIDYWKHMRLECA	27	41	15	232674	P03120	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366606	24824905
HPV16	E2	FKHINHQVVPTLAVS	51	65	15	232637	P03120	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366607	24824905
HPV16	E2	VPTLAVSKNKALQAI	59	73	15	232681	P03120	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366608	24824905
HPV16	E2	QLTLETIYNSQYSNE	76	90	15	232670	P03120	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366609	24824905
HPV16	E2	LEVYLTAPTGCIKKH	99	113	15	232659	P03120	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366610	24824905
HPV16	E2	GLYYVHEGIRTYFVQ	156	170	15	232643	P03120	HLA-DRB1	II	T cell CD4+	ELISPOT	IFNg release	2366611	24824905
HPV16	E2	PEIIRQHLANHPAAT	208	222	15	174220	P03120	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366612	24824905
HPV16	E2	ILTAFNSSHKGRINC	267	281	15	232648	P03120	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366613	24824905
HPV16	E2	IVHLKGDANTLKCLR	288	302	15	232652	P03120	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366614	24824905
HPV16	E2	CLRYRFKKHCTLYTA	300	314	15	232622	P03120	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366615	24824905
HPV16	E2	DQFLSQVKIPKTITV	344	358	15	232626	P03120	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366616	24824905
HPV16	E5	MTNLDTASTTLLACF	1	15	15	232667	P06927	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366617	24824905
HPV16	E5	RPLLLSVSTYTSLIL	30	44	15	232675	P06927	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366618	24824905
HPV16	E5	LLSVSTYTSLILLVL	33	47	15	232661	P06927	HLA-DRB1	II	T cell CD4+	ELISPOT	IFNg release	2366619	24824905
HPV16	E5	LVLVLWITAASAFRC	45	59	15	232663	P06927	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366620	24824905
HPV16	E5	ASAFRCFIVYIVFVY	54	68	15	232621	P06927	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366621	24824905
HPV16	E5	FIVYIVFVYIPLFLI	60	74	15	232636	P06927	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366622	24824905
HPV16	E5	VYIPLFLIHTHARFL	67	81	15	232684	P06927	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366623	24824905
HPV16	E5	IPLFLIHTHARFLIT	69	83	15	232649	P06927	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366624	24824905
HPV16	E6	LKFYSKISEYRHYCY	74	88	15	232660	P03126	HLA-DRB1	II	T cell CD4+	cytometric bead array	TNFa release	2366636	24824905
HPV16	E6	LKFYSKISEYRHYCY	74	88	15	232660	P03126	HLA-DRB1	II	T cell CD4+	cytometric bead array	IFNg release	2366637	24824905
HPV16	E6	LKFYSKISEYRHYCY	74	88	15	232660	P03126	HLA-DRB1	II	T cell CD4+	cytometric bead array	GM-CSF release	2366638	24824905
HPV16	E7	MLDLQPETTDLYCYE	12	26	15	232665	P03129	HLA-DRB1	II	T cell CD4+	cytometric bead array	TNFa release	2366642	24824905
HPV16	E7	MLDLQPETTDLYCYE	12	26	15	232665	P03129	HLA-DRB1	II	T cell CD4+	cytometric bead array	IFNg release	2366643	24824905
HPV16	E7	MLDLQPETTDLYCYE	12	26	15	232665	P03129	HLA-DRB1	II	T cell CD4+	cytometric bead array	GM-CSF release	2366644	24824905
HPV16	E7	TLRLCVQSTHVDIRT	64	78	15	232679	P03129	HLA-DRB1	II	T cell CD4+	cytometric bead array	TNFa release	2366648	24824905
HPV16	E7	TLRLCVQSTHVDIRT	64	78	15	232679	P03129	HLA-DRB1	II	T cell CD4+	cytometric bead array	IFNg release	2366649	24824905
HPV16	E7	TLRLCVQSTHVDIRT	64	78	15	232679	P03129	HLA-DRB1	II	T cell CD4+	cytometric bead array	GM-CSF release	2366650	24824905
HPV16	E2	GLYYVHEGIRTYFVQ	156	170	15	232643	P03120	HLA-DRB1	II	T cell CD4+	cytometric bead array	TNFa release	2366654	24824905
HPV16	E2	GLYYVHEGIRTYFVQ	156	170	15	232643	P03120	HLA-DRB1	II	T cell CD4+	cytometric bead array	IFNg release	2366655	24824905
HPV16	E2	GLYYVHEGIRTYFVQ	156	170	15	232643	P03120	HLA-DRB1	II	T cell CD4+	cytometric bead array	GM-CSF release	2366656	24824905
HPV16	E5	LLSVSTYTSLILLVL	33	47	15	232661	P06927	HLA-DRB1	II	T cell CD4+	cytometric bead array	IFNg release	2366661	24824905
HPV16	E5	LLSVSTYTSLILLVL	33	47	15	232661	P06927	HLA-DRB1	II	T cell CD4+	cytometric bead array	GM-CSF release	2366662	24824905
HPV16	E6	LKFYSKISEYRHYCY	74	88	15	232660	P03126	HLA-DR	II	PBMC	ELISPOT	IFNg release	2366666	24824905
HPV16	E7	MLDLQPETTDLYCYE	12	26	15	232665	P03129	HLA-DR	II	PBMC	ELISPOT	IFNg release	2366675	24824905
HPV16	E7	TLRLCVQSTHVDIRT	64	78	15	232679	P03129	HLA-DR	II	PBMC	ELISPOT	IFNg release	2366676	24824905
HPV16	E2	GLYYVHEGIRTYFVQ	156	170	15	232643	P03120	HLA-DR	II	PBMC	ELISPOT	IFNg release	2366677	24824905
HPV16	E5	LLSVSTYTSLILLVL	33	47	15	232661	P06927	HLA-DR	II	PBMC	ELISPOT	IFNg release	2366678	24824905
HPV16	E6	PRKLPQLCTELQTTI	16	30	15	110967	P03126	HLA-DRB1	II	PBMC	ELISPOT	IFNg release	2366704	24824905
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	2378022	25207820
HPV16	E5	LSVSTYTSL	29	37	9	110664	P06927	H2-Db	I	T cell CD8+	ICS	IFNg release	2384304	25575128
HPV16	E6	NKPLCDLLI	100	108	9	240903	P03126	H2-Db	I	Splenocyte	ELISPOT	IFNg release	2384311	25575128
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	ELISPOT	IFNg release	2384318	25575128
HPV16	E5	LSVSTYTSL	29	37	9	110664	P06927	H2-Db	I	Splenocyte	ELISPOT	IL-2 release	2384325	25575128
HPV16	E6	NKPLCDLLI	100	108	9	240903	P03126	H2-Db	I	Splenocyte	ELISPOT	IL-2 release	2384332	25575128
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	ELISPOT	IL-2 release	2384339	25575128
HPV16	E5	YCIHNITGV	1	9	9	190594	P06927	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384343	25575128
HPV16	E5	TSLIILVLL	35	43	9	110726	P06927	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384344	25575128
HPV16	E5	IILVLLLWI	38	46	9	110636	P06927	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384345	25575128
HPV16	E5	LSVSTYTSL	29	37	9	110664	P06927	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384346	25575128
HPV16	E5	SLIILVLLL	36	44	9	110711	P06927	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384347	25575128
HPV16	E5	STYTSLIIL	32	40	9	110712	P06927	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384348	25575128
HPV16	E5	LLSVSTYTS	28	36	9	190469	P06927	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384349	25575128
HPV16	E6	EQQYNKPLC	96	104	9	240872	P03126	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384350	25575128
HPV16	E6	KCLKFYSKI	72	80	9	112558	P03126	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384351	25575128
HPV16	E6	KLPQLCTEL	18	26	9	32085	P03126	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384352	25575128
HPV16	E6	NKPLCDLLI	100	108	9	240903	P03126	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384353	25575128
HPV16	E6	YRDGNPYAV	61	69	9	153171	P03126	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384354	25575128
HPV16	E6	RTAMFQDPQ	5	13	9	240918	P03126	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384355	25575128
HPV16	E6	VYRDGNPYA	60	68	9	111941	P03126	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384356	25575128
HPV16	E7	VDIRTLEDL	74	82	9	240934	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384357	25575128
HPV16	E7	DTPTLHEYM	4	12	9	152481	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384358	25575128
HPV16	E7	FCCKCDSTL	57	65	9	152531	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384359	25575128
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384360	25575128
HPV16	E7	PDRAHYNIV	47	55	9	152884	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384361	25575128
HPV16	E7	THVDIRTLE	72	80	9	153065	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384362	25575128
HPV16	E7	GDTPTLHEY	3	11	9	240876	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	2384363	25575128
HPV16	E5	LSVSTYTSL	29	37	9	110664	P06927	H2-Db	I	Splenocyte	3H-thymidine	proliferation	2384389	25575128
HPV16	E5	LSVSTYTSL	29	37	9	110664	P06927	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	2384390	25575128
HPV16	E5	LSVSTYTSL	29	37	9	110664	P06927	H2-Db	I	T cell CD4+	ICS	IFNg release	2384391	25575128
HPV16	E6	FAFRDLCIVYR	52	62	11	241190	P03126	HLA-DR11	II	T cell CD4+	ELISPOT	IFNg release	2390018	25685851
HPV16	E6	FAFRDLCIVYR	52	62	11	241190	P03126	HLA-DR11	II	T cell CD4+	ELISPOT	IFNg release	2390026	25685851
HPV16	E7	RRYPYPAR	0	0	8	244063	P03129	HLA-B*27:05	I	T cell CD8+	ELISA	IFNg release	2399529	25799237
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCV + AIB(C16, C17, C19, C26)	43	69	53	242555	P03129	-	-	-	in vivo assay	tumor burden after challenge	2399539	25660830
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	2399540	25660830
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCV + AIB(C16, C17, C19, C26)	43	69	53	242555	P03129	-	-	-	in vivo assay	survival from challenge	2399542	25660830
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	2467447	26113972
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	2487890	26351680
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	intracellular staining	granzyme B release	2487906	26351680
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD4+	multimer/tetramer	qualitative binding	2515707	26351680
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	2515787	26429982
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	ELISA	IFNg release	2515788	26429982
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	ELISA	TNFa release	2515789	26429982
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	2515790	26429982
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	2515791	26429982
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	2517044	25786869
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	2517045	25786869
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR	43	77	35	110276	P03129	H2-Db	I	-	in vivo assay	survival from challenge	2604749	25501579
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	2604751	25501579
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR	43	77	35	110276	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	2604753	25501579
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR	43	77	35	110276	P03129	H2-Db	I	T cell CD8+	ICS	TNFa release	2604754	25501579
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR	43	77	35	110276	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	2604755	25501579
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR	43	77	35	110276	P03129	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	2604756	25501579
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	-	-	Splenocyte	ELISPOT	IFNg release	2642890	26607604
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR	43	77	35	110276	P03129	-	-	-	in vivo assay	tumor burden after challenge	2642893	26607604
HPV6b	E7	VGLHCYEQL	21	29	9	510243	P04020	H2-Db	I	T cell CD8+	ICS	IFNg release	2723355	26759151
HPV6b	E7	LLLGTLNIV	82	90	9	110323	P04020	HLA-A*02:01	I	T cell CD8+	ICS	IFNg release	2723358	26759151
HPV6b	E7	LLLGTLNIV	82	90	9	110323	P04020	HLA-A*02:01	I	T cell CD8+	in vitro assay	cytotoxicity	2723360	26759151
HPV6b	E7	LLLGTLNIV	82	90	9	110323	P04020	HLA-A*02:01	I	-	in vivo assay	cytotoxicity	2723361	26759151
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	2724303	26949512
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	survival from challenge	2724304	26949512
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	2724305	26949512
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	2724306	26949512
HPV6b	E7	VGLHCYEQLVDSSEDEVDEVDGQDSQPLKQ	21	50	30	510244	P04020	H2-Db	I	T cell CD8+	ICS	IFNg release	2724318	26759151
HPV16	E2	KGDANTLKCL	292	301	10	540474	P03120	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	2833134	27058179
HPV16	E2	SEPDTGNPCH	243	252	10	540594	P03120	H2-Db	I	Splenocyte	51 chromium	cytotoxicity	2833137	27058179
HPV11	E7	TLKDIVLDL	7	15	9	110438	P04020	HLA-A*02:01	I	PBMC	biological activity	activation	2851377	26509579
HPV1a	E7	NIVCPLCTL	82	90	9	547005	P06465	HLA-A*02:01	I	T cell CD8+	51 chromium	cytotoxicity	2853078	26846725
HPV16	E7	QAEPDRAHYNIVTF	44	57	14	111662	P03129	-	-	-	in vivo assay	survival from challenge	2857696	27475535
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	-	-	-	in vivo assay	tumor burden after challenge	2883253	27313455
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	-	-	Splenocyte	ELISPOT	IFNg release	2883262	27313455
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	Splenocyte	ELISPOT	IFNg release	3001300	27977791
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	3001302	27977791
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	3001303	27977791
HPV16	E7	AHYNIVTFCC	50	59	10	567353	P03129	HLA-A*33:03	I	T cell CD8+	ICS	IFNg release	3001383	27873494
HPV16	E7	YNIVTFCCKC	52	61	10	568913	P03129	HLA-A*33:03	I	T cell CD8+	ICS	IFNg release	3001418	27873494
HPV16	E7	AHYNIVTFCC	50	59	10	567353	P03129	HLA-A*33:03	I	T cell CD8+	51 chromium	cytotoxicity	3001419	27873494
HPV16	E7	YNIVTFCCKC	52	61	10	568913	P03129	HLA-A*33:03	I	T cell CD8+	51 chromium	cytotoxicity	3001420	27873494
HPV16	E7	RAHYNIVTFCCKCDS	49	63	15	109785	P03129	HLA-A*33:03	I	T cell CD8+	ELISPOT	IFNg release	3001424	27873494
HPV16	E7	RAHYNIVTFCCKCDS	49	63	15	109785	P03129	HLA-A*33:03	I	T cell CD8+	51 chromium	cytotoxicity	3001468	27873494
HPV16	E7	YNIVTFCCKC	52	61	10	568913	P03129	HLA-A*33:03	I	T cell CD8+	51 chromium	cytotoxicity	3063798	27873494
HPV16	E7	AHYNIVTFCC	50	59	10	567353	P03129	HLA-A*33:03	I	T cell CD8+	51 chromium	cytotoxicity	3063799	27873494
HPV16	E6	KLPQLCTEL	11	19	9	32085	P03126	HLA-A*02:01	I	T cell	ELISA	IFNg release	3193726	28389098
HPV16	E6	KISEYRHYC	72	80	9	111456	P03126	HLA-A*02:01	I	T cell	ELISA	IFNg release	3193728	28389098
HPV16	E6	QQYNKPLCDL	90	99	10	604613	P03126	HLA-A*02:01	I	T cell	ELISA	IFNg release	3193730	28389098
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	T cell	ELISA	IFNg release	3193732	28389098
HPV16	E7	TLHEYMLDL	7	15	9	64830	P03129	HLA-A*02:01	I	T cell	ELISA	IFNg release	3193734	28389098
HPV16	E7	RTLEDLLMGT	77	86	10	139234	P03129	HLA-A*02:01	I	T cell	ELISA	IFNg release	3193736	28389098
HPV16	E6	KLPQLCTEL	11	19	9	32085	P03126	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	3193738	28389098
HPV16	E6	KISEYRHYC	72	80	9	111456	P03126	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	3193740	28389098
HPV16	E6	QQYNKPLCDL	90	99	10	604613	P03126	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	3193742	28389098
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	3193744	28389098
HPV16	E7	TLHEYMLDL	7	15	9	64830	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	3193746	28389098
HPV16	E7	RTLEDLLMGT	77	86	10	139234	P03129	HLA-A*02:01	I	T cell	51 chromium	cytotoxicity	3193748	28389098
HPV16	E6	KLPQLCTEL	11	19	9	32085	P03126	HLA-A*02:01	I	T cell	ELISA	IFNg release	3193750	28389098
HPV16	E6	QQYNKPLCDL	90	99	10	604613	P03126	HLA-A*02:01	I	T cell	ELISA	IFNg release	3193752	28389098
HPV16	E7	RTLEDLLMGT	77	86	10	139234	P03129	HLA-A*02:01	I	T cell	ELISA	IFNg release	3193754	28389098
HPV16	L1	QIFNKPYWL	305	313	9	175639	P03101	HLA class I	I	PBMC	ELISPOT	IFNg release	3193779	28413500
HPV18	E6	KCIDFYSRI	67	75	9	111442	P06463	H2-Kb	I	T cell CD8+	ICS	IFNg release	3340278	28599791
HPV18	E6	KCIDFYSRI	67	75	9	111442	P06463	HLA-A*02:01	I	T cell CD8+	ICS	IFNg release	3340279	28599791
HPV16	E7	DLLMGTLGIVC	81	91	11	688709	P03129	HLA-A*02:01	I	T cell CD8+	in vitro assay	cytotoxicity	3467762	28811980
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	3468558	28852471
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	3468635	28852471
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	3468636	28852471
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	survival from challenge	3468637	28852471
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	3477154	28564390
HPV16	E5	SAFRCFIVY	55	63	9	110702	P06927	HLA-B*15:01	I	T cell CD8+	ELISA	IFNg release	3795074	28950731
HPV16	E5	SAFRCFIVY	55	63	9	110702	P06927	HLA-B*15:01	I	T cell CD8+	ELISA	IFNg release	3795078	28950731
HPV16	E6	AMFQDPQERPRKLPQ	7	21	15	111108	P03126	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830465	29544689
HPV16	E6	QERPRKLPQLCTELQ	13	27	15	111665	P03126	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830466	29544689
HPV16	E6	LPQLCTELQTTIHDI	19	33	15	111508	P03126	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830467	29544689
HPV16	E6	QLLRREVYDFAFRDL	43	57	15	111677	P03126	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830471	29544689
HPV16	E6	VYDFAFRDLCIVYRD	49	63	15	111938	P03126	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830472	29544689
HPV16	E6	EKQRHLDKKQRFHNI	121	135	15	110829	P03126	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830484	29544689
HPV18	E6	MARFEDPTRRPYKLP	1	15	15	111538	P06463	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830489	29544689
HPV18	E6	KLPDLCTELNTSLQD	13	27	15	111460	P06463	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830491	29544689
HPV18	E6	EVFEFAFKDLFVVYR	43	57	15	111263	P06463	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830492	29544689
HPV18	E6	EKLTNTGLYNLLIRC	91	105	15	111246	P06463	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830500	29544689
HPV18	E6	HYRGQCHSCCNRARQ	133	147	15	111408	P06463	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830507	29544689
HPV18	E6	HSCCNRARQERLQRR	139	153	15	111402	P06463	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830508	29544689
HPV18	E6	ARQERLQRRRETQV	145	158	14	111121	P06463	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830509	29544689
HPV16	E7	SSEEEDEIDGPAGQA	31	45	15	111031	P03129	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830514	29544689
HPV16	E7	EIDGPAGQAEPDRAH	37	51	15	111241	P03129	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830515	29544689
HPV16	E7	GQAEPDRAHYNIVTF	43	57	15	111366	P03129	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830516	29544689
HPV16	E7	RAHYNIVTFCCKCDS	49	63	15	109785	P03129	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830517	29544689
HPV16	E7	VTFCCKCDSTLRLCV	55	69	15	111928	P03129	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830518	29544689
HPV18	E7	TLQDIVLHLEPQNEI	7	21	15	111838	P06788	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830525	29544689
HPV18	E7	LHLEPQNEIPVDLLC	13	27	15	111484	P06788	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830526	29544689
HPV18	E7	NEIPVDLLCHEQLSD	19	33	15	111579	P06788	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830527	29544689
HPV18	E7	LLCHEQLSDSEEEND	25	39	15	111491	P06788	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830528	29544689
HPV18	E7	LSDSEEENDEIDGVN	31	45	15	111519	P06788	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830529	29544689
HPV18	E7	ENDEIDGVNHQHLPA	37	51	15	111253	P06788	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830530	29544689
HPV18	E7	GVNHQHLPARRAEPQ	43	57	15	111389	P06788	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830531	29544689
HPV18	E7	LPARRAEPQRHTMLC	49	63	15	111504	P06788	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830532	29544689
HPV18	E7	EPQRHTMLCMCCKCE	55	69	15	111257	P06788	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830533	29544689
HPV18	E7	MLCMCCKCEARIKLV	61	75	15	111554	P06788	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830534	29544689
HPV18	E7	KCEARIKLVVESSAD	67	81	15	111441	P06788	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830535	29544689
HPV18	E7	KLVVESSADDLRAFQ	73	87	15	111463	P06788	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830536	29544689
HPV18	E7	SADDLRAFQQLFLNT	79	93	15	111753	P06788	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830537	29544689
HPV16	E6	YCKQQLLRREVYDFAFRDLCIVYRDGNPY	39	67	29	753555	P03126	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830543	29544689
HPV16	E7	DGPAGQAEPDRAHYNIVTFCCKCDSTLRL	39	67	29	753491	P03129	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830544	29544689
HPV18	E7	CKCEARIKLVVESSADDLRAFQQLFLNTL	66	94	29	753489	P06788	H2-b class I	I	T cell CD8+	ICS	IFNg release	3830546	29544689
HPV16	E6	YCKQQLLRREVYDFAFRDLCIVYRDGNPY	39	67	29	753555	P03126	H2-b class I	I	T cell CD8+	ICS	TNFa release	3830548	29544689
HPV16	E7	DGPAGQAEPDRAHYNIVTFCCKCDSTLRL	39	67	29	753491	P03129	H2-b class I	I	T cell CD8+	ICS	TNFa release	3830549	29544689
HPV18	E7	CKCEARIKLVVESSADDLRAFQQLFLNTL	66	94	29	753489	P06788	H2-b class I	I	T cell CD8+	ICS	TNFa release	3830550	29544689
HPV16	E6	YCKQQLLRREVYDFAFRDLCIVYRDGNPY	39	67	29	753555	P03126	-	-	-	in vivo assay	survival from challenge	3830559	29544689
HPV16	E7	DGPAGQAEPDRAHYNIVTFCCKCDSTLRL	39	67	29	753491	P03129	-	-	-	in vivo assay	survival from challenge	3830560	29544689
HPV16	E6	YCKQQLLRREVYDFAFRDLCIVYRDGNPY	39	67	29	753555	P03126	-	-	-	in vivo assay	survival from challenge	3830572	29544689
HPV16	E7	DGPAGQAEPDRAHYNIVTFCCKCDSTLRL	39	67	29	753491	P03129	-	-	-	in vivo assay	survival from challenge	3830573	29544689
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	-	-	-	in vivo assay	tumor burden after challenge	3838120	29271696
HPV16	E7	QAEPDRAHYNIVTFCCKCD	44	62	19	50241	P03129	H2-b class I	I	T cell CD8+	ICS	IFNg release	3838121	29271696
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	3930097	29603667
HPV16	E7	RTLEDLLMGTL	77	87	11	768628	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	3930098	29603667
HPV16	E7	TLHEYMLDL	7	15	9	64830	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	3930100	29603667
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	3930101	29603667
HPV16	E7	YMLDLQPETTD	11	21	11	768729	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	3930102	29603667
HPV16	E7	RTLEDLLMGT	77	86	10	139234	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	3930103	29603667
HPV16	E7	TLEDLLMGT	78	86	9	111833	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	3930104	29603667
HPV16	E7	EDLLMGTLGIV	80	90	11	768404	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	3930105	29603667
HPV16	E7	DLLMGTLGIV	81	90	10	139028	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	3930106	29603667
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	3930107	29603667
HPV16	E7	MLDLQPET	12	19	8	768546	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	3930108	29603667
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Kb	I	-	in vivo assay	survival from challenge	3980513	29792298
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Kb	I	T cell CD8+	ELISPOT	IFNg release	3980514	29792298
HPV58	E7	DLHPEPTDL	14	22	9	137617	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	4072957	30008894
HPV58	E7	STTTDVRTL	72	80	9	835377	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	4072959	30008894
HPV58	E7	STTTDVRTL	72	80	9	835377	P03129	HLA-A*02:01	I	Splenocyte	ELISPOT	IFNg release	4072962	30008894
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	4562860	30054333
HPV16	E7	QSTHVDIRTLEDLLMGTLGI	70	89	20	52441	P03129	HLA-DRB1*04:01	II	T cell CD4+	ICS	IFNg release	4570554	30136612
HPV16	E7	QSTHVDIRTLEDLLMGTLGI	70	89	20	52441	P03129	HLA-DRB1*04:01	II	T cell CD8+	ICS	IFNg release	4570555	30136612
HPV16	E7	QSTHVDIRTLEDLLMGTLGI	70	89	20	52441	P03129	HLA-DRB1*04:01	II	T cell CD4+	ICS	IL-2 release	4570556	30136612
HPV16	E7	QSTHVDIRTLEDLLMGTLGI	70	89	20	52441	P03129	HLA-DRB1*04:01	II	T cell CD8+	ICS	IL-2 release	4570557	30136612
HPV16	E7	QSTHVDIRTLEDLLMGTLGI	70	89	20	52441	P03129	HLA-DRB1*04:01	II	T cell CD4+	ELISA	IFNg release	4570558	30136612
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	-	in vivo assay	cytotoxicity	4570864	30227079
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	-	in vivo assay	tumor burden after challenge	4583468	30227079
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	4988211	30131378
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	4988213	30131378
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	TNFa release	4988214	30131378
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	intracellular staining	granzyme B release	4988215	30131378
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR	43	77	35	110276	P03129	H2-Db	I	-	in vivo assay	tumor burden after challenge	4988219	30131378
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	T cell CD8+	ICS	IFNg release	5003066	30546964
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	T cell CD8+	in vitro assay	cytotoxicity	5003067	30546964
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	-	in vivo assay	decreased disease	5003068	30546964
HPV16	E7	TLHEYMLDL	7	15	9	64830	P03129	HLA-A*02:01	I	T cell CD8+	ICS	IFNg release	5003069	30546964
HPV16	E7	TLHEYMLDL	7	15	9	64830	P03129	HLA-A*02:01	I	T cell CD8+	in vitro assay	cytotoxicity	5003070	30546964
HPV16	E7	TLHEYMLDL	7	15	9	64830	P03129	HLA-A*02:01	I	-	in vivo assay	decreased disease	5003071	30546964
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	-	in vivo assay	decreased disease	5003072	30546964
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	T cell CD8+	ICS	IFNg release	5003073	30546964
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	T cell CD8+	in vitro assay	cytotoxicity	5003074	30546964
HPV16	E6	ELQTTIHDI	25	33	9	111250	P03126	HLA-A*02:01	I	-	in vivo assay	decreased disease	5003075	30546964
HPV16	E6	ELQTTIHDI	25	33	9	111250	P03126	HLA-A*02:01	I	T cell CD8+	ICS	IFNg release	5003076	30546964
HPV16	E6	ELQTTIHDI	25	33	9	111250	P03126	HLA-A*02:01	I	T cell CD8+	in vitro assay	cytotoxicity	5003077	30546964
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	5020289	28523003
HPV16	E7	VQSTHVDIRTLEDLLMGTLGIVCPI	69	93	25	869594	P03129	HLA-A*02:01	I	Splenocyte	ELISPOT	IFNg release	5032084	30631324
HPV16	E6	KQQLLRREVYDFAFRDLCIVYRDGN	41	65	25	867483	P03126	HLA-A*02:01	I	Splenocyte	ELISPOT	IFNg release	5032085	30631324
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	in vivo assay	proliferation	5036498	28523003
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Kb	I	T cell CD8+	51 chromium	cytotoxicity	5036549	11886264
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Kb	I	T cell CD8+	multimer/tetramer	qualitative binding	5036550	11886264
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	-	-	-	in vivo assay	decreased disease	5048777	30743204
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR	43	77	35	110276	P03129	-	-	-	in vivo assay	decreased disease	5049608	30743204
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR	43	77	35	110276	P03129	H2-b class I	I	-	in vivo assay	cytotoxicity	5049670	30743204
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR	43	77	35	110276	P03129	H2-b class II	II	T cell CD4+	ICS	IFNg release	5049677	30743204
HPV16	E7	GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR	43	77	35	110276	P03129	H2-b class I	I	T cell CD8+	ICS	IFNg release	5049678	30743204
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	Splenocyte	ELISPOT	IFNg release	5351782	30880104
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-b class I	I	-	in vivo assay	protection from challenge	5351785	30880104
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	multimer/tetramer	qualitative binding	5562832	24877765
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	5564241	30418433
HPV16	E2	SPEIIRQHL	207	215	9	911857	P03120	HLA-B*07:02	I	PBMC	ELISPOT	IFNg release	5566220	30154146
HPV16	E2	QVILCPTSV	191	199	9	911835	P03120	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	5566222	30154146
HPV16	E2	KSAIVTLTY	329	337	9	911785	P03120	HLA-B*15:01	I	PBMC	ELISPOT	IFNg release	5566223	30154146
HPV16	E2	NTTPIVHLK	284	292	9	911819	P03120	HLA-A*11:01	I	PBMC	ELISPOT	IFNg release	5566224	30154146
HPV16	E2	YYVHEGIRTY	158	167	10	911911	P03120	HLA-B*15:01	I	PBMC	ELISPOT	IFNg release	5566225	30154146
HPV16	E2	TLQDVSLEV	93	101	9	109984	P03120	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	5566226	30154146
HPV16	E2	YICEEASVTV	138	147	10	110125	P03120	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	5566227	30154146
HPV16	E2	LTAPTGCIKK	103	112	10	911803	P03120	HLA-A*68:01	I	PBMC	ELISPOT	IFNg release	5566228	30154146
HPV16	E2	HPAATHTKAV	218	227	10	911753	P03120	HLA-B*07:02	I	PBMC	ELISPOT	IFNg release	5566229	30154146
HPV16	E2	YLTAPTGCI	102	110	9	441864	P03120	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	5566230	30154146
HPV16	E2	TLKCLRYRFK	297	306	10	911865	P03120	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	5566231	30154146
HPV16	E2	VVEGQVDYY	147	155	9	911884	P03120	HLA-A*01:01	I	PBMC	ELISPOT	IFNg release	5566675	30154146
HPV16	E2	ALQAIELQL	69	77	9	108770	P03120	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	5566676	30154146
HPV16	E2	ILTAFNSSHK	267	276	10	911768	P03120	HLA-A*03:01	I	PBMC	ELISPOT	IFNg release	5566677	30154146
HPV16	E2	NPCHTTKLL	249	257	9	911815	P03120	HLA-B*07:02	I	PBMC	ELISPOT	IFNg release	5566678	30154146
HPV16	E2	DSAPILTAF	263	271	9	911721	P03120	HLA class I	I	PBMC	ELISPOT	IFNg release	5566679	30154146
HPV16	E2	RLECAIYYK	37	45	9	911836	P03120	HLA-A*11:01	I	PBMC	ELISPOT	IFNg release	5566680	30154146
HPV16	E2	TLYTAVSST	310	318	9	911866	P03120	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	5566681	30154146
HPV16	E2	LQDVSLEVY	94	102	9	911799	P03120	HLA-B*15:01	I	PBMC	ELISPOT	IFNg release	5566682	30154146
HPV16	E2	YRFKKHCTL	303	311	9	911909	P03120	HLA-B*08:01	I	PBMC	ELISPOT	IFNg release	5566683	30154146
HPV16	E2	LAVSKNKAL	62	70	9	911791	P03120	HLA-B*08:01	I	PBMC	ELISPOT	IFNg release	5566684	30154146
HPV16	E6	RPRKLPQLCT	15	24	10	911841	P03126	HLA-B*07:02	I	PBMC	ELISPOT	IFNg release	5566688	30154146
HPV16	E6	YGTTLEQQY	91	99	9	911904	P03126	HLA-B*35:01	I	PBMC	ELISPOT	IFNg release	5566689	30154146
HPV16	E6	NPYAVCDKCL	65	74	10	911816	P03126	HLA-B*07:02	I	PBMC	ELISPOT	IFNg release	5566690	30154146
HPV16	E6	FAFRDLCIV	52	60	9	15173	P03126	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	5566691	30154146
HPV16	E6	CPEEKQRHL	118	126	9	110197	P03126	HLA-B*07:02	I	PBMC	ELISPOT	IFNg release	5566692	30154146
HPV16	E6	AVCDKCLKFY	68	77	10	911710	P03126	HLA-A*11:01	I	PBMC	ELISPOT	IFNg release	5566693	30154146
HPV16	E6	TIHDIILECV	29	38	10	64320	P03126	HLA class I	I	PBMC	ELISPOT	IFNg release	5566694	30154146
HPV16	E6	KLPQLCTEL	18	26	9	32085	P03126	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	5566696	30154146
HPV16	E6	LLIRCINCQK	106	115	10	37421	P03126	HLA-A*03:01	I	PBMC	ELISPOT	IFNg release	5566697	30154146
HPV16	E6	TTLEQQYNK	93	101	9	66689	P03126	HLA-A*68:01	I	PBMC	ELISPOT	IFNg release	5566698	30154146
HPV16	E6	YAVCDKCLKF	67	76	10	911887	P03126	HLA class I	I	PBMC	ELISPOT	IFNg release	5566699	30154146
HPV16	E6	IILECVYCK	33	41	9	26568	P03126	HLA-A*03:01	I	PBMC	ELISPOT	IFNg release	5566700	30154146
HPV16	E6	VCDKCLKFY	69	77	9	67833	P03126	HLA-A*01:01	I	PBMC	ELISPOT	IFNg release	5566701	30154146
HPV16	E6	CVYCKQQLLR	37	46	10	911713	P03126	HLA-A*11:01	I	PBMC	ELISPOT	IFNg release	5566702	30154146
HPV16	E6	EYRHYCYSL	82	90	9	110846	P03126	HLA class I	I	PBMC	ELISPOT	IFNg release	5566703	30154146
HPV16	E6	ISEYRHYCY	80	88	9	28484	P03126	HLA-A*01:01	I	PBMC	ELISPOT	IFNg release	5566704	30154146
HPV16	E7	TPTLHEYML	5	13	9	911868	P03129	HLA-B*07:02	I	PBMC	ELISPOT	IFNg release	5566754	30154146
HPV16	E7	LLMGTLGIV	82	90	9	37573	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	5566761	30154146
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	5566762	30154146
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	5566763	30154146
HPV16	E7	QAEPDRAHY	44	52	9	50240	P03129	HLA class I	I	PBMC	ELISPOT	IFNg release	5566764	30154146
HPV16	E7	GTLGIVCPI	85	93	9	22738	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	5566765	30154146
HPV16	E7	IVCPICSQK	89	97	9	29222	P03129	HLA-A*11:01	I	PBMC	ELISPOT	IFNg release	5566766	30154146
HPV16	E7	GIVCPICSQK	88	97	10	20471	P03129	HLA-A*11:01	I	PBMC	ELISPOT	IFNg release	5566767	30154146
HPV16	E7	TLHEYMLDL	7	15	9	64830	P03129	HLA-A*02:01	I	PBMC	ELISPOT	IFNg release	5566768	30154146
HPV16	E7	HGDTPTLHEY	2	11	10	111395	P03129	HLA class I	I	PBMC	ELISPOT	IFNg release	5566769	30154146
HPV16	E7	HYNIVTFCCK	51	60	10	164805	P03129	HLA-A*03:01	I	PBMC	ELISPOT	IFNg release	5566770	30154146
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	HLA-B*07:02	I	PBMC	ELISPOT	IFNg release	5566775	30154146
HPV16	E7	LQPETTDLY	15	23	9	911800	P03129	HLA-B*15:01	I	PBMC	ELISPOT	IFNg release	5566776	30154146
HPV16	E2	TLQDVSLEV	93	101	9	109984	P03120	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	5566969	30154146
HPV16	E2	YICEEASVTV	138	147	10	110125	P03120	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	5566970	30154146
HPV16	E6	FAFRDLCIV	52	60	9	15173	P03126	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	5566971	30154146
HPV16	E6	KLPQLCTEL	18	26	9	32085	P03126	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	5566972	30154146
HPV16	E7	YMLDLQPETT	11	20	10	75075	P03129	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	5566973	30154146
HPV16	E7	YMLDLQPET	11	19	9	75074	P03129	HLA-A*02:01	I	T cell CD8+	multimer/tetramer	qualitative binding	5566974	30154146
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	5590868	31170937
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	TNFa release	5590870	31170937
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	5590871	31170937
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IL-2 release	5590873	31170937
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	cytotoxicity	5590874	31170937
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	multimer/tetramer	qualitative binding	5590878	31170937
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IFNg release	5590879	31170937
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	TNFa release	5590880	31170937
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	T cell CD8+	ICS	IL-2 release	5590881	31170937
HPV16	E7	RAHYNIVTF	49	57	9	53112	P03129	H2-Db	I	-	in vivo assay	survival from challenge	5590882hpvbcell-iedb-1687	31170937